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ABSTRACT 
 
The application of composite tissue techniques is constrained by the susceptibility of 
skin to rejection.  The aim of this thesis is to improve our understanding of skin 
rejection and find ways to avoid it, in order to enable expansion of the application of 
composite tissue transplantation techniques. 
 
The first part of the thesis explores the consequences and mechanism of skin rejection in 
rat models. These studies indicate that in the event of allograft failure, there is minimal 
damage to the vascular pedicle of a composite tissue allotransplant, even after full 
rejection, making retransplantation possible. Furthermore, there is only mild damage to 
the recipient tissues, indicating that the second transplant would not be limited in form 
or function by recipient tissue bed damage.  Finally, the studies indicate that there are 
significant differences between the mechanism of rejection of skin in composite tissue 
transplants and conventional skin grafts.  This means that much of the historical data 
relating to skin graft rejection is not necessarily relevant to composite tissue 
allotransplantation. 
 
The second part of the thesis uses swine models to explore ways to overcome skin 
rejection while avoiding the toxicity of chronic systemic immunosuppression, through 
tolerance induction, and site specific therapy. Previous experience in organ and 
composite tissue allotransplantation models are analysed to develop the hypothesis that 
high-level chimeras are tolerant to vascularised skin allotransplants.  In utero and adult 
chimerism induction models are then used in an attempt to attain moderate-level 
chimeras.  A vascularised skin allotransplant model is developed.  Finally, the 
hypothesis is confirmed with the transplantation of a vascularised skin allotransplant on 
to moderate-level chimeras with the achievement of tolerance.  In addition, site-specific 
therapy is used in an attempt to avoid the side-effects of chronic high-dose systemic 
immunosuppression.  This led to prolongation of skin survival, but eventual skin 
rejection.   5
ACKNOWLEDGEMENTS 
 
The author would like to thank the following people, without which this work would not 
have been possible: 
 
Sarah Horner, Peter Butler, Mark Randolph, Christene Huang, Shehan Hettiaratchy, 
David Sachs, Diana Lo, Erica Hirsh, Kelly Ferguson, Alexander Teague, Patricia Cho, 
Krysztof Wikiel, Christian Leguern, Adam Griesemer, Kazuhiko Yamada, Stuart 
Houser, Akira Shimizu, Henry Win, Kyle Eberlin, Jonathan Summers, Mona Soliman, 
Heung Bae Kim, Meghna Misra, Arthur Nedder, Isabel Mcmorrow, John Hanekamp, 
Ahmed Ghazi, Charles Lin, Joel Spencer, Alicia Carlson, Bram Lutton, Raimon Duran-
Struuck, Robert Cina, Henry Win, Jim Winter, Meaghan Shields, Steven Hatch, Jeffrey 
Petit, Richard Hurley, Crystal Aroujo and Peter Medawar,.   6
 CONTENTS 
 
Chapter   Page 
  Publications and Presentations  7-8 
  Tables and Figures  9-11 
  Abbreviations  12-14 
    
1 Introduction  15-19 
2  Background: review of the field 20-35 
3  Materials and Methods  36-56 
    
PART A  IMMUNOLOGICAL REJECTION  57 
4  Consequences of rejection  58-69 
5  Mechanism of skin rejection 70-81 
    
PART B  OVERCOMING SKIN REJECTION  82 
6A  Predictors of tolerance in organ transplantation  83-95 
6B  Application of organ tolerance findings to CTA  96-103 
7  Pig composite tissue allotransplantation models  104-115 
8  Boosting chimerism with DLI  116-126 
9  In Utero induction of chimerism  127-143 
10  Induction of skin tolerance  144-159 
11  The use of site-specific therapy to prevent skin rejection  160-170 
    
12 Conclusions  171-181 
     
References    182-202   7
PUBLICATIONS AND PRESENTATIONS  
 
PUBLISHED 
Horner, B. M., Cina, R., Wikiel, K., Lima, B., Ghazi, A., Lo, D., Yamada, K., Sachs, 
D., Huang, C. A. (2006). “Predictors of Organ Allograft Tolerance Following 
Hematopoietic Cell Transplantation” Am J Transplant 6(12):2894-902. 
 
Horner, B. M., Randolph, M. A., Huang, C. A., Butler, P. E. M. (2008). “Skin 
tolerance: in search of the Holy Grail” Transpl Int. 21(2):101-12. 
 
Horner, B. M., Eberlin, K., Ferguson, K. K., Hirsh, E., Randolph, M. A., Butler, P. E. 
M. (2008). “Recipient damage following musculocutaneous transplant rejection. 
Transplant” Transplantation. 86(8):1104-10. 
 
Horner, B. M., Spencer, J. A., Ferguson, K. K., Carlson, A. L., Hirsh, E. L., Randolph, 
M. A., Lin, C. P., Butler, P. E. M.  “In vivo observations of cell trafficking in 
allotransplanted vascularized skin flaps and conventional skin grafts”. 
Accepted for publication in JPRAS. 
 
Horner, B.M., Randolph, M.A., Duran-Struuck, R., Hirsh, E. L., Ferguson, K. K., 
Teague, A., Butler, P. E. M., Huang, C. A.  “Induction of tolerance to skin flaps in a 
preclinical large animal model”. 
Accepted for publication in Transplantation Proceedings. 
 
SUBMITTED 
Horner, B. M., Cho, P., Hettiaratchy, S., Hirsh, E. L., Ferguson, K. K., Teague, A., 
Summers, J., Huang, C. A.  “Suppression of donor leukocyte infusion effects in 
minimally conditioned recipients of haploidentical hematopoietic cell transplantation”. 
 
Horner, B. M., Nazzal, J., Randolph, M. A., Birch, W., Lee, A., Brown, C., Mistry, R., 
Butler, P. E. M. “Pig composite tissue transplantation models relevant for facial 
transplantation”. 
 
   8
ORAL PRESENTATIONS 
Horner, B. M., Cina, R., Wikiel, K., Lo, D., Randolph, M. A., Huang, C. A. (January 
2006). “Steps towards tolerance in composite tissue allotransplantation” World CTA 
Symposium. Tuscon, Arizona.  (Won conference prize for best presentation). 
 
Horner, B. M., Cina, R., Lo, D., Wikiel, K., Huang, C. A. (May 2006). “Steps Towards 
CTA Tolerance Induction” Plastic Surgery Research Council. Dana Point, California.   
 
Horner, B. M., Eberlin, K., Ferguson, K. K., Hirsh, E. L., Lin, C., Randolph, M. A., 
Butler, P. E. M. (Jun 2007). “Vascularized musculocutaneous allotransplant rejection: 
the implications for face transplantation” Plastic Surgery Research Council. Stanford, 
California. 
 
Horner, B. M., Randolph, M. A., Duran-Struuck, R., Hirsh, E. L., Ferguson, K. K., 
Teague, A., Butler, P. E. M., Huang, C. A. (May 2008). “Induction of tolerance to skin 
flaps in a preclinical large animal model” Plastic Surgery Research Council. 
Springfield, Illinios.  
 
Horner, B. M., Randolph, M. A., Duran-Struuck, R., Hirsh, E. L., Ferguson, K. K., 
Teague, A., Butler, P. E. M., Huang, C. A. (July 2008). “Induction of tolerance to skin 
flaps in a preclinical large animal model” The 1st American Confererence on 
Reconstructive Transplantation Surgery. Philidelphia, Pennsylvania. 
 
POSTER PRESENTATIONS 
Horner, B. M., Wikiel, K., Cho, P., Cina, R., Fuchimoto, Y., Gleit, Z., Huang, C. A. 
(Jul 2006). “Relationship between Cyclosporine-A treatment and incidence of Graft-
versus-Host disease in minimally conditioned recipients of hematopoietic cell 
transplants” World Transplant Congress. Boston, Massachusetts.    9
TABLES AND FIGURES  
Tables 
Table 2.1  Methods of immune manipulation to achieve tolerance 
Table 3.1   HCT protocols  
Table 3.2   Histological grading scale for recipient tissue damage in rats 
Table 4.1   Outline of recipient tissue damage experimental design 
Table 4.2   Scoring of recipient tissue damage 
Table 5.1   Experimental groups 
Table 6.1   Summary of chimerism induction and delayed organ transplant animals 
Table 6.2   Chimerism in each peripheral blood lineage at organ transplantation 
Table 6.3   Summary of the outcomes and assay results from chimerism induction and  
  limb transplant study 
Table 7.1  Donor leukocyte infusion outcomes 
Table 7.2   Summary of incidence of GvHD in chimeras that underwent  
 non-myeloablative  conditioning 
Table 8.1   Swine CTA models and outcomes 
Table 9.1   Outcomes from in utero injections 
Table 10.1   White blood cells removed by DLI, and in the peripheral blood before and  
  after DLI  
Table 10.2   Summary of results of vascularised skin flap allotransplantation 
Table 11.1  Summary of experimental groups 
Table 11.2  Summary of skin allotransplant survival in animals with normal  
 alloreactivity 
Table 11.3  Summary of skin allograft survival in animals with reduced alloreactivity 
 
Figures 
Figure 3.1   Massachusetts General Hospital (MGH) miniature swine 
Figure 3.2   Positioning of the rodent musculocutaneous flap 
Figure 3.3   Examples of each grading of recipient muscle damage using the 
 histological  grading  scale 
Figure 4.1  Group 1 experimental summary 
Figure 4.2  Histology of damage to recipient muscle following rejection 
Figure 4.3   In vitro assessment of immune response to donor 
Figure 5.1   Experimental overview 
   10
Figure 5.2   Representative examples of recipient cell influx into skin grafts and skin  
  flaps transplanted across isogeneic and allogeneic barriers 
Figure 5.3   Endothelial class II expression on vasculature of rejecting skin  
Figure 5.4   Recipient cell types within transplanted skin 
Figure 5.5  Clustering of infiltrating cells observed around blood vessels and hair 
  follicles in allogeneic skin transplants 
Figure 6.1  Histology of accepted organs 
Figure 6.2  Animal 14040’s immune alloresponse  
Figure 6.3  Both central deletional and regulatory mechanisms involved in tolerance  
  induction in chimeras.  
Figure 6.4   Chimerism induction and limb transplant study outline. 
Figure 6.5  Likely mechanism of tolerance induction for limb allografts 
Figure 6.6   Hypothesis to achieve tolerance to skin  
Figure 7.1  Suppression of graft versus host alloresponses following DLI in chimeric 
 recipients 
Figure 7.2   Suppression of donor-vs.-host response is mediated by CD25+ cells in 
  chimeric recipients   
Figure 7.3  Absolute levels of CD4+CD25+FoxP3+ cells increase post DLI 
Figure 7.4   Donor-vs.-host alloreactive cells persist in chimeras even without GvHD.   
Figure 8.1   Radial artery flap 
Figure 8.2   Groin flap, technically possible, but long pedicle with narrow calibre 
 vessels 
Figure 8.3  Saphenous flap: identifiable sensory nerve, with minimal dissection 
  allowing recovery of the donor  
Figure 8.4  Gastrocnemius myocutaneous flap: identifiable motor and sensory nerves,  
  with utility for functional recovery assessment 
Figure 9.1   Summary of in utero experimental outline 
Figure 9.2   CAFC growth after 10 weeks in unmanipulated, T cell depleted and T cell 
  add back bone marrow from round 1 
Figure 9.3   CFU Growth in unmanipulated, T-cell depleted and T cell add back bone 
 marrow 
Figure 9.4   Microchimerism in the liver of foetuses three days after in utero injection 
Figure 9.5   Peripheral blood chimerism detectable by FACS perinatally in piglet    
 2252-1     11
Figure 9.6   rt-PCR assessment of microchimerism in live- and still-born piglets using 
  Class I D primers 
Figure 9.7  q-PCR assessment of chimerism in piglet 263-1 using Class II D  
 primers/probe 
Figure 9.8   Relationship between mortality and T cell percentage in the inoculum for  
  injections performed by different operators 
Figure 10.1  Summary of experimental plan  
Figure 10.2  Cyclosporine levels during chimerism induction 
Figure 10.3  Peripheral blood chimerism following chimerism induction protocol 
Figure 10.4  Lymphocytes in the peripheral blood before and after DLI 
Figure 10.5  Increase in thymic chimerism following leukapheresis and DLI  
Figure 10.6  Peripheral blood chimerism following leukapheresis and DLI 
Figure 10.7  In vitro assessment of donor-vs.-host suppression pre and post 
  leukapheresis and DLI  
Figure 10.8  Assessment of in vitro responsiveness to the donor prior to skin flap 
 allotransplantation 
Figure 10.9  Skin survival outcomes: photographs and histology 
Figure 10.10 Animal 17469 had donor (AC) specific unresponsiveness 91 days after 
 skin  flap  allotransplantation 
Figure 11.1  Unresponsiveness to donor MHC demonstrated in animals prior to skin 
 grafting 
Figure 11.2  Evidence of skin allograft rejection in animal 16626: photograph and 
 histology 
Figure 11.3  Responsiveness to donor MHC following skin rejection. 
 
   12
ABBREVIATIONS 
@ Anti 
Ab Antibody 
Allo Allogeneic 
ATG Anti-thymocyte  globulin 
BFU-E burst-forming  unit-erythroid 
BMC Bone  marrow  cell 
BM-CFUs  Bone marrow colony forming units 
bp Base  pair 
CAFC  Cobblestone area-forming cell 
CFU  Colony forming unit 
CFU-GEMM  Colony forming unit granulocyte-erythroid-monocyte-megakaryocyte 
CFU-GM  Colony forming unit granulocyte-monocyte 
cGy Centi-Gray 
Chim Chimerism 
CM Cytokine  mobilised 
CML Cell  mediated  lymphocytotoxicity 
CO2 Carbon  dioxide 
Cpm  Counts per minute 
C-section Caesarian  section 
CSG  Conventional skin graft 
CTA Composite  tissue  allotransplantation 
CyA Cyclosporine-A 
D Day 
DC Dendritic  cell 
dDC Donor  dendritic  cell 
DLI  Donor leukocyte infusion 
DNA Deoxyribonnucleic  acid 
E:T Effector:target 
FACS  Fluorescence activated cell sorting 
Fig Figure 
FN False  negative 
FP False  positive 
FT Full  thickness 
G Grade   13
g Gram 
GA Gestational  age 
GFP  Green fluorescent protein 
GvHD Graft-versus-host disease 
H&E  Heaematoxylin and eosin 
HBSS  Hanks balanced salt solution 
HCT  Haematopoietic stem cell transfer 
HSCs hematopoietic  stem  cells 
I.P. Intra-peritoneal 
Ig Immunoglobin 
IL Interleukin 
Iso Isogeneic 
kg Kilogram 
Leuko Leukapheresis 
Lew Lewis 
Lew-GFP  Lewis GFP transgenic 
M Molar 
MACS  Magnetic activated cell sorting 
mg Milligram 
MGH  Massachusetts general hospital 
MHC  Major histocompatibility complex 
Min minute 
MLR Mixed  lymphocyte  response 
ng Nanogram 
NIH  National institute for health 
NK Natural  killer 
NPV  Negative predictive value 
PAA Pig  allelic  antigen 
PB Peripheral  blood 
PBL  Peripheral blood lymphocytes 
PBMC  Peripheral blood mononuclear cell 
PCR Polymerase  chain  reaction 
PPV  Positive predictive value 
PSL  Percent specific lysis 
PT Partial  thickness   14
qPCR Quantitative  PCR 
rDC Recipient  dendritic  cell 
RPMI  Roswell park memorial institute media 
RRRC  Rat resource and research center 
RT-1  RT-1 complex (rat MHC) 
rt-PCR Reverse  transcriptase  PCR 
SB Southern  blot 
SCF Stem  cell  factor 
SCTT  Skin within a composite tissue allotransplant 
SI Stimulation  index 
SLA  Swine leukacyte antigen (swine MHC) 
TBRC  Transplantation biology research center 
TN True  negative 
TP True  positive 
Treg  Regulatory (CD4+CD25+FoxP3+) T cell  
Tx Transplant 
U Unit 
US Ultrasound 
USS Ultrasound  scan 
WBC  White blood cell 
WF Wistar  Furth 
w/v Weight/volume 
YUC Yucatan 
 
   15
CHAPTER 1: INTRODUCTION 
 
1.1 THE FIRST CLINICAL APPLICATIONS OF COMPOSITE TISSUE 
ALLOTRANSPLANTATION 
The primary aim of reconstructive surgery is to “replace like with like”
1.  However, 
many people have physical defects (e.g. severe facial burns or limb amputations) for 
which there are limited reconstructive surgery options using tissue from parts of their 
own bodies.  In these cases, transplanting tissue (e.g. hand and face) from other people 
offers an effective way to reconstruct the defect.   
 
The development of microsurgical techniques made possible the first composite tissue 
allotransplants in animal models more than a century ago (Carrel, A. et al. 1906). 
However, it was not until the advent of modern transplant immunology after World War 
II that clinicians seriously started to consider clinical composite tissue 
allotransplantation (CTA).  The first recorded attempt was a hand allotransplant 
performed in Ecuador in 1964.  However, this was lost early to acute rejection.  The 
first successful reconstruction using a composite tissue allotransplant was a hand 
transplant performed in France in 1998. The initial success of this transplant paved the 
way for more procedures with 38 reported hand transplants (Lanzetta, M. et al. 2007), 8 
abdominal wall transplants (Levi, D. M. et al. 2003), scalp (Jiang, H. Q. et al. 2005), 5 
knee transplants and 3 face transplants (Kanitakis, J. et al. 2006) reported to date. 
 
This introduction will examine the problem of risk associated with the clinical use of 
composite tissue allotransplantation techniques, and then outline how this study aims to 
address a key element of this risk. 
 
1.2 THE PROBLEM 
Skin makes up a central element of many composite tissue allotransplants and is 
considered to be the most antigenic of all the tissues (Lee, W. P. et al. 1991).  The 
success of the reconstructive allotransplantation programme has been possible because 
of the efficacy of modern chronic immunosuppression regimens preventing 
immunological rejection of skin and other elements within the allograft. However, these 
medications have significant side-effects including predisposition to skin cancers, 
kidney damage and metabolic disorders.  Furthermore, there still is the risk of chronic 
                                                 
1 Attributed to Harold Gilles   16
rejection several years after transplantation. These risks are also relevant for recipients 
of other types of allograft such as bone marrow, organs and islets. There are three issues 
that specifically affect the assessment of potential risks of reconstructive 
transplantation: these procedures improve quality of life but do not directly extend life, 
there is a risk of chronic rejection, and there are significant psychological risks as well 
as benefits: 
 
1.2.1 Quality not quantity of life 
For a patient to consider it worthwhile to receive a transplant, the potential benefits 
following a procedure have to at least balance the risks associated with it.  For life-
saving transplants (e.g. heart), even if there are significant risks associated with the 
procedure, it may be still be considered more beneficial to undergo the procedure than 
to face the consequences of not receiving the transplant. Other organ allografts (e.g. 
kidney) are not immediately-life saving but are usually life prolonging.  Therefore, the 
benefits will outweigh the risk of serious consequences.  Composite tissue 
allotransplantation (CTA) can profoundly enhance quality of life but not directly 
prolong life.  In such cases, the possibility of serious consequences, such as skin cancers 
and diabetes, may outweigh the possible benefits of receiving the transplant for some 
people.  However, there have already been cases where the risk-benefit analysis has 
been considered supportive of performing CTA.  It can be even beneficial to perform 
transplantation when the risk-benefit ratio is even smaller than in CTA: islet cell 
transplantation is similar to composite tissue allotransplantation in that it may not 
prolong life, but has the potential to significantly improve the quality of the recipient’s 
life by curing them of diabetes.  However, modern insulin regimens offer a good 
alternative to islet cell transplantation.  In contrast there is no comparably good 
alternative to many composite tissue allotransplants.  
 
1.2.2 Chronic Rejection  
The risk of chronic rejection is unknown in composite tissue allotransplantation because 
it is still in its infancy.  However, it is possible that chronic rejection may be more 
frequent and have more serious consequences for CTA than other forms of 
allotransplantation. Many recipients of organ allografts may have significant co-
morbidity and so die before their allograft develops chronic rejection, or before they can 
develop significant consequences from it.  However, recipients of composite tissue 
allotransplants will often have a life-expectancy of several decades allowing more time   17
for chronic rejection to develop.  Furthermore, the effects of chronic rejection may have 
more severe consequences for composite tissue allotransplants than many organ 
allografts:  a kidney allograft can function adequately even if half of it has become 
scarred by the chronic rejection process, whereas a hand allotransplant would only 
retain very limited function if half of its tissues were non-functional.   
 
1.2.3 Psychology  
Some of the major potential benefits from CTA may be psychological; for example, 
from reducing physical impairment and social stigma.  However, the psychological risks 
associated with CTA may be higher than with many other forms of transplantation.  The 
hand, and particularly the face, are important elements in our definition of personhood.  
Transplantation of tissues that significantly change one’s appearance could have a major 
effect on sense of self and self-worth.  There can also be secondary effects on the 
recipient due to the response of friends and family: two of the three US hand transplant 
recipients have divorced within 3 years of receiving a hand transplant, and one of these 
has also developed alcohol dependency.  Furthermore, in the possible event of a 
composite tissue allotransplant failure, there may profound psychological effects. Most 
hand transplant recipients have incorporated their transplant into their image of 
personhood within 3-6 months, referring to the transplant as “my hand” instead of “the 
hand”.  In the event that a composite tissue allotransplant recipient lost the same part of 
their body for a second time, it is possible that this would be more difficult to deal with 
psychologically than the loss of a non-life sustaining organ transplant.  The recipient 
would actually see the effects of their own body attacking the allograft, which may 
negatively affect their sense of wholeness and identity. 
 
1.3 STUDY AIMS 
The aims of this study are: (1) to examine the rejection process of skin and composite 
tissues and its effects, and (2) to explore ways to overcome skin rejection while 
avoiding the toxicity of chronic systemic immunosuppression.  These questions were 
examined separately in parts A and B of the thesis. 
 
1.3.1 Part A.  The mechanism and consequences of rejection of skin and other 
composite tissues 
In the first part of the thesis, questions relating to the consequences of rejection of skin 
and other composite tissues and the mechanism of skin rejection are explored.     18
 
The consequences of rejection of many composite tissue allotransplants are not known.  
For some composite tissue allotransplants (e.g. hand) the failed transplant can simply be 
amputated. This is not possible for other composite tissue allotransplants (e.g. face and 
abdominal wall) because the resulting defect cannot be left unreconstructed.  The plan 
in many cases is to replace the failed composite tissue allotransplant with another one. 
However, it is possible that the underlying tissues will be so damaged by the rejection 
process that it would not be possible to perform another transplant.  In Chapter 4 the 
consequences of composite tissue allograft rejection on the recipient tissues are 
examined in a rat model. 
 
Much of the previous data relating to the mechanism of skin rejection was obtained 
from observations of conventional skin graft rejection.  Conventional skin grafts only 
pick up a blood supply over the first few days after transplantation.  In contrast, the skin 
within composite tissue allografts has a blood supply immediately following 
transplantation.  The effects of vascularisation on the mechanism of rejection have not 
previously been examined.  In Chapter 5 the mechanisms involved in the rejection of 
vascularised skin with a composite tissue transplant and a conventional skin graft are 
examined in a rat model using in vivo confocal microscopy to follow cell trafficking.   
 
1.3.2 Part B Prevention of skin rejection while avoiding the risks of chronic high-
dose systemic immunosuppression 
The ultimate aim of transplant immunology research is to induce a state of selective 
immunological acceptance of the allograft without the need for chronic 
immunosuppression (i.e. tolerance).  There has been some success clinically with renal 
allografts.  However, skin tolerance across major histocompatability barriers has so far 
only been achieved in small animals.  Previous work in a swine chimerism induction 
model achieved only prolonged survival of the skin element of a composite tissue 
allograft, despite achieving tolerance to the musculoskeletal element (Hettiaratchy, S. et 
al. 2004).  The first part of this section (Chapter 6a) reviews the more extensive 
experience in organ allotransplantation in the swine chimerism induction model to 
identify predictors for achievement of tolerance.  These predictors are then applied to 
the previous swine composite tissue allotransplant data to understand further why skin 
tolerance was not achieved and to develop a hypothesis on how to achieve skin 
tolerance (Chapter 6b).  To test the resulting hypothesis two elements were required: a   19
vascularised skin allotransplant model in swine, and high-level chimeras to receive the 
allotransplant.  A reliable skin flap model is developed (Chapter 7), and methods to 
boost chimerism to achieve high level-chimeras using Donor Leukocyte Infusion is 
examined (Chapter 8). In utero (Chapter 9) and adult (Chapter 10) chimerism induction 
models are then used in an attempt to attain high-level chimeras on which to perform a 
vascularised skin allograft.  Finally, the use of site-specific therapy to try and prevent 
skin rejection while avoiding the side-effects of chronic high-dose systemic 
immunosuppression is examined (Chapter 11).   20
CHAPTER 2: REVIEW OF THE LITERATURE 
 
2.1 INTRODUCTION 
In 1943 Thomas Gibson and Peter Medawar opened the modern era of transplantation 
research with a paper on the problem of skin allograft rejection (Gibson, T. et al. 1943).  
Ten years later, taking into account the observations by Owen that naturally occurring 
chimeric twin calves accepted reciprocal skin grafts (Owen, R. D. 1945), Billingham, 
Brent and Medawar went on to demonstrate that it was possible to induce selective 
immune acceptance of skin grafts in mice: a state of tolerance (Billingham, R. E. et al. 
1953). After over six decades, however, the precise mechanism of skin allograft 
rejection is still ill-defined. Furthermore, it has not been possible to reliably achieve 
clinical tolerance, which would allow the widespread application of skin 
allotransplantation techniques. 
 
This chapter summarizes the alternatives to enlarge the scope of skin allotransplantation 
techniques, the current understanding of mechanisms of skin rejection, and the utility 
and limitations of animal models used to study skin rejection and tolerance induction.  
Finally, the manipulation strategies that have been explored to achieve skin tolerance 
are outlined.   
 
2.2 ROUTES TO WIDESPREAD APPLICATION OF SKIN 
ALLOTRANSPLANTATION TECHNIQUES 
There are three options to overcome the difficulties limiting the expansion of the use of 
skin allotransplantation: A) reduction of the toxicity of chronic immunosuppression, B) 
reduction of the dose of immunosuppression by induction of a less alloreactive state, 
and C) obviating the requirement for immunosuppression by tolerance induction. 
 
2.2.1 Reduction of chronic immunosuppression regimen toxicity 
The development of novel and less morbid immunosuppressants opened the way for the 
successes achieved so far in composite tissue allotransplantation.  In the short term, 
reduction of toxicity of chronic immunosuppression regimens may be the most easily 
achievable with more specific systemic immunosuppressive therapies, or the use of site-
specific therapies with reduction or removal of systemic immunosuppression.   
   21
Future immunosuppressants are likely to offer only modest toxicity reduction on current 
medications as it is difficult to selectively suppress the graft alloresponse without 
influencing immune response to other stimuli. Site-specific therapies have been used 
with some success to treat early rejection episodes in some of the hand transplant 
recipients (Lanzetta, M. et al. 2005).  However, it is unclear whether this is an effective 
clinical strategy for reducing the maintenance dose of systemic immunosuppression:  in 
small animal models, indefinite skin survival has not been achieved using site-specific 
therapies (Fujita, T. et al. 1997; Inceoglu, S. et al. 1994; Yuzawa, K. et al. 1996). 
 
2.2.2 Induction of a less alloreactive state 
Some have speculated that the initial hand transplants may have coincidentally induced 
a less alloreactive state due to the donor bone marrow in the graft: hand transplant 
recipients have required less immunosuppression than was initially expected, with 
stable graft function using dosage regimens comparable to renal allotransplants despite 
the presumed higher antigenic load due to the inclusion of skin in the transplant.  In 
addition, cells with a regulatory phenotype (CD4+CD25+FoxP3+) were detected in the 
allograft dermis of  one of the French hand transplant recipients (Eljaafari, A. et al. 
2006), although the functional significance of this is unclear as the patient was still on 
immunosuppression. 
 
Interventions to reduce alloreactivity have not been effective for skin 
allotransplantation.  Anti-thymocyte globulin (ATG) and anti-CD25 monoclonal 
antibodies were administered in two of the hand transplants (Lanzetta, M. et al. 2005), 
anti-CD52 mAb in abdominal wall allograft transplants, and post-transplant bone 
marrow infusion in the first French face transplant (based on regimens used in organ 
transplants (Ricordi, C. et al. 1997), all with no measurable success.    
 
2.2.3 Tolerance 
The ultimate goal for skin transplantation is to achieve donor specific tolerance. This 
will avoid risks from chronic medication, and possibly the risk of chronic rejection.  
This goal has been shown to be clinically achievable in renal transplantation (Fehr, T. et 
al. 2004), with further work required to improve the reliability of the regimen.  Skin 
holds the unenviable title of being the most difficult of all transplanted tissues to 
achieve a state of tolerance towards.  However, there are anecdotal reports of   22
achievement of skin tolerance in patients (Achauer, B. M. et al. 1986; Woodruff, M. F. 
et al. 1959), indicating that clinical skin tolerance is achievable. 
 
2.3 MECHANISMS OF SKIN REJECTION 
It has long been thought that transplanted skin is more susceptible to rejection than other 
tissues (Lee, W. P. et al. 1991; Sheil, A. G. et al. 1964).  Four factors that may 
contribute to skin’s particular susceptibility to rejection are its usual mode of 
transplantation, skin specific alloantigens, its composition, and allograft size; each of 
these will now be examined in more detail: 
 
2.3.1 Mode of transplantation 
The method of skin allograft transfer may influence their immunogenicity: primarily 
vascularised skin allografts have a small survival advantage over secondarily 
vascularised skin allografts in some studies (Bushell, A. et al. 1995; Steinmuller, D. 
1998).  Possible mechanisms for the difference in immunogenicity between primarily 
and secondarily vascularised skin allografts are initial post-transplant ischemic damage 
and the route of interaction of the allograft with the recipient immune system.  
 
2.3.1.1 Ischemic damage 
In a primarily vascularised allograft, vessels supplying the skin are anastomosed to 
recipient vessels establishing an immediate blood supply to the skin and minimizing any 
ischemic damage.  In contrast, in a secondarily vascularised graft there is a period of 
relative ischaemia for the first 48-72 hours until the microvasculature connects to 
vessels in the wound bed. This causes degeneration and even death of the epidermis 
(Medawar, P. B. 1944; Steinmuller, D. 1962) stimulating an inflammatory response 
within the graft which could be a trigger for rejection.   
 
2.3.1.2 Route of immune interaction 
It is likely that the trafficking of immune cells differs radically between primarily and 
secondarily vascularised skin allografts immediately following transplantation.   
 
There is little data regarding primarily vascularised skin allografts.  However, 
extrapolating from primarily vascularised heart transplant data in mice it is likely that 
initial influx and efflux is mainly via the bloodstream involving both recipient and 
donor dendritic cells (Saiki, T. et al. 2001).  In contrast, initial cell trafficking in   23
secondarily vascularised skin allografts is via lymphatics, as demonstrated by the 
prolonged survival of secondarily vascularised alymphatic skin allografts (Barker, C. F. 
et al. 1968; Tilney, N. L. et al. 1971), with no evidence of recipient dendritic cell 
involvement (Larsen, C. P. et al. 1990a). 
 
It is possible that it is not the route of sensitisation itself that is a cause for a difference 
in immunogenicity between primarily and secondarily vascularised skin allografts.  
Rather the route of sensitisation affects the maturity, function and final destination of 
the dendritic cells, which in-turn are the cause the immunological difference between 
primarily and secondarily vascularised skin allografts (Emmanouilidis, N. et al. 2006; 
Moser, M. 2003; Ochando, J. C. et al. 2006). 
 
Both the route of immune interaction and ischaemic damage may contribute to skin’s 
antigenicity.  However, the mode of transplantation does not fully explain skin’s 
immunogenicity as primarily vascularised skin is still more easily rejected than other 
tissues (Perloff, L. J. et al. 1979).  
 
2.3.2 Skin specific antigens 
The proposal that the susceptibility of skin to rejection is due to expression of tissue 
specific antigens (Boyse, E. A. et al. 1968; Silverman, M. S. et al. 1962) was based on 
the observation that in certain chimeric rodent models, allogeneic donor bone marrow 
was accepted while skin was rejected.  Three skin specific antigens have been described 
in mice: Skn-1, Skn-2 and Epa-1.  
 
2.3.2.1 Skn antigens 
Skn antigens (Skn-1 and Skn-2) seem to be truly skin specific. However, some chimeras 
accept skin grafts despite making Skn antibodies (Scheid, M. et al. 1972).  The reason 
for this disparity may be that Skn antigens are not transplantation antigens: acute 
rejection is T cell mediated, whereas Skn antigens are primarily serologically defined, 
with incomplete evidence that they can stimulate a T cell response.   
 
2.3.2.2 Epa-1 antigen 
Epa-1 antigen can stimulate T cell mediated skin rejection, and has a possible 
homologue in humans; however, it is not skin specific. Consequently, Epa-1 can trigger 
rejection of other tissues (e.g. heart) (Steinmuller, D. 1998).  The other tissues on which   24
Epa-1 is expressed are less immunogenic than skin, suggesting that the cause of skin 
antigenicity is not just Epa-1. 
 
2.3.3 Skin composition 
Skin is a barrier to the outside world. It is conceptually coherent that for skin to act as 
an effective first line of defence to any pathogen it is biased towards a rejection 
response. The intestine and the lungs perform a similar barrier function and are also 
particularly susceptible to rejection (Goss, J. A. et al. 1993; Prop, J. et al. 1985; Zhang, 
Z. et al. 1996).  The cells that make up the skin and dermal structure may both play a 
role in the particular susceptibility of skin to rejection.   
 
2.3.3.1 Cells within the skin 
The term “Skin Immune System” was coined by Bos (Bos, J. D. et al. 1997) to indicate 
that skin is an immunological organ, with approximately half of its cells having 
immunological function.  Of the many specialized immune cells within the skin 
Langerhans cells are likely to be the most important: the immunogenicity of skin 
allografts correlates directly with the density of Langerhans cells they contain 
(Bergstresser, P. R. et al. 1980; Chen, H. D. et al. 1983; Mathieson, B. J. et al. 1975; 
Sena, J. et al. 1976).    However, skin allografts from class II knockout mice are acutely 
rejected at the same rate as wild type skin grafts (Illigens, B. M. et al. 2002) 
demonstrating that direct stimulation by donor class II expressed on these cells is not the 
sole cause of skin’s susceptibility to rejection. 
 
2.3.3.2 Dermal structure 
The dermis is composed predominantly of collagen and glycosoaminoglycan matrix, 
which are only weakly immunogenic (Hoffman, D. K. et al. 1994; Wu, J. et al. 1995).  
However, this highly structured environment contains a high concentration of 
lymphocyte adhesion molecules, thereby making an ideal platform from which effector 
cells can mount an immune response.  Furthermore, the dermis is highly vascular which 
allows for rapid immune cell trafficking to the skin. 
 
2.3.4 Graft size 
The volume of tissue within the allograft may affect the immune response.  Evidence 
for this comes from both murine models and clinically.  In a minor mismatch mouse 
transplant model, smaller skin and cardiac grafts are rejected acutely whereas larger   25
grafts can avoid acute rejection and are rejected more slowly (He, C. et al. 2004).  In the 
clinic it has been observed that there is a lower incidence of acute cellular rejection in 
recipients of larger volume kidney allografts (Poggio, E. D. et al. 2006; Sanchez-
Fructuoso, A. I. et al. 2001).  The correlation between allograft size and avoidance of 
acute rejection puts transplanted skin at a relative disadvantage as the average skin 
allograft contains a lot less tissue than the average organ allograft.  Additionally, the 
volume of skin required to avoid acute rejection may be proportionately more than other 
tissues (Jones, N. D. et al. 2001). 
 
The difference in the speed of rejection between large and small grafts appears to be at 
the effector stage rather than the priming stage (He, C. et al. 2004), and may be due to 
immunomodulation as well as the influence of graft volume:donor-reactive T cell ratio.   
A larger graft may stimulate a stronger regulatory T cell response than a small graft, 
these in turn may down-modulate the rejection response (Sho, M. et al. 2002).   Graft 
size can also influence the speed of rejection by changing the ratio of graft volume to 
number of donor-reactive T cells.  Immediately following transplantation, a threshold 
number of donor-reactive T cells has to be reached to acutely reject an allograft of a 
certain size (He, C. et al. 2004; Jones, N. D. et al. 2001).  A graft recipient may have 
enough donor-reactive T cells to reach the threshold required to cause acute rejection of 
small graft, but this may only be sub-threshold for rejection of a larger graft.    
 
Graft size may play a role in making skin more susceptible to acute rejection, 
particularly in MHC-matched minor-mismatch models.   However, the influence of 
graft size is limited to acute rejection; there is no evidence that larger grafts have a 
lower incidence of chronic immune damage. 
 
In summary, no single dominant mechanism for skin’s antigenicity and susceptibility to 
rejection has been identified.  The mode of transplantation, skin specific antigens, the 
composition of skin and the allograft volume may all contribute, but more research is 
required to further understand their specific roles. 
 
2.4 UTILITY OF ANIMAL MODELS IN THE DEVELOPMENT OF A 
STRATEGY FOR CLINICAL SKIN TOLERANCE INDUCTION 
Skin tolerance can be reliably induced across major histocompatibility complex barriers 
in several small animal models; this has not been possible in large animals or humans.    26
The difficulty in translating between small and large mammals is likely to be due to 
differences between the models including resilience to toxic induction regimens, 
endothelial MHC Class II expression, and bystander activation. 
 
2.4.1 Resilience to toxic induction regimens 
Rodents are resilient to treatments that cause significant morbidity and mortality in large 
animal models and the clinic (e.g. lethal irradiation) (van Bekkum, D. W. 1984).  This 
may be partly due to extrinsic factors such as the highly controlled environment small 
animals are kept in, with minimal exposure to infections, as well as their much shorter 
lifespan, with death occurring before many complications can develop.  However, they 
are also intrinsically less susceptible to certain complications, such as thrombo-
embolism following co-stimulatory blockade (Kawai, T. et al. 2000). 
   
2.4.2 Vascular endothelium immune function 
Vascular endothelium is a likely principle target for the host-anti-graft response.  There 
are significant differences in the expression of molecules involved in the immune 
response on rodent versus human and large animal endothelial cells (Pober, J. S. et al. 
2003).  For example, large animals constitutively express MHC Class II on their 
endothelium, where as in rodents it is only inducible (Houser, S. L. et al. 2004; Kreisel, 
D. et al. 2001).  This difference in Class II expression may not actually lead to a 
difference in a transplant scenario, as MHC Class II expression may be induced on 
rodent endothelium by the act of transplantation. It is also possible that endothelial class 
II MHC has different functions in small animals compared to large animals.  In mice, 
endothelial class II MHC does not activate alloreactive CD4+ cells (Grazia, T. J. et al. 
2004), and may even induce the generation of CD4+25+FoxP3+ regulatory cells 
(Krupnick, A. S. et al. 2005); this has not been examined in large animals. 
 
2.4.3 Bystander activation 
Large animals and humans are exposed to a variety of antigenic stimuli to which they 
mount an immune response with the consequent formation of memory cells.  One or 
more clones of these memory cells may also be activated by the allograft due to 
antigenic similarity between the original stimulus and the graft (“heterologous 
immunological memory”) (Adams, A. B. et al. 2003; Koyama, I. et al. 2007).  In 
contrast, small animals are often bred in controlled environments and therefore are less 
likely to have previously formed memory cells that can be activated by the allograft.   27
 
In summary, differences between large and small animals mean that it is possible to 
induce skin tolerance in many small animal models, but rarely in large animals or 
humans.  So although small animals are useful for outlining new approaches and for 
mechanistic studies, large animals, with their greater physiological and immunological 
similarity to humans, possibly better simulate the human condition and the development 
of clinically translatable protocols. 
 
2.5 STRATEGIES FOR SKIN TOLERANCE INDUCTION 
A tolerance induction strategy involves two elements.  Firstly, the stage of immune 
development to induce tolerance is selected.  Secondly, the method of immune 
manipulation used to induce one or more tolerance mechanisms is chosen. Each of these 
elements will be considered in turn. 
 
2.5.1 Stage of immune development 
Tolerance can be induced in utero, or during neonatal or adult life.  Less manipulation is 
required to induce donor-specific tolerance in the immature immune system of in utero 
models.  Adult tolerance induction models often require more aggressive manipulation, 
however they have a much wider scope of application as they can be used to treat 
acquired disorders not present in utero and avoid risk of triggering abortion by in utero 
manipulation.  Neonatal models theoretically combine advantages of both in utero and 
adult models, with minimal manipulation required of the still developing immune 
system to achieve tolerance without risk of abortion.  Initial work in small animal 
neonatal models was successful at achieving donor tolerance across a major MHC 
barrier to a delayed musculoskeletal allograft with the infusion of bone marrow cells 
(Butler, P. E. et al. 2000).  However, similar strategies to induce skin tolerance with 
neonatal injection of bone marrow into the thymus (Cober, S. R. et al. 1999) or the 
simple intra-peritoneal injection of bone marrow with or without epithelial cells (Petit, 
F. et al. 2004) only resulted in modest prolongation of skin graft survival.  There has 
been no improvement in induction of skin tolerance neonatally since  Boyse and Old’s 
successful neonatal skin tolerance radiation mouse model (Boyse, E. A. et al. 1973) 
which was no less toxic than successful regimens used in adult models.  The theoretical 
advantage of the neonatal model does not seem to be bourne out in practice for skin 
tolerance induction.   
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2.5.2 Method of immune manipulation 
Manipulations that have been used for skin tolerance induction attempts can be divided 
into two groups: those that involve donor haematopoietic stem cell transfer (HCT) and 
those that do not (non-HCT) (see table 2.1). 
 
 
Table 2.1: Methods of immune manipulation to achieve tolerance 
 
 
The transfer of donor haematopoietic stem cells (HSCs) to the recipient as part of 
tolerance induction has fundamental effects on the mechanism of tolerance induction.  
HSCs have the ability to indefinitely replicate as well as differentiate into cells of all 
lympho-haematologic lineages.  If donor HSCs stably engraft in the recipient they will 
provide donor antigen to the thymus allowing life-long negative selection of newly 
arising donor-reactive thymocytes (‘Central Deletion’) (Sykes, M. 2001) and creation of 
naturally occurring regulatory cells.  It is likely that with near complete replacement of 
recipient by donor HSCs central deletional mechanisms are dominant.   However, at 
lower levels of HSC chimerism the mechanism of tolerance induction may not be very 
different from non-HCT approaches with regulatory cells having a greater role 
(Bemelman, F. et al. 1998; Domenig, C. et al. 2005; Kurtz, J. et al. 2004).  Regulatory 
cells can be ‘naturally occurring' thymic derived or be ‘inducible’ in the periphery 
(Waldmann, H. et al. 2006).  Inducible regulatory T cells can stimulate mature T cells to 
change to a regulatory phenotype (‘Infectious Tolerance’ (Qin, S. et al. 1993)).   
To attain tolerance it has been reported that regulatory T cells may only be required to a 
small number of antigens in an allograft; cells within the allograft expressing other 
Method  Additional Procedure 
Immunosuppression 
T-cell depletion 
Non-HCT 
Costimulatory blockade 
HCT alone 
Immunosuppression 
T cell/lymphocyte depletion 
Costimulatory blockade  
HCT 
Dendritic dells   29
antigens attain protection by ‘linked’ or ‘bystander’ suppression (Chen, Z. K. et al. 
1996; Davies, J. D. et al. 1996).  However, it is unlikely that this mechanism will be 
relevant to attaining skin tolerance within a composite tissue allograft because bystander 
suppression appears to require both regulatory cells and bystander cells to exist in the 
same tissue and not just adjacent to each other (Chen, Z. K. et al. 1996).   This is 
supported by the observation of “split tolerance” in composite tissue allotransplantation 
models with tolerance to the musculoskeletal element but eventual rejection of the skin 
element of the allograft (Hettiaratchy, S. et al. 2004). 
 It is possible that small numbers of donor cells are transferred in some non-HCT 
approaches with the achievement of microchimerism (i.e. detectable only by polymerase 
chain reaction).  Some have suggested that a microchimeric state can lead to tolerance 
(Starzl, T. E. et al. 1992), and there is evidence of  central deletion with microchimerism 
(Bonilla, W. V. et al. 2006).  However, microchimerism and tolerance do not always 
correlate (Elwood, E. T. et al. 1997; Fuchimoto, Y. et al. 1999b; Wood, K. et al. 1996). 
The apparent disparity may be because the term ‘microchimerism’ is often used without 
specifying the donor cell type or their location (e.g. peripheral blood, bone marrow, 
thymus), meaning there are differing immunological processes occurring in different 
models all demonstrating ‘microchimerism’.  
HCT approaches are of particular interest in CTA because many allografts contain 
vascularised bone marrow.  Donor marrow cells within CTAs may contribute to 
tolerance induction (Ozmen, S. et al. 2006).  However, it is unclear what role they have 
in the maintenance of tolerance: Siemionow found that recipient marrow cells are 
substituted by donor cells over time in a rat model (Klimczak, A. et al. 2006); however, 
Mathes found in a pig model that the presence of donor cells within the allograft 
diminished over time with no evidence for donor substitution in recipient marrow 
(Mathes, D. W. et al. 2002).   In addition, vascularised bone marrow may have limited 
application clinically: the bones contained within a hand transplant have minimal 
haematopoietic activity in adult life, and face transplants will contain little, or no, bone 
marrow.  To counteract the possible effect of lack of bone marrow within the transplant, 
donor bone marrow infusions were given to the first facial allotransplant recipient 
(Kanitakis, J. et al. 2006). 
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2.5.2.1 Non-HCT approaches 
 
2.5.2.1.1 Short course of immunosuppression 
There are clinical reports of skin tolerance following just a short course of 
immunosuppression (Achauer, B. M. et al. 1986; Frame, J. D. et al. 1989).  However, 
these were not formally studied to confirm pre-transplant alloreactivity or their immune 
status post-transplant.   
 
A short course of FK506 in the MGH miniature swine induced tolerance to kidney 
allografts across full double-haplotype MHC barriers (Utsugi, R. et al. 2001).  However, 
subsequently applied donor skin grafts were rejected, without rejection of the organ 
allograft.  
 
2.5.2.1.2 T-cell depletion 
Depletion of alloreactive T cells reduces the initial alloreactive response allowing 
development of peripheral tolerance mechanisms.  This is often combined with a short 
course of immunosuppression to give further bias towards a tolerogenic versus an 
alloreactive state.   This has been successful in small animals.  Siemionow demonstrated 
prolonged survival of vascularised skin allografts in rats treated with αβTCR Ab and a 
short course of cyclosporine or FK506 (Demir, Y. et al. 2005).  Strom attained skin 
graft tolerance across MHC barriers using rapamycin with an IL2-IL15 fusion protein 
that depleted cytopathic T cells while sparing regulatory T cells (Zheng, X. X. et al. 
2003).  In murine models CD4 and CD8 antibody blockade without T-cell depletion can 
achieve tolerance to class 1 MHC mismatch as well as minor mismatched skin allografts 
(Qin, S. X. et al. 1989) indicating that T cell blockade rather than actual depletion is 
important in achieving skin tolerance via peripheral mechanisms in small animals.  
 
T-cell depletion has been less successful in large animals with only prolonged skin 
allograft survival (from 9.25 to 22-26 days) achieved in non-human primates by the 
administration of ATG (Preville, X. et al. 2001). 
 
2.5.2.1.3 Costimulatory blockade 
Costimulatory blockade is usually considered to act by preventing activation of 
alloreactive T cells.  However, there is evidence that anti-CD154 may heighten the 
suppressive activity of regulatory cells as well (Jarvinen, L. Z. et al. 2003). Tolerance to   31
skin allografts has been achieved using costimulatory blockade in mice (Larsen, C. P. et 
al. 1996).   
 
Simple costimulatory blockade has not been as successful in achieving skin tolerance in 
large animal models.  Repeated intravenous injection of anti-CD154 achieved only a 
modest increase in skin allograft survival (7.3 to 13.3 days) across MHC barriers in 
primates.  Survival was significantly prolonged with the addition of both rapamycin and 
DST (mean: 142.7 days) (Xu, H. et al. 2003).  Also, repeated anti-CD154 antibody 
treatment given both intravenously and into the graft bed achieved markedly prolonged 
skin allograft survival to greater than >202 days (Elster, E. A. et al. 2001a) with only a 
marginal increase in survival (>236 days) with the addition of DST (Elster, E. A. et al. 
2001b). 
 
Other co-stimulatory molecules, including CD28 (Larsen, C. P. et al. 1996), CD134 
(Habicht, A. et al. 2007) and OX40 (Demirci, G. et al. 2004), have all been shown to 
prolong skin allograft survival in murine MHC mismatch models.  The utility of these in 
large animal models has not yet been reported on. 
 
2.5.2.2 HCT approaches 
 
2.5.2.2.1 HCT alone 
The permissive immunological environment of the foetus in utero allows for HCT and 
engraftment without additional therapy.  Tolerance is attained by central deletion, with 
peripheral mechanisms to control alloreactive T cells that escape thymic processing 
(Hayashi, S. et al. 2002).  In utero induction of skin tolerance in mice was first 
demonstrated by Medawar (Billingham, R. E. et al. 1953).  However, this was in part 
due to a fortuitous strain combination with only a MHC class 1 mismatch (CBAÆA). In 
utero induction of skin tolerance has subsequently been attained, in the small animal, 
across MHC class 1 and 2 barriers (Kim, H. B. et al. 1998).    
 
Skin grafts showed only prolonged acceptance (27 days vs. 7-9 days for controls) in 
swine with stable low-level multilineage chimerism (Mathes, D. W. et al. 2005).   
Interestingly, these animals did not demonstrate a second set reaction, or develop 
antibodies upon regrafting from the same donor; it is possible that this may have been   32
due to regulatory tolerance mechanisms that limited accelerated rejection following 
regrafting, but were not strong enough to completely prevent rejection. 
 
Marginally prolonged secondarily vascularised skin allograft survival was demonstrated 
in primate models following donor leukocyte (Jonker, M. et al. 2001) and antigen (van 
Vreeswijk, W. et al. 1980) infusions.  The mechanism of prolongation may be similar to 
following donor specific transfusion with stimulation of a regulatory response (Bushell, 
A. et al. 2003). 
 
2.5.2.2.2 HCT and a short course of immunosuppression 
In the MGH miniature swine model, administration of a 12-day course of cyclosporine 
induced tolerance to MHC-matched, minor mismatched musculoskeletal allografts (Lee, 
W. P. et al. 2001).  Biopsies demonstrated non-inflammatory graft infiltrating 
lymphocytes indicating a possible regulatory mechanism (Baron, C. et al. 2001a).  
However, subsequent skin grafts (non-vascularised) from the donors were rejected, 
without breaking of tolerance to the musculoskeletal graft (Lee, W. P. et al. 1998) (a 
state of “split tolerance”) demonstrating the skin’s susceptibility to rejection.   
 
In further development of this approach, a vascularised hind limb allograft which 
included a skin paddle was transplanted across a MHC-matched minor-mismatched 
barrier in six animals (Mathes, D. W. et al. 2003).  The musculoskeletal element was 
accepted in all animals.  In addition, one animal accepted the skin element of its 
vascularised graft with the others demonstrating split tolerance. This acceptor animal 
received a cryopreserved donor skin graft 120 days later.  The skin graft was rejected by 
60 days with simultaneous rejection of the epidermal element of the hind limb graft.   
 
This finding suggests three things.  Firstly, skin tolerance can be achieved across a 
minor mismatch barrier using this approach.  The variability in success may have been 
due to a more close matching of minor antigens (although the skin graft rejection 
demonstrated that they were not completely matched), or may have been due to the 
recipient having a tolerant phenotype (Roussey-Kesler, G. et al. 2006).  Secondly, the 
mode of transplantation may affect the outcome of skin transplantation, with acceptance 
of immediately vascularised skin while rejecting the skin graft. Thirdly, tolerance to the 
epidermis in this model can be broken more easily than to the dermal and 
musculoskeletal elements.    33
2.5.2.2.3 HCT and T cell/lymphocyte depletion 
Transplanted donor HSCs (i.e. not transferred in the bone marrow contained in the 
graft) will not engraft in an adult without manipulation of the immunological 
environment.  Some regimens have used high-dose irradiation to deplete alloreactive T 
cells and create “immunological space” to allow the donor HSCs to engraft in the 
recipient bone marrow.  This has led to skin graft tolerance across MHC barriers in 
rodent models (Main, J. M. et al. 1955), and across a minor histocompatibility barrier in 
dog models (Tillson, M. et al. 2006; Yunusov, M. Y. et al. 2006).   Other regimens have 
achieved HSC engraftment with lower doses of irradiation by the addition of T cell 
depleting antibodies. This approach has achieved skin graft tolerance across MHC 
barriers in the mouse (Cobbold, S. P. et al. 1986).  In the MGH miniature swine, 
tolerance to skin grafts between MHC-matched, minor-mismatched animals was 
achieved in two out of six cases (Fuchimoto, Y. et al. 2001).  The others rejected their 
skin grafts despite showing prior tolerance to a cardiac allograft (a state of split 
tolerance). Tolerance to the cardiac graft was not broken by rejection of the skin.  
 
Some regimens have used T cell depleting antibodies without irradiation.  Siemionow 
demonstrated tolerance to a hind-limb allograft (containing both vascularised bone 
marrow and skin) across a MHC barrier in rats conditioned with either anti-lymphocyte 
serum (Ozer, K. et al. 2003) or αβTCR Ab (Siemionow, M. et al. 2002; Siemionow, M. 
et al. 2004; Siemionow, M. Z. et al. 2003) followed by a short course of cyclosporine.  
The mechanism of tolerance induction was thymus dependent (Siemionow, M. et al. 
2006), indicating a role for either central deletion and/or naturally occurring regulatory 
cells.  In contrast, Waldmann achieved skin tolerance in murine MHC class 1 mismatch 
models with bone marrow transplantation following CD4 and CD8 antibody blockade 
instead of T-cell depletion. A peripheral tolerance mechanism is likely in this model as 
the mature T cells are not removed (Qin, S. X. et al. 1990). . 
 
In the MGH miniature swine, tolerance was achieved to the musculoskeletal elements of 
a limb transplanted immediately following T-cell depletion with a porcine CD3 
immunotoxin, pCD3-CRM9 (Huang, C. A. et al. 1999b) under the cover of a short 
course of cyclosporine across a full MHC mismatch barrier.  However, the skin only 
showed prolonged acceptance of between 42-70 days (immunosuppression was stopped 
on day 30) (Hettiaratchy, S. et al. 2004).  In two of the five long-term survivors, just the 
epidermis was rejected, with full-thickness skin rejection in the other three cases.   34
Peripheral mechanisms are likely to be involved in tolerance induction in this model 
because the induction regimen does not completely T cell deplete the recipient. The 
involvement of the dermis in skin rejection may, in some cases, be due to selective 
epidermal alloresponse with the secondary destruction of dermal bystander cells in an 
antigen non-specific manner (Doody, D. P. et al. 1994). 
 
2.5.2.2.4 HCT and costimulatory blockade 
Costimulatory blocking agents to the CD40/CD154 or CD28/B7.1/B7.2 pathway, and 
an increased HCT dose can achieve skin graft tolerance across MHC barriers without 
the need for irradiation or T-cell depletion in mouse models (Durham, M. M. et al. 
2000; Seung, E. et al. 2003; Wekerle, T. et al. 1999; Wekerle, T. et al. 2000).  In these 
models anergy, suppression and peripheral deletion are important in the induction of 
tolerance with central deletion being the dominant mechanism in the long-term 
maintenance of tolerance (Kurtz, J. et al. 2004; Wekerle, T. et al. 2002). 
 
2.5.2.2.5 HCT and dendritic cells 
Both recipient and donor dendritic cell infusions have been used in protocols attempting 
to achieve skin tolerance. Unactivated recipient dendritic cells loaded with donor 
antigen and injected prior to transplantation of a hind limb allograft across a major 
MHC barrier in rats achieved only a small increase in survival (8 vs. 5 days) (Nguyen, 
V. T. et al. 2007).   This may have been via a thymic dependent mechanism (Garrovillo, 
M. et al. 2001).  Beriou achieved tolerance to skin transplanted across a major 
allogeneic barrier in mice that were already tolerant to a cardiac transplant following 
infusion of immature bone marrow-derived recipient dendritic cells with a short course 
of a deoxyspergualin analogue (LF 15-0195) (Beriou, G. et al. 2005).   
 
The use of donor dendritic cells has only achieved prolonged skin graft survival.  
Markees showed rapid rejection of major mismatched allogeneic skin grafted on to mice 
treated with Flt3-ligand induced donor dendritic cells, and only prolonged survival with 
the addition of anti-CD154 (61 vs. 7 days) (Markees, T. G. et al. 1999). 
 
2.6 CONCLUSIONS 
The widespread use of skin allotransplantation techniques would transform the field of 
reconstructive surgery. The risk-benefit ratio of immunosuppression is still an issue.  
Part A of this study attempts to further understand the risks involved in CTA.     35
 
For many a tolerogenic process would rebalance the risk-benefit ratio in favour of CTA.  
The methods used so far to induce tolerance have not achieved clinical tolerance against 
skin.  The mode of skin transplantation, skin specific antigens and skin’s composition 
may all contribute to the susceptibility of skin to rejection.  Although there has been 
success in small animal models in achieving indefinite skin survival across MHC 
barriers, tolerance in the large animal model has only been attained across minor antigen 
barriers with prolonged survival between MHC mismatched animals. 
 
It may not be always necessary to reach the ultimate goal of true tolerance to achieve a 
favourable risk-benefit ratio required for a wider-spread application of CTA techniques.  
Adequate reduction of systemic immunosuppressive toxicity may be possible with 
novel immunosuppressive therapies, site-specific adjuvant treatments, or by the 
induction of a less alloreactive state. 
 
However, induction of skin tolerance offers the potential for transplantation free from 
immunological risk.  This would facilitate the widest possible application of 
reconstructive transplantation techniques.  Fifty-four years after Medawar first 
demonstrated that it was possible to induce tolerance to skin in a murine model, the 
Holy Grail of clinical skin tolerance has yet to be unearthed.  Furthermore the barrier of 
transferring techniques that are effective in the small animal to large animal models is 
largely unbreached.  Part B of this study explores an approach to induce tolerance to 
allotransplanted skin in a large animal model.  
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 ANIMALS 
All studies were approved by the Institutional Animal Care and Use Committee of 
Massachusetts General Hospital (MGH) and followed the policies outlined in the 
National Institutes for Health (NIH) Guide for the care and use of laboratory animals. 
 
3.1.1 Rats 
All procedures were performed using 8-12 week-old Lewis (LEW; RT-1
l) and Wistar 
Furth (WF; RT-1
u) rats (180-220g) obtained from Harlan Sprague Dawley Inc. 
(Indianapolis, IN) as donor animals in the study examining the mechanism of skin 
rejection (Chapter 5), and as both donor and recipient animals in the study assessing 
recipient tissue damage following allograft failure (Chapter 4).   Recipient animals in 
the study examining the mechanism of skin rejection were 8 week to 6 month old Lewis 
GFP transgenic rats (Rat Resource and Research Center (RRRC), Columbia, MO); these 
rats were derived from Lewis rats obtained from Harlan.  Syngenicity between the 
donor Lewis rats (from Harlan) and recipient Lewis GFP transgenic (Lew-GFP) rats 
(from RRRC) was confirmed by observing conventional skin graft survival between the 
two strains (LewÆ Lew-GFP) for >100 days.   
 
3.1.2 Swine 
Three breeds of swine were used in the experiments: Massachusetts General Hospital 
(MGH) MHC-inbred miniature swine, Hanford mini-swine, and Yorkshire outbred 
swine. 
 
3.1.2.1 Massachusetts General Hospital (MGH) MHC partially-inbred miniature 
swine 
Donor and recipient animals for the adult chimerism induction (Chapters 6, 7 and 10), 
skin flap model (Chapter 8) and site-specific therapy studies (Chapter 11), and donor 
animals for the in utero chimerism induction study (Chapter 9) were selected from our 
herd of MGH partially-inbred, MHC-defined miniature swine; more detailed 
immunogenetic characteristics of the herd have been previously reported (Sachs, D. H. 
et al. 1976; Sachs, D. H. 1992).  This is a unique herd of partially inbred animals that 
have been developed over the last 30 years. The MHC loci of these animals have been 
fixed for both class I and II by inbreeding. Three main lines are maintained and are   37
referred to by their swine leukocyte antigen (SLA (the swine equivalent of human 
leukocyte antigen (HLA)) types A, C and D. By interbreeding, any combination of these 
three haplotypes can be created (fig 3.1). Only the MHC has been fixed in each line, 
with non-MHC minor antigen differences being maintained.  This allows transplantation 
to be performed across a range of MHC and non-MHC minor disparities, simulating 
potential clinical immunological mismatch combinations.   
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Massachusetts General Hospital (MGH) miniature swine.  The immunogenetics of 
the MGH miniature swine (a) show the different major histocompatibility complex (MHC) types for 
both class I and II. A three month old animal is shown in (b).  
 
 
One line of the SLA
dd haplotype pigs has been further inbred in an attempt to eliminate 
minor antigen differences. MGH MHC defined inbred miniature swine of SLA
dd (class 
I
d/II
d) between 2 and 6 months were used as bone marrow donors for the in utero study 
(Chapter 9).  These animals were offspring of at least 12 generations of inbreeding with 
a coefficient of inbreeding of >94%.  Tolerance to reciprocal skin grafts has been 
observed since reaching 7 generations of inbreeding (Mezrich, J. D. et al. 2003).   
 
Donors ranged in age from 6 months to 2 years. Recipients for the adult chimerism 
induction studies were from 8 to 12 weeks at the time of HCT.  Recipients for the skin 
flap model and site-specific therapy studies ranged in age from 3 months to 2 years.   
 
Haplotype
Origin of Regions
Class II Class I
A
C
D
F
G
H
L
AB CD X
K
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In the adult chimerism induction studies, donors and recipients were chosen to differ by 
at least one haplotype at both class I and class II loci.  All donor-recipient combinations 
were chosen so that the donors were either heterozygous or homozygous for the SLA
c 
haplotype, whereas the recipients contained only SLA
a or SLA
d haplotype 
combinations.  To facilitate the detection of chimerism, all donors were chosen to be 
positive for Pig Allelic Antigen (PAA), a non-histocompatibility cell-surface antigen 
that is present on all differentiated haematopoietic cells in animals that express this 
allele (Fuchimoto, Y. et al. 1999a).  All recipients were chosen to be PAA-negative.    
  
3.1.2.2 Hanford mini-swine and Yorkshire swine 
Unborn litters of pregnant sows selected from either Hanford mini-swine (Sinclair 
Research Center, Columbia, MO) or Yorkshire swine (Parsons Farm, Springfield, MA) 
were used as recipients for the in utero study (Chapter 9).  They were selected because 
they are genetically and immunologically distinct from the MGH miniature swine.  
Consequently, both breeds could be used as recipients from MGH miniature swine 
donors to test tolerance induction across a full MHC barrier.  Both Hanford and 
Yorkshire breeds are outbred and immunologically heterogeneous; to confirm a full 
MHC mismatch to MGH miniature swine, the animals selected for the in utero study 
had to be screened by mixed lymphocyte response (MLR).  
 
3.2 HAEMATOPOIETIC STEM CELL TRANSFER (HCT) AND DONOR 
LEUKOCYTE INFUSION (DLI) PROTOCOLS 
The HCT protocol to induce chimerism consisted of irradiation, T-cell depletion and 
haematopoietic cell infusion from a MHC mismatched donor, with cyclosporine cover 
for the peri/post infusion period; the amount and combination of these were varied 
during the time period analysed as the protocol was refined (see table 3.1)  (Cina, R. A. 
et al. 2006; Fuchimoto, Y. et al. 2000; Horner, B. M. et al. 2006; Huang, C. A. et al. 
2000). 
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PROTOCOL  Irradiation 
(Location:Dose) 
T-cell depletion 
(Yes/ No) 
Cyclosporine 
(Course 
Length) 
A 30  days 
B 
Thymic:  
700-1000 cGy 
Yes 
  60 days 
C 30  days 
D 
None Yes 
  60 days 
E No  45  days 
F 45  days 
G 
Whole Body:  
100 cGy  Yes 
  30 days 
 
Table 3.1 HCT protocols.  Summary of the amount and combination of each of the elements within the 
different HCT protocols used in the animals analysed. 
 
 
Irradiation and T-cell depletion were administered two days prior to HCT.  Irradiation 
was delivered from a Cobalt source (Fuchimoto, Y. et al. 2000; Gleit, Z. L. et al. 
2002b). T-cell depletion was achieved using a single intravenous dose of 0.05mg/kg 
pCD3-CRM9 immunotoxin two days prior to HCT. This conjugate toxin consists of an 
antibody subunit that selectively binds to porcine CD3 and a diphtheria toxin subunit 
which then kills the bound cells (Huang, C. A. et al. 1999b).  
 
Donor animals haematopoietic cells were cytokine mobilised for 5 to 7 days with either 
recombinant porcine interleukin-3 (IL-3) and porcine stem-cell factor (SCF) (each at a 
dose of 0.1mg/kg for the first 30 kgs, and 0.05 mg/kg for each additional kg (Immerge 
Biotherapeutics, Cambridge, Massachusetts)), or by recombinant human granulocyte-
colony simulating factor (10 µg/kg (Filgrastim, Amgen).  Peripheral blood mononuclear 
cells (PBMCs) were collected by leukapheresis (COBE BCT Inc., Lakewood, Colorado, 
USA) beginning on the fifth day of cytokine therapy and continuing until the target cell 
number was attained.  Following the initial leukapheresis, 1x10
9 to 15x10
9 PBMCs per 
kg were infused intravenously daily until the target dose was achieved.    40
 
Enteral cyclosporine-A (CyA; Sandimmune) was administered via a gastrostomy tube, 
beginning one day prior to the mobilised PBMC infusion and continuing for 30 to 60 
days. CyA whole blood levels were maintained between 300-800ng/mL for the first 30 
days before being tapered in the animals receiving a longer course. 
 
Some animals subsequently received a DLI.  Non-mobilised leukocytes were collected 
by leukapheresis from either the original haematopoietic cell donor or a MHC-matched 
animal and then infused intravenously into the recipient at a dose adjusted to include 
5x10
7 donor T cells/kg of recipient body weight.  One animal received a sensitised DLI: 
the DLI donor was pre-sensitised with a skin graft from a MHC recipient matched 
animal (i.e. MHC-mismatched to the donor) 10 weeks prior the DLI.  DLI was defined 
as ineffective if there was no sustained increase in peripheral blood chimerism, thereby 
excluding the small, transient rise in lymphocyte chimerism seen immediately after DLI 
infusion due to the donor cells within the infusion. 
 
In Chapter 10, animals underwent leukapheresis prior to DLI.  This was performed in 
the same way as leukapheresis to collect the cytokine mobilised PBMCs.  
 
3.3 IN UTERO BONE MARROW TRANSPLANTATION PROTOCOL 
Bone marrow was harvested from the inbred SLA
dd donor pig.  The inoculum was 
prepared by T-cell depletion of a portion of the bone marrow and then addition of 
unmanipulated bone marrow to attain a T cell level of 1.5%.  The inoculum was then 
injected into the foetuses. 
 
3.3.1 Bone Marrow Harvest and Processing 
The donor animal was exsanguinated and long bones and vertebrae were harvested 
sterilely.  Bone marrow fragments were removed and processed into a single cell 
suspension.  The cells were washed with Roswell Park Memorial Institute media 
(RPMI) supplemented with 5% DNAase, lysed with ammonium chloride potassium 
lysing solution and stored in media consisting of RPMI 1640 supplemented with 5% 
donor animal serum, 1mM glutamine, 50 U/ml penicillin, 50µg/mL streptomycin, 
50µg/mL gentamicin and 5% DNAase. 
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3.3.2 T-cell depletion 
Bone marrow cells were coated with murine antibody 898H2-6-15 (IgG2a anti-swine 
CD3) for 30 minutes.  Cells were then washed in Hanks balanced salt solution (HBSS) 
three times and incubated with magnetic beads coated with rat, anti-mouse IgG2a/b 
antibodies for 15 minutes. Cell were then washed three times and passed through a 
magnetic separation column to remove CD3+ cells. 
 
3.3.3 In vitro confirmation of T cell composition of inoculum 
Harvested bone marrow was assessed for its T cell content using flow cytometry prior to 
manipulation, after T-cell depletion, and following reconstitution to make up the 
inoculum.  The T cell depleted bone marrow was mixed with unmanipulated bone 
marrow with the aim of attaining an inoculum containing 1.5% T cells (from now 
marrow that has undergone this manipulation is described as ‘Add Back’ bone marrow). 
 
3.3.4 In utero bone marrow transplantation 
Bone marrow cells were harvested about 24 hours prior to injection.  Bone marrow 
processing commenced immediately following harvest, with injection into foetuses 
within hours after completion of processing.  Transplantations were performed during 
mid-gestation (day 55-56 of a full gestation of approximately 113 days) in each 
pregnancy. The pregnant sow was brought to the operating room and underwent a 
laparotomy to expose the uterus.  Under ultrasound guidance, the bone marrow 
inoculum was delivered into the hepatic vein of each foetal pig via transuterine 
injection.  Each bone marrow inoculum consisted of 1.3-5x10
8 cells suspended in 1 ml 
normal saline aiming for a total dose of 2x10
9 cells per kilogram.  Injections were 
performed using a 3-cc syringe with a 25-gauge spinal needle using live stream 
ultrasonography.  At the end of the procedure the sow’s abdomen was closed and the 
animal returned to her cage for recovery.  All sows received 22mg oral progestin 
(Regumate, Hoechst Roused Vet, Warren, NJ, USA) per day beginning 3 days prior to 
injection, continuing until at least gestation day 100. 
 
3.3.5 Freezing and thawing of bone marrow 
Bone marrow remaining after each round of in utero injections was frozen.  The bone 
marrow cells were mixed sterilely at a concentration of 5x10
7/ml in media consisting of 
IMDM, 20% foetal porcine serum, 10% DMSO, 40ug/ml α-tocopherol acetate,   42
100ug/ml catalase, 80ug/ml ascorbic acid. Two 1ml aliquots were also frozen as test 
vials.   
 
Frozen bone marrow was thawed in a 37°C water-bath and then immediately diluted 
with HBSS supplemented with DNAse 1mg/ml at a ratio of 1:12 cells:solution.  The 
cells were then washed 3 times in 0.9% saline. 
 
3.3.6 In vitro comparison of haematopoietic growth potential of bone marrow 
Different preparations of bone marrow were analysed using CFU and CAFC assays as 
described below.  The preparations of bone marrow included 1) unmanipulated bone 
marrow 2) T cell depleted bone marrow 3) T cell depleted bone marrow with 
unmanipulated bone marrow added back to bring the T cells to 1.5%  (as in the 
inoculum for in utero injection). 
 
3.3.6.1 Cobblestone area-forming cell (CAFC) assay to assess in vitro growth 
potential of the bone marrow inoculum  
This assay has been described in detail (Ploemacher, R. E. et al. 1989).  Briefly, bone 
marrow cells from different preparations were plated over a series of dilutions in 96-
well plates on pre-established confluent murine stromal cell lines and cultured at 37°C 
and 5% C02 for 5 weeks in medium consisting of Myelocult (H5100; Stem Cell 
Technologies) supplemented with 25 ng/ml porcine stem cell factor, 2ng/ml porcine 
interleukin-3, and 10
-6M hydrocortisone (Sigma, St Louis, MO, USA). Percentages of 
wells with at least one phase-dark haematopoietic colony of at least five cells (i.e. 
cobblestone area) beneath the stromal layer were determined bi-weekly.  Frequencies 
were calculated using ‘L-Calc’ (Stem Cell Technologies), and were compared among 
the different bone marrow preparations. 
 
3.3.6.2 Colony forming unit (CFU) assay to assess in vitro growth potential of the 
bone marrow inoculum 
Mononuclear cells from the initial bone marrow were plated at concentration of 2.5 x 
10
4 cells in 35-mm Petri dishes in a total volume of 1.5mL methylcellulose-based 
medium (Methocult H4230; Stem Cell Technologies, Vancouver BC, Canada) 
supplemented with 11 ng/ml recombinant porcine stem cell factor, 0.85 ng/mL 
recombinant porcine interleukin-3, 1ng/mL recombinant porcine granulocyte-colony 
stimulating factor, and 0.85 U/mL recombinant human erythropoietin (Amgen Inc,   43
Thousand Oaks, CA, USA).  Following 10 to 14 days incubation in 5% CO2 at 37°C, 
each culture dish was visually scored through an inverted microscope and evaluated for 
presence of burst-forming unit-erythroid (BFU-E), colony-forming unit granulocyte-
monocyte (CFU-GM), and colony-forming unit granulocyte-erythroid-monocyte-
megakaryocyte (CFU-GEMM).  Only colonies containing >50 cells were counted and 
classified based on morphology 
 
3.4 RAT SURGICAL PROCEDURES  
Both donor and recipient animals were deeply anesthetized with an intra-peritoneal 
injection of sodium pentobarbital (50mg/kg).  All animals were monitored continuously 
for heart rate, respiration, body temperature and adequate analgesia while under 
anaesthesia.  The abdomen and the lower limb of the donor and recipient were shaved, 
and the donor was also depilated with a commercially available depilatory ointment, 
Nair® (this facilitated easy differentiation of donor and recipient skin during confocal 
imaging). The surgical area was prepped with povidone iodine solution.  All procedures 
were performed using sterile technique. 
 
3.4.1 Musculocutaneous flap transplant 
In donor animals, the composite musculocutaneous flap, containing both the epigastric 
skin flap and gastrocnemius muscle, was raised based on the femoral vessels.  An 
oblique quadrangular skin flap was marked out (as described by Nishikawa (Nishikawa, 
H. et al. 1991)), raised with the underlying subcutaneous tissues, and isolated on the 
epigastric vessels.  The gastrocnemius muscle was isolated on the sural vessels, which 
in turn were isolated on the femoral vessels. The composite flap was removed from the 
donor by dividing the femoral vessels at the inguinal ligament.  The flap was flushed 
with 1ml of heparinised saline solution.  The donor animal was then euthanized while 
still anesthetized with an overdose of pentobarbital (200mg/kg i.p.).   
 
In recipient animals an incision was made in the groin crease on the contra-lateral side 
to which the musculocutaneous flap had been harvested from the donor.  The femoral 
vessels were exposed distal to the inguinal ligament, isolated, clamped with haemoclips, 
and divided proximal to the origin of the epigastric vascular pedicle.  The vessels were 
flushed with heparinised saline solution.  Using microsurgical technique the donor and 
recipient femoral vessels were anastomosed end-to-end using 10-0 nylon suture under 
magnification of 6-25x as required.  An average of eight sutures was used for both the   44
artery and the vein.  After completing the anastomosis the venous clamp and then the 
arterial clamp were released.   
 
In the experiment examining the mechanism of skin rejection (Chapter 5) the 
transplanted flap was simply secured into place.  In the experiment assessing damage to 
recipient tissues (Chapter 4) the recipient tissue bed for the transplanted flap was 
prepared so that the composite tissue allograft would overlie recipient tissues commonly 
found in the bed of clinical composite tissue allografts (i.e. muscle, fascia and cartilage; 
see fig 3.2a).   
 
a .            b .  
           
 
Figure 3.2 Positioning of the rodent musculocutaneous flap.  (a) Recipient tissues are prepared 
exposing rectus fascia (blue outline), abdominal muscles (red outline) and cartilage (green outline) of the 
inferior pubic ramus. (b) Muscle and skin elements (white outlines) of the allograft are carefully 
positioned and then secured so that they overlay the different recipient tissues commonly found in contact 
with each of those elements following clinical composite tissue transplantation (arrow indicates final 
position of medial end of skin flap element). 
 
  
An ellipse of skin was excised from the superio-medial aspect of the recipient’s groin 
wound exposing the rectus sheath. The superior edge of the wound was dissected off the 
underlying abdominal muscles and rectus fascia creating a subcutaneous pocket. 
Muscles inserting into the anterior pubic ramus were dissected back to expose the pubic 
bone, which is still cartilaginous in the young rats used in these studies.  The composite 
musculocutaneous allograft was carefully positioned and secured with 6.0 prolene 
sutures (see fig 3.2b).  The gastrocnemius was placed to lie in the subcutaneous pocket 
overlying recipient abdominal muscles and rectus fascia, and underlying recipient skin.  
The skin flap was placed so that it overlay abdominal muscles, rectus fascia and 
Muscle Muscle
Skin Skin
Muscle Muscle
Skin Skin
Fascia Fascia
Muscle Muscle
Cartilage Cartilage
Fascia Fascia
Muscle Muscle
Cartilage Cartilage  45
cartilaginous pelvis to which it was secured with a single 5.0 prolene stitch looping 
around the inferior pubic ramus passing through the pubic ring. All animals received 
buprenorphine 0.03mg/kg subcutaneously 12 hourly for 3 days post-operatively. 
 
3.4.2 Conventional skin graft transplant 
 On both donor and recipient animals a 2x2cm rectangular piece of skin was raised over 
the posterior thorax, taking care to remove the panniculus carnosis.  The skin raised 
from the donor was then secured to the margins of the wound bed of the recipient using 
5-0 prolene interrupted sutures with the ends left long; these stitches were then used to 
secure a gauze tie-over dressing in place. 
 
3.4.3 Injection of Evans blue dye 
To visualize blood vessels within the transplanted skin, Evans blue dye was injected.  
The Evans blue dye within the vessel is distinguished from GFP positive recipient cells 
because it is detected at a different wavelength on confocal microscopy, this facilitates 
the assessment of recipient cell clustering around the vasculature.  A groin incision on 
the contralateral side to the flap was made to expose the femoral vessels.  A 1% (w/v) 
solution of Evans blue dye in phosphate buffered saline was mixed in equal parts with a 
5% (w/v) solution of bovine albumin.  A 2.5ml aliquot of the solution was injected into 
the right femoral vein with a 30G needle under magnification.  The groin wound was 
closed directly with 4.0 Vicryl.  
 
3.5 SWINE SURGICAL PROCEDURES 
The swine composite tissue allotransplantation procedures used in these studies were 
developed as part of this study and are included in Chapter 7 as part of the results. 
 
3.6 SITE SPECIFIC THERAPY: TOPICAL FK506 
Some skin allograft recipients received topical 0.1% FK506 ointment (Astellas, 
Deerfield, IL) applied daily.  No dressing was placed over the treated area.  Systemic 
FK506 levels were monitored weekly. 
 
3.7 ASSESSMENT OF REJECTION AND TOLERANCE  
In rats, rejection and its consequences were followed in vivo with confocal microscopy 
and subsequent histological analysis.  Recipient-anti-donor rejection response was 
assessed in rats using MLR and antibody assays.   46
 
In swine, tolerance was tested both in vivo with placement of an allograft, and in vitro 
by combination of CML, MLR and antibody cytotoxicity assays.   
 
3.7.1 In vivo video rate confocal microscopy 
Recipient cell trafficking in allotransplanted skin flaps and grafts were analysed using 
fluorescence confocal microscopy.  Animals were anaesthetized and placed on the stage 
of a video-rate scanning laser confocal microscope platform (Sipkins, D. A. et al. 2005).  
High-resolution images were obtained at 30 frames-per-second, with 30 frame 
averaging, through intact rat skin at depths of up to 275µm from the surface using a 30x 
0.90NA (Lomo, St. Petersburg, Russia) and a 60x 1.2NA water-immersion objective 
lens (Olympus, Melville, NY) providing a field width of either 330µm or 660µm. At 
each location a stack of images at depth increments of 25µm from the skin surface were 
obtained.  In some animals Evans blue dye was injected (as described above) to 
visualize the vessels.   GFP positive recipient cells were excited with a helium neon 
laser at 491nm (Dual Calypso, Cobolt AB, Stockholm, Sweden) and Evans blue dye at 
638nm (Radius, Coherent Inc., Santa Clara, CA); these were then detected with a 
photomultiplier tube at 507nm and 610nm respectively through a +/- 27.5nm bandpass 
filters transmitting 500-550nm (Chroma, Rockingham, filter (Omega Optical, VT) and 
667.5-722.5nm (Omega Optical, Brattleboro, VT), respectively.  
 
Images were attained within 4 hours of transplantation, on days 1, 2, 3, 4 and then 3 
times over the following week.  Isogeneic transplants were imaged up to at least 10 days 
after transplantation.  It was not possible to attain images from allogeneic transplants at 
timepoints later than 4 days because of autofluorescence on the skin surface due to cell 
death caused by the rejection process.   
 
Ischaemia-reperfusion studies have demonstrated that initially the distal edges of a 
primarily vascularised skin flap have the poorest blood supply (Carroll, W. R. et al. 
2000; Kuntscher, M. V. et al. 2002).  This property was utilised to assess the importance 
of the vasculature as a route for cellular influx. Image stacks were obtained from areas 
at the centre of the transplanted skin as well as areas along the edges furthest from the 
pedicle at each timepoint. Comparison was then made between the centre and edge of 
the transplanted skin for variations in cellular influx secondary to differences in blood 
flow.    47
 
Evaluation of infiltrating cell numbers was made by identifying the depth of greatest 
cell density and then counting the number of cells per field at that depth.  Evaluation of 
clustering of infiltrating cells around vasculature and hair follicles was performed by 
first merging the location of all vessels and hair follicles in the stack on to a single 
image. Vessels and the number of cells within 20µm of hair follicles within 40µm of 
each other were eliminated to avoid double-counting. The number of cells within 20µm 
of a hair follicle or part of a vessel were counted at the depth best visualization of the 
structure and compared to the number of cells in an immediately adjacent area of 
exactly the same size that was not within 20µm of another blood vessel or hair follicle 
(again, to avoid double-counting). 
 
3.7.2 Histological assessment of rat biopsies 
In the recipient tissue damage study (Chapter 4) biopsies were taken of the donor and 
recipient tissues including each interface at which they came into contact with each other; in 
the confocal study (Chapter 5) centre and edge biopsies were taken from donor tissues of 
each experimental animal at sacrifice.  These were placed immediately into either 
cryomedia (Tissue-Tek®. Sakura Finetek U.S.A, Inc. Torrence, CA), and then kept at -
80°C, or 4% paraformaldehyde solution for 24 hours and then transferred to phosphate 
buffered saline before processing.  Haematoxylin and eosin stains were obtained for all 
specimens.  Donor skin and muscle rejection was confirmed histologically.  An objective 
histological grading scale was constructed to score recipient tissue damage for the 
experiment described in Chapter 4 (outlined in table 3.2, with examples of different grades 
of recipient muscle damage in figure 3.3).  The recipient tissue at the interface between the 
donor and recipient was then examined by a qualified pathologist in a blinded fashion and 
scored for damage on the histological grading scale. Haematoxylin and eosin stains were 
obtained for all specimens.  Some specimens received immunostaining with mouse 
monoclonal antibodies [3D6] to MHC Class II and [15-11C5] to CD8 (Abcam, Cambridge, 
MA). The slides were examined by a qualified pathologist in a blinded fashion.      48
 
 
 
 
 
 
 
Key 
a  Mild (G1) damage to recipient cartilage and fascia was not identifiable histologically 
 
Table 3.2 Histological grading scale for recipient tissue damage in rats 
 
 
  GRADE OF RECIPIENT TISSUE DAMAGE 
  G0 
(No 
Damage) 
G1 
(Mild) 
G2 
(Moderate) 
G3 
(Severe) 
Recipient 
Muscle 
Undamaged Oedema 
 Wavy 
fibres,  
Decreased 
striations  
Myocyte dropout, Focal 
mononuclear infiltrate 
Multifocal 
Necrosis 
Recipient 
Cartilage 
Undamaged N/A
a Focal  Chondromalacia 
 
Multifocal 
Chondramalacia  
Recipient 
Fascia 
Undamaged 
 
N/A
a 
 
 
Focal Mononuclear 
infiltrate 
Multifocal 
Destruction 
Recipient 
Skin 
Undamaged 
 
Oedema 
 
Mononuclear infiltrate 
Focal necrosis 
Multifocal  
Necrosis   49
 
    
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Examples of each grading of recipient muscle damage using the histological grading 
scale (x25 magnification) 
 
 
G0: No damage 
G1: Mild damage 
G2: Moderate damage 
G3: Severe damage 
Oedema, with no 
artefactual space 
between myocytes 
Myocyte drop-out 
Multifocal Necrosis 
Mononuclear infiltrate   50
 
3.7.3 Assessment of donor-anti-recipient alloreactivity in rats 
3.7.3.1 Antibody detection by flow cytometry analysis 
Antibody response to the composite tissue transplant was assayed by flow cytometry 
using sera collected at full rejection (or the time of biopsies in the isografted animals) to 
stain peripheral blood mononuclear cells (PBMC) MHC matched to the donor. Briefly, 
10 µl of serum from each recipient was added to 1x10
6 cells of WF (RT1-1
u) and/or 
Lew (RT1-1
l) PBMC.   Following 30 minutes incubation with serum, cells were washed 
twice and incubated with a fluorescein conjugated secondary antibody (FITC goat anti-
rat IgM and IgG, 3010-02, Southern Biotech, Birmingham, AL).  Sera from a previously 
skin grafted animal was used as a positive control.  Detection of antibody was reported 
as a difference in mean fluorescence intensity when compared to the reaction against 
recipient-matched PBMCs.  The level of detectable antibody was also titered by serial 
dilutions of the sera samples.   
 
3.7.3.2 Mixed Lymphocyte Response (MLR) assay: responder and stimulator cells were 
harvested from spleens taken from naïve rats and recipient rats at the time of allograft 
rejection (or at a matched time point in the isografts).  Responders (4x10
5) and 
stimulators (4x10
5) irradiated with 25 Gy were cultured together in 200 µl of MLR 
media (RPMI 1640, hepes, gentamicin, NEAA, L glutamine, 2ME and foetal calf 
serum) in triplicate, and incubated for 3 days at 37°C in 5% CO2 and 100% humidity. 
On the third day 1 µCi of 3[H] thymidine was added to each well and the cultures were 
incubated for 18 hours.  Proliferation of responder cells was assessed by the uptake of 
3H thymidine and measured on a beta counter as counts per minute (cpm).  Proliferation 
of recipient responder cells to donor stimulator cells was quantified with a stimulation 
index (calculated as the ratio of the proliferation of recipient cells to donor (cpm): 
recipient cells to self (cpm)). 
 
3.7.4 In vivo assessment of tolerance in Swine 
Tolerance in chimeras in Chapter 6a was tested in vivo by the acceptance or rejection of 
an organ or tissue allograft.  Kidney and heart allografts were used in the chimeras 
assessed for the development of the hypothesis to induce skin tolerance (Chapter 6).  A 
vascularised skin flap allotransplant was used to test the hypothesis (Chapter 10).  
Transplantation of organ allograft was performed using previously described techniques 
(Kirkman, R. L. et al. 1979; Madsen, J. C. et al. 1996).  The technique of skin flap   51
transplantation is described in more detail in Chapter 7.  Allografts were regularly 
biopsied for histological assessment.  Samples were prepared for light microscopy using 
standard techniques. A board-certified pathologist assessed the histological slides in a 
blinded fashion.  In addition, organ transplant function was assessed as an indicator of 
rejection: serum creatinine was measured initially daily and then when clinically 
indicated in renal allografts, and electrocardiographic analysis was performed weekly 
on heart allografts (Madsen, J. C. et al. 1996). Tolerance was defined as acceptance of 
the allograft, with no histological findings of rejection, and, in the case of the organ 
transplants, stable function (Kidney: Cr<2; heart: normal ECG), for greater than 3 
months. 
 
3.7.5 In vitro assessment of tolerance in swine 
CML and MLR assays were used to assess T lymphocyte tolerance (i.e. 
unresponsiveness) to donor in vitro. Yucatan peripheral blood mononuclear cells were 
used to assess 3
rd party response.  These assays were performed as previously described 
(Fuchimoto, Y. et al. 2000; Gleit, Z. L. et al. 2002a; Thistlethwaite JR, J. r. et al. 1984).  
Antibody cytotoxicity assays were used to assess B-cell tolerance.   
 
3.7.5.1 Mixed Lymphocyte Response (MLR) assay  
Primary MLR and primary coculture MLRs were performed.  In primary MLR, 
responders (4x10
5 cells) and stimulators (4x10
5; irradiated with 25 Gy) were cultured 
together.  In primary coculture MLR, 2x10
5 responders were incubated with 4x10
5 
stimulators; suppression was tested by adding 2x10
5 PBMC from a mixed chimera to 
the baseline cultures thereby increasing the total number of responders to 4x10
5.  The 
responders and stimulators were plated at 200µl/well in triplicate, and incubated for 5 
days at 37°C in 5% CO2 and 100% humidity.  Proliferation of responder cells was 
assessed by measuring the uptake of H
3 thymidine after 5 hours of incubation. 
 
3.7.5.2 Cell-Mediated Lymphocytotoxicity (CML) assay 
Responders and stimulators (4x10
6, irradiated with 2,500 cGy/mL) were cultured 
together and incubated in 2 ml of medium for 6 days at 37ºC in 5% CO2 and 100% 
humidity.  Targets were labelled with 
51Chromium (
51Cr) (Amersham Pharmacia, 
Arlington Heights, IL) and plated in 96-well round-bottomed plates with effector cells 
at four effector:target (E:T) ratios (100:1, 50:1, 25:1, 12.5:1).  
51Cr release in the 
supernatant was determined using a gamma counter and compared to background and   52
maximum release (expressed as percent specific lysis (PSL)).  An animal was 
considered responsive if PSL was >15% over background at 100:1 E:T ratio with 
reduction on two successive E:T titrations; hyporesponsive if PSL was 5-15% over 
background at 100:1 E:T ratio with reduction over two successive titrations; and 
unresponsive if  PSL  was <5% over background with no significant change over 
successive titrations. 
 
3.7.5.3 Antibody cytotoxicity assay 
 This assay was used to assess a group of SLA
ad MGH miniature swine chimeras that 
had undergone chimerism induction and organ transplantation from SLA
ac donors.  
Target cell suspensions (SLA
ac PBMC) in medium 199 (Cellgro, Herdon, VA), 
supplemented with 2% foetal calf serum (culture medium), were incubated with 
serially-diluted heat-inactivated experimental animal serum samples, or foetal porcine 
serum (negative control), for 15 min at 37ºC, and then with diluted rabbit complement 
(1:8 in medium 199).  Dead cells were counted by 7-Aminoactinomycin (Sigma-
Aldrich, MO).  Serum cytotoxicity was considered positive if the percentage of cells 
lysed was >20% more than negative control in 1:8 serum dilution with reducing toxicity 
over at least three successive dilutions of sera. 
 
3.8 ASSESSMENT OF CHIMERISM 
Animals were assessed for peripheral blood donor chimerism by fluorescence activated 
cell sorting (FACS), thymic donor macrochimerism (defined as detectable by FACS) 
and/or donor microchimerism (defined as only detectable by polymerase chain reaction 
(PCR) and Southern Blot analysis).  Mouse data indicates that detection of bone marrow 
colony forming units (BM-CFUs) longer than 12 weeks after HCT correlates with 
engraftment of HSCs (Christensen, J. L. et al. 2001).  Consequently, presence of donor-
derived BM-CFUs (detected by PCR analysis) greater than 12 weeks after PBMC 
transplantation, was used to indicate the presence of haematopoietic stem cells. As part 
of this study (Chapter 6a) it was found that thymic chimerism and multilineage 
peripheral blood chimerism present at 14 weeks always correlates with presence of BM-
CFUs (Horner, B. M. et al. 2006).  Consequently, from Chapter 7 onwards engraftment 
was defined as the presence of any of these three markers (donor-derived BM-CFUs, 
thymic chimerism or multilineage peripheral blood chimerism) at 14 weeks post HCT. 
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3.8.1 Flow cytometry 
Flow cytometry was performed on a Becton-Dickinson FACS scanner (San Jose, Ca), as 
previously described (Fuchimoto, Y. et al. 1999a).  A full range of SLA class specific 
mouse anti-swine monoclonal antibodies have been developed, allowing differentiation 
to be made between donor and recipient tissues and cells in the MGH miniature swine.  
The following swine specific antibodies were used: CD3ε (898H2-6-15, mouse 
IgGaK)(Huang, C. A. et al. 1999a), CD4 (74-12-4, Mouse IgG2bK), CD8α (76-2-11, 
mouse IgG2aK), CD172 (744-22-15, mouse IgG1K) (Pescovitz, M. D. et al. 1984; 
Pescovitz, M. D. et al. 1985; Saalmuller, A. et al. 1994; Smith, R. E. et al. 2003), 
CD5(Pescovitz, M. D. et al. 1998), CD1 (76-7-4, mouse IgG2aK), CD16 (G7, mouse 
Ig), CD25 (231-3B2, mouse IgG1) , SLA
d Class 1 (2.12.3A, mouse IgM), PAA (1038H-
10-9, IgMK)(Fuchimoto, Y. et al. 1999a) and FoxP3 (FJK-165, eBioscience), with 
human CD16 (3G8, BD Pharmingen) used as a negative control.  For assessment of 
chimerism, PAA staining was used to distinguish donor- and recipient-origin cells 
(Sachs. D. H. 1992).  Monocyte and granulocyte chimerism was determined by gating 
on CD172-positive mononuclear cells and granulocytes respectively.   Three colour 
staining was used to determine the proportion of CD4+CD25+ FoxP3+ cells. The 
absolute number of CD4+CD25+FoxP3+ cells in the animal was then calculated from 
the absolute white cell count of the animal at that time point. Peripheral blood 
chimerism was considered detectable if the percent of PAA staining cells was at least 
0.5% above the background staining seen with the isotype matched control. 
 
3.8.2 PCR detection of donor-derived DNA 
Assessment of donor chimerism was performed in rats and swine.  In rats PCR analysis 
was used in the mechanism of skin rejection study (donor Wistar FurthÆrecipient 
Lewis rats).  In swine PCR analysis was used in the in utero study (donor 
SLA
ddÆrecipient outbred swine), and the adult chimerism induction study (donor 
SLA
ac Ærecipient SLA
ad). For all PCR reactions genomic DNA was isolated with the 
DNeasy Kit (Qiagen, Valencia, CA) according to manufacturer’s directions.   
 
3.8.2.1 Wistar Furth and Lewis DNA microsatellite repeat PCR Analysis  
Biopsies of recipient tissues (allograft, bone marrow, thymus, lymph node, spleen, 
blood) were taken at sacrifice. Donor origin (Wistar Furth; Harlan) and recipient origin 
(Lew-GFP; RRRC) cells within recipient tissues were differentiated by PCR analysis of   54
two microsatellite repeat regions which differ in length between each strain.  The 
microsatellite repeat D1Mgh14 is 128 base-pairs (bp) long in Wistar Furth and 156bp 
long in Lewis; it was amplified with the primer pair Fam-
CCGCACTGAGCTCTCAGAG (F) and CCCAACCATTGAGCTAGTAAGG (R).  The 
microsatellite repeat D11Mgh3 is 180 bp long in Wistar Furth and 140bp long in Lewis; 
it was amplified with primer pair Fam-GGAGCTGAAATACGAGAGAAATAA (F) 
and GTCCTGCTGGCTGTGCAT (R).   
 
PCR amplification was performed using a PTC-100 programmable Thermal Cycler (MJ 
Research Inc., Watertown, MA) with template denaturation at 94ºC for 15 minutes, and 
44 cycles of melting at 94ºC for 15 seconds, annealing at 54ºC for 15 seconds, and 
extension at 72ºC for 30 seconds, followed by a final extension at 72ºC for ten minutes.   
A mixing assay indicated that the strains could be distinguished down to a relative 
concentration of 1% WF:99% Lew-GFP.  
 
3.8.2.2 MHC class I
d and Class II
d DNA PCR analyses  
For Class I
d PCR primers GAGGCCCTGGAGCAGAAG (sense 5’) and 
GCCTTCCTCTATCTGGTAGTTGTG (antisense 3’) were used.   For Class IId PCR 
primers 569 (CGAGTGCTACTTCTACAACGGA exon 2) and 571 
(GTCGTGCCTTCCTCTATCTGGTAG exon 2 (reverse)) were used. Genomic DNA 
(50ng) was amplified in a reaction mix consisting of 1x HotStart Taq buffer (Qiagen), 
1µM of each primer, 80µM each dNTP and 2.5U HotStart Taq polymerase (Qiagen) in 
a final volume of 50µl.  PCR amplification was performed using a PTC-100 
programmable thermal cycler (MJ Research Inc., Watertown, MA) with template 
denaturation at 94ºC for 15 minutes, and 44 cycles of melting at 94ºC for 15 seconds, 
annealing at 54ºC for 15 seconds, and extension at 72ºC for 30 seconds, followed by a 
final extension at 72ºC for ten minutes. The DNA-PCR product was then digested with 
Alu I restriction enzyme producing 184bp and 47bp products which distinguishes SLA
d 
from other haplotypes. 
 
3.8.2.3 MHC class 1
d quantitative PCR (QPCR) analysis  
MHC Class 1
d DNA was quantitatively assessed by real-time PCR analysis.  The 
reaction mix included DNA template, 800nM of forward primer 
GAGGCCCTGGAGCAGAAG, 800nM reverse primer 
GCCTTCCTCTATCTGGTAGTTGTG, with 200 nM of labelled probe   55
TTTBCACACAGTTGTCCA and ‘Absolute QPCR Rox Mix’ (Abgene, Rochester, 
NY). Amplification was performed with a Stratagene Mx 3005 system (La Jolla, CA) 
with cycling conditions of  95°C for 10min, and 50 cycles of  95°C for 30s, 55°C for 1 
min, and 72°C for 30s. Class I quantification was based on amplification of a plasmid 
reference standard, from 10
8-10
1 copies.  
 
3.8.2.4 MHC class I
c DNA PCR analysis   
PCR analysis was performed according to previously established methods (Lima, B. et 
al. 2003). Negative controls were extracted from whole blood of SLA
dd and SLA
aa 
animals, and positive controls from SLA
cc animals.  The primers used in the PCR 
amplification were: no. 136 (CACTCCCTGAGCTATTTC), no.138 
(GCTCTGGTTGTAGTAGCC), and no.146 (GTGTCCCTTTGTATCTGTGTC).  The 
primer combination 136/138 amplified a 254-base pair (bp) segment of the SLA class I 
gene common to the A, C and D SLA haplotypes; this served as a positive control.  The 
primer pair 136/146 amplified a 199-bp segment of the SLA class I gene unique to the 
SLA
c haplotype (SLA Class I 
c) which was only present on donor cells.  
 
PCR amplification was performed using a PTC-100 programmable Thermal Cycler (MJ 
Research Inc., Watertown, MA) with template denaturation at 94ºC for 15 minutes, and 
45 cycles of melting at 94ºC for 15 seconds, annealing at 53ºC for 15 seconds, and 
extension at 72ºC for 30 seconds, followed by a final extension at 72ºC for ten minutes.  
Southern blot analysis was performed on 136/146 amplification products using an 
internal oligonucleotide probe, no.162 (TACGTCGACGACACGCAGTTCG), specific 
for Class I of SLA
c.  
 
3.9 ASSESSMENT OF ADVERSE EFFECTS 
3.9.1 GvHD 
Animals were monitored for development of GvHD by daily clinical examination, blood 
counts and liver function tests.  Baseline skin and large bowel biopsies were obtained 
prior to conditioning and biopsies were repeated at monthly intervals.  Biopsies were 
also taken at the first sign of possible GvHD.  Biopsy samples were evaluated by a 
board-certified pathologist in blinded fashion.  Severity of GvHD was scored according 
to Glucksberg-Seattle criteria (Glucksberg, H. et al. 1974). 
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3.9.2 Vascularised skin flap viability 
Skin flaps were monitored daily for viability by direct observation of colour, 
temperature and capillary refill. 
 
3.10 MAGNETIC BEAD DEPLETION 
Magnetic bead depletion was used for two purposes: depletion of CD3+ cells from bone 
marrow for preparation of the inoculum for in utero induction of chimerism (Chapter 9), 
and depletion of CD25+ cells from PBMCs for use in in vitro assays. 
 
3.10.1 Depletion of CD3+ cells 
CD3+ cell depletion is described in the bone marrow transplant protocol (Section 3.3.2) 
 
3.10.2 Depletion of CD25+ cells  
PBMCs were coated with the anti-porcine CD25 antibody 231.3B2 (murine IgG1) 
(Denham, S. et al. 1994) for 30 minutes in magnetic activated cell sorting (MACS) 
buffer.  Cells were washed in HBSS three times and incubated with magnetic beads 
coated with rat-anti-mouse IgG1 antibodies (Miltenyi Biotech) for 15 minutes. Cells 
were washed three times and passed through a magnetic separation column to remove 
CD25+ cells (according to the manufacturer’s directions). 
 
3.11 STATISTICAL METHODS 
For parametric distributions student t-test (paired or unpaired as appropriate) was used 
to calculate statistical significance.  For non-parametric distributions Fisher’s exact test 
was used to calculate statistical significance for categorical data and Mann-Whitney U 
for ordinal and continuous data. R2 statistic was used to assess correlation in bivariate 
analyses. 
 
Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were used to 
compare the predictive accuracy of assays in Chapter 6a:   
PPV = True Positive (TP)/ (TP + False Positive (FP)) 
NPV = True Negative (TN)/ (False Negative (FN) + TN) 
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PART A:  
IMMUNOLOGICAL 
REJECTION   58
CHAPTER 4: CONSEQUENCES OF REJECTION 
Recipient tissue damage following musculocutaneous transplant rejection 
 
4.1 INTRODUCTION 
The aim of this study was to assess if recipient tissue damage following composite tissue 
allotransplant failure would limit the function of a second transplant, or even make it 
impossible to perform a retransplant. 
 
In the event of allograft failure the current plan, in many cases, is to replace the allograft 
with another allograft.  This is particularly relevant for allografts such as a face transplant, 
because it is not possible to simply amputate the failed allograft without reconstructing the 
defect.  However, it is not known whether retransplantation would even be possible: 
allograft failure may damage the underlying vessels and tissues to such an extent that it may 
be impossible to repeat the procedure. Even if it is possible to retransplant, there may be 
underlying tissue changes that would restrict the function of a retransplant and make any 
further procedures more complex to perform. 
 
The risk of composite tissue allograft failure is unknown as the clinical composite tissue 
program is still in its infancy.  However, experience from CTA and from organ 
transplantation indicates that both acute and chronic rejection could be important causes of 
graft failure.  There have been acute rejection episodes in the majority of the hand and face 
transplants, with graft failure in some recipients (Kanitakis, J. et al. 2003; Lanzetta, M. et al. 
2007).  In renal transplantation chronic rejection is the cause for loss of the majority of 
grafts after the first year (Magee, J. C. et al. 2007); it is possible that this will be the case for 
composite tissue allotransplantation also.   
 
Previous studies have focused on the consequences of rejection on the donor tissue 
(Buttemeyer, R. et al. 1996; Lee, W. P. et al. 1991).  Damage to the recipient tissues has not 
been formally examined, even though it is of central importance for further reconstruction 
in the event of allograft failure.  This study assesses the damage following composite 
allograft failure by: (1) examining the damage to the recipient blood vessels supplying the 
allograft to assess whether retransplantation is possible, and (2) quantifying the damage to 
the recipient tissue bed and identifying the factors that contribute to that damage. 
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4.2 OVERVIEW OF EXPERIMENT 
This study used 24 donor and 24 recipient animals according to the experimental outline 
(table 4.1).  A further 3 donor and 3 recipient animals were used during the 
development of the immunosuppression regimen in this model and other animals were 
used for the set-up of the immunological assays. 
 
Table 4.1 Outline of recipient tissue damage experimental design 
 
 
Animals were divided into four experimental groups (table 4.1). All recipient animals 
received a musculocutaneous flap allotransplant which was carefully positioned so that the 
transplanted tissue overlaid recipient tissues commonly found adjacent to composite tissue 
allotransplants clinically (i.e. muscle, fascia and cartilage; see section 3.4.1 for more 
details).  
 
Group I was designed to model the clinical situation, in which a CTA is rejected following 
healing in while the recipient is still taking immunosuppression.  This group received a 
composite musculocutaneous allotransplant (WFÆLew) with FK506 immunosuppressive 
cover to permit incorporation of the flap before being tapered to a subtherapeutic level to 
allow rejection.  Initially a single 5mg/kg intramuscular dose of FK506 was used on day 1 
post operatively; this was based on a previous paper by Godha et al (Gohda, T. et al. 2003) 
in a rat limb allotransplantation model, which achieved a median of 49 days survival. 
However, this regimen did not significantly prolong survival in our model (n=3; full skin 
rejection: day 7, 8, 9). Consequently, a tapering immunosuppression regimen was 
developed consisting of intramuscular administration of FK506 at a dose of 2mg/kg daily 
Group  n  Immune Barrier  Tapered FK506 
I 
 
6 Allograft 
(WFÆLew) 
Yes 
II 
 
7 Allograft 
(WFÆLew) 
No 
III 
 
5 Isograft 
(LewÆLew) 
No 
IV 
 
6 Isograft 
(LewÆLew) 
Yes   60
from Day 0-7, 2mg/kg on alternate days from days 8-14, 1mg/kg 2x/week from days 15-21, 
and then 1mg/kg weekly from day 21 onwards.  With this regimen we achieved a median of 
41 days survival (range 37-43 days), compared to a median of 8 days survival (range 7-9 
days) without immunosuppression. The recipient tissues were biopsied at the time of full 
rejection of the allograft.  The definition of full rejection was when the entire surface of the 
skin flap was escharified (see fig 4.1) 
 
 
       
 
      
      
 
 
 
 
Figure 4.1 Group 1 experimental summary 
 
 
The three other groups were designed to delineate the contributions of different 
elements to recipient tissue damage.  
 
Group II received a composite musculocutaneous allotransplant (WFÆLew) without 
immunosuppression to assess the effect of the rejection process on recipient tissues.  
The recipient tissues were biopsied at the time of full rejection of the allograft. One 
animal in group II received a retransplant.  Instead of biopsying the recipient tissues the 
first transplant was carefully removed from the recipient at full rejection, an isogeneic 
musculocutaneous graft was then transplanted.   
 
Group III received a composite musculocutaneous isotransplant (LewÆ Lew) without 
immunosuppression to assess the effect of the healing process on recipient tissues.  The 
recipient tissues were biopsied at time points matched to group II.   
 
Group IV received a composite musculocutaneous isotransplant (LewÆLew) with the 
same tapered FK506 immunosuppressive regimen as group I to assess the influence of 
   
 
FK506 
   
 
Allograft
Biopsies 
Rejection
n=6   61
immunosuppression on the recipient tissues. Biopsies were performed at time points 
matched to group I.   Recipient tissue biopsies were graded for tissue damage based on 
an objective histological grading scale ranging from ‘0’ for undamaged tissue to ‘3’ for 
multifocal necrosis (see table 3.2). 
 
4.3 RESULTS 
4.3.1 Recipient vascular pedicle is viable making retransplantation possible 
 following  rejection 
The recipient element of the vascular pedicle was patent to within 1mm (+/-1mm) of the 
anastomosis in all rejected allografts. However, in some there was macroscopic 
endothelial damage proximal to the level of patency with separation of the vessel 
endothelium from the media up to 4mm proximal to the anastomosis. There was no 
significant difference in damage between groups I and II (allotransplant with FK506 cf. 
allotransplant without FK506; p>0.5).  In two rejected allografts the donor femoral 
vessels were still patent to the origin of the epigastric vessels.  To confirm that the 
recipient vascular pedicle findings are a valid indication that retransplantation is 
possible, a retransplant was performed in one animal from the group II.   The second 
graft healed in promptly, being indistinguishable from the primary allografts at 
equivalent timepoints, and went on to survive long-term (>45 days). 
 
4.3.2  Minimal recipient tissue bed damage following rejection under 
subtherapeutic FK506 cover 
There was mild damage (grade 1; fig 4.2a) to recipient animals receiving an 
allotransplant with FK506 taper (group I) following rejection (see table 4.3).  This 
damage occurred to the bed underlying the donor muscle, which was at an advanced 
stage of rejection. There was no damage to any other recipient tissues adjacent to donor 
muscle or any recipient tissues underlying donor skin.    62
a.                  
            
 
 
 
b. 
- 
 
 
Figure 4.2 Histology of damage to recipient muscle following rejection.  Biopsies taken from the 
recipient tissue bed following full rejection of the allograft. There is only mild damage to the recipient 
muscle (a) in animals receiving an allograft with FK506 that was subsequently tapered to a subtherapeutic 
level allowing rejection (group I). In contrast, there was severe (grade 3) damage to the recipient muscle 
(b) in animals following rejection of an allograft without FK506 (group II) (x25 magnification).   
 
 
Oedema 
Multifocal necrosis 
Mononuclear infiltrate 
(Wavy fibres and loss 
of striations on 
longitudinal sections)   63
 
Key 
* Significantly more severe damage (p<0.05) at that tissue interface than in any other group 
NOTE: Scores represent median grade of recipient tissue damage for that group (see table 3.2 for details 
on grading). 
 
Table 4.2 Scoring of recipient tissue damage 
 
 
4.3.3 Rejection process is the major cause of recipient tissue damage 
Three groups were used to delineate the contribution of different elements to the 
damage to the recipient tissues (see table 3.2 for scoring system and table 4.2 for 
results). There was severe damage (grade 3) to the recipient muscle (fig 4.2b), and 
moderate damage (grade 2) to the recipient skin in animals receiving an allotransplant 
without immunosuppression (group II).  In contrast, there was only mild damage to the 
recipient muscle and mild-to-no damage to the recipient cartilage in animals receiving 
an isotransplant without immunosuppression (group III).  Similarly, there was no 
damage to any recipient tissues in animals receiving an isotransplant with 
immunosuppression (group IV).  
 
The animal that received a second allograft did not undergo repeat biopsies because of 
the potential of inadvertent inclusion of an area damaged from the first biopsies. 
 
Donor Tissue 
 
Donor Muscle  Donor Skin 
Recipient 
Tissue 
Skin  Muscle  Fascia  Muscle  Fascia  Carti-
lage 
Group I 
(Allo; FK506 Taper) 
0 1 0 0 0 0 
Group II 
(Allo; No FK506) 
2* 3*  0  3*  0 0 
Group III 
(Iso; No FK506) 
0 0 0 1 0  0.5 
Group IV 
(Iso, FK506 Taper) 
0 0 0 0 0 0   64
4.3.4 Subtherapeutic immunosuppression prevents recipient tissue damage 
There was significantly more damage to the underlying recipient muscle and overlying 
recipient skin in animals in group II than group I (p<0.05).  Both groups I and II 
received a musculocutaneous allotransplant across the same major immunological 
barrier. The only difference between groups I and II was that group I received 
immunosuppression which was then tapered down to subtherapeutic levels whereas the 
group II received no immunosuppression.   
 
In vitro assays were performed to investigate why immunosuppression was associated 
with less damage to the recipient tissues.  Mixed lymphocyte response in group II at the 
time of rejection revealed normal alloresponsiveness with a stimulation index of 7 (fig 
4.3a).  However, there was no response in group I (fig 4.3b).  Furthermore, antibody 
FACS at the time of rejection revealed over one hundred-fold stronger response in 
group II (fig 4.3c) than in group I (fig 4.3d).   65
 
 
Figure 4.3 In vitro assessment of immune response to donor. There was strong alloreactivity to donor 
at the time of full allograft rejection (a: shaded bar; “@WF”; stimulation Index=7) in a mixed lymphocyte 
response in animals (Lew) receiving an allograft without immunosuppression (group II).  In comparison, 
there was no alloreactivity to donor (b: black bar; “@WF”; stimulation index=1) in animals (Lew) 
receiving an allograft with subtherapeutic FK506 (group I) despite full allograft rejection. Flow cytometry 
analysis of antibody in both groups at the time of allograft rejection demonstrated of anti-donor antibody 
production in both group I (c) and group II (d).  However, titration of the antibody level indicated that 
antibody production was >x100 less in group I compared to group II. 
 
4.4 DISCUSSION 
Composite tissue allotransplantation techniques offer the possibility of reconstructing 
tissue defects for which there are no other good reconstructive solutions.  However, it is 
possible that the composite tissue allograft may fail necessitating its removal. 
Extrapolating from other organ transplant programs, it has been estimated that the risk 
of chronic rejection may be as high as 30-50% at 5 years in composite tissue 
allotransplants (Morris, P. et al. 2007).  In addition, composite tissue allotransplants 
may be at an increased lifetime risk of failure compared to organ transplants because 
they are often performed on young recipients who have an otherwise normal life 
expectancy and no co-pathology.  Although only in a small animal model, this study 
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suggests that in the event of clinical allograft failure, there would be minimal damage to 
the vascular pedicle even after full rejection, making retransplantation possible. 
Furthermore, there was only mild damage to the recipient tissues in the clinically 
relevant subtherapeutic immunosuppression group, suggesting that a second transplant 
would not be limited in form or function by recipient tissue bed damage.  These findings 
have not been reported previously. 
 
4.4.1 Selection of musculocutaneous composite allograft model 
Several orthotopic face transplant and limb transplant models have already been 
described (Lipson, R. A. et al. 1981; Siemionow, M. Z. et al. 2005; Unal, S. et al. 2005). 
These models are useful for studying functional recovery, but do not have particular 
utility for studying recipient tissue damage. The model used here has two advantages 
over previously described models. Firstly, it allows for semi-independent placement of 
the skin and muscle components.  This makes it possible to individually assess the 
effect of each component on the recipient tissues.  Secondly, both the skin and muscle 
elements are a significant size, facilitating a large amount of each type of donor tissue to 
be in contact with recipient tissues.  A limitation of this model is that the interfaces 
between donor and recipient bone, and donor and recipient nerve, were not included.  
However, it is likely that damage to recipient bone would have been minimal as in 
fascia and cartilage, which are similarly robust and quiescent tissues.  Furthermore, in 
most cases, any damage to the recipient nerve adjacent to the first anastomosis could be 
excised, and a fresh undamaged stump exposed for anastomosis to the second 
transplant. 
 
4.4.2 Retransplantation is possible with no likely functional limitation due to 
recipient damage 
In this model there was little damage to the recipient vascular pedicle supplying the 
allograft, with retransplantation possible even after full allograft rejection. Furthermore, 
there was minimal damage to recipient tissues in animals receiving an allotransplant 
with immunosuppression that is subsequently tapered allowing rejection (group I), 
indicating that the second transplant would not be limited in function by damage to the 
adjacent recipient tissues.  
 
This is a particularly stringent model, with full rejection occurring before the tissues are 
examined and retransplantation is attempted.  It is likely that in a clinical scenario   67
retransplantation may occur well before the level of rejection seen in this model is 
reached, because chronic rejection would cause functional allograft failure long before 
full rejection occurred. Consequently, at the time of retransplantation in patients there 
may be less damage to the recipient vascular pedicle and tissues than observed in this 
model. 
 
A limitation of this model is that there may be different mechanisms involved in the 
rejection process of clinical composite tissue allotransplant failure. Graft loss in clinical 
composite tissue allotransplantation is likely to be largely due to chronic rejection, 
whereas in this model, rejection occurs due to tapering of immunosuppression a 
subtherapeutic level. These different rejection processes may in turn influence the level 
of recipient tissue damage.   However, similar findings to this model in the organ 
transplantation program regarding vascular pedicle damage, support the relevance of 
this model.  In organ transplants where repeat transplantation has to be performed on to 
the same vascular pedicle (e.g. heart and lung), damage to the pedicle has not been a 
significant limitation on repeat transplantation (Magee, J. C. et al. 2007). Recipient 
tissue damage is less important in organ transplants as this has little impact on their 
function, and consequently, to our knowledge, has not been reported on.   
 
Even in the event of successful CTA retransplantation there may be an increased 
likelihood of rejection of the second transplant.  This has been the case in repeat kidney, 
liver, heart and lung transplants (Magee, J. C. et al. 2007).  The cause of this is thought 
to be heterologous immunological memory (Adams, A. B. et al. 2003; Koyama, I. et al. 
2007): clones of memory cells to the first allograft are activated by the replacement 
allograft due to antigenic similarity between the two allografts.  In kidney 
transplantation, some have investigated delaying transplantation of the replacement 
allograft following removal of the failed allograft in the hope that this would allow time 
for desensitisation of the recipient.  This actually results in a spike in panel reactive 
antibodies (Smak Gregoor, P. J. et al. 2001) following removal of a failed renal 
transplant, indicating that the renal allograft may be performing the useful function of 
acting like a sponge for circulating antibody due to sensitisation.   However, the 
significance of this is not clear: some of the worst outcomes from renal retransplantation 
have been in patients that had their first failed renal allograft removed before 
retransplantation (Abouljoud, M. S. et al. 1995), while others have reported no   68
difference in outcomes with raised circulating antibodies (Douzdjian, V. et al. 1996; 
Sumrani, N. et al. 1992). 
 
Rejection of a second CTA transplant may also cause more damage than rejection of the 
first transplant due to a more intense rejection response caused by the heterologous 
immunological memory.  The increased damage could have a significant impact on any 
further transplants.  This was not examined in this study and is an avenue for future 
research. 
 
4.4.3 Subtherapeutic immunosuppression protects against recipient tissue damage 
despite not preventing donor tissue rejection 
In this model, the major cause of damage to the recipient tissues appeared to be the 
rejection process.  The healing process caused minor damage, with immunosuppression 
having a protective effect.  Both groups I and II received allografts across a MHC 
barrier; the only difference between the groups was that the group I received FK506, 
which was tapered down to a subtherapeutic level allowing rejection after the allograft 
had healed in, whereas group II did not receive immunosuppression. These groups 
differed in the severity of recipient muscle and skin damage due to the rejection process: 
there was severe damage to recipient muscle and skin in group II with only mild 
damage to the muscle and no damage to the skin in group I.  This difference between 
the two groups was due to the subtherapeutic immunosuppression, which had a 
protective effect on group I.  
 
The in vitro data suggests a reason for this protective effect.  The MLR and flow 
cytometry analysis of antibody production indicated that the strength of the immune 
response in animals on subtherapeutic immunosuppression (group I), although present, 
was greatly diminished in comparison to animals not receiving immunosuppression 
(group II).  It is unclear whether this protective effect is specific to the type of 
immunosuppression used or would be present whichever immunosuppressant is used.  
This finding may be important for clinical CTA as all patients are on some form of 
immunosuppression. 
 
4.5 CONCLUSIONS 
In conclusion, in the event of an allograft failure, these results suggest that the recipient 
vasculature would be intact making retransplantation possible.  Furthermore, the   69
recipient tissue bed would have minimal damage meaning that the retransplant would 
not be limited in form or function.  These findings indicate it is realistic to plan to 
perform a retransplant in the event of allograft failure. However, it is still possible that 
sensitisation to the first transplant may increase the risk of rejection of the second 
transplant.  This could pose a significant problem, as restricting the donor pool to an 
immunological subtype would make it even more difficult to find donors.   
 
The finding that retransplantation may be a realistic possibility, in the event of allograft 
failure, is encouraging.  However, it would be better if the allograft did not fail in the 
first instance.  Skin has been the tissue most susceptible to rejection in composite tissue 
allotransplants so far.  A better understanding of the mechanism of skin rejection may 
help to guide future research to avoid rejection episodes.  This will be the focus of the 
next chapter.   70
CHAPTER 5: MECHANISM OF SKIN REJECTION 
 In vivo observations of cell trafficking in allotransplanted vascularised skin flaps 
and conventional skin grafts 
 
5.1 INTRODUCTION 
The aim of this study is to objectively assess in vivo if there is a difference in the 
immune response to conventional skin grafts and skin within composite tissue 
transplants.  In addition, this study aims to identify unique characteristics of the immune 
response to skin within composite tissue transplants that may be useful for directing the 
development of approaches to overcome composite tissue allotransplant rejection.  The 
role of the vasculature, cell types involved, and the target of the immune response are 
examined. 
Much of the understanding of skin rejection has been derived from histological studies 
examining the mechanism of rejection of conventional skin grafts (CSG).  However, 
both the method of observation and the type of transplant used, limit the application of 
these findings to skin within composite tissue transplants (SCTT).  The use of 
histological specimens to examine the rejection mechanism is restricted by artefact from 
fixation techniques, and the frequency that biopsies can be taken.  Consequently, only 
subjective comparisons can be made as there are not enough observations to reach 
statistical significance.  In addition, it is possible that there are differences between CSG 
and SCTT in their interaction with the immune system, making observations of CSG 
not directly applicable to SCTT.  For example SCTT differ from CSG in the timing of 
vascularisation. The blood vessels in SCTT are anastomosed directly to recipient vessels 
resulting in immediate restoration of a blood supply to the skin.  In contrast, CSG are 
not vascularised primarily, and survive initially by absorbing oxygen and nutrients from 
plasma in the graft bed.  This is likely to have effects on the speed and route of 
trafficking of immune cells involved in the rejection response to and from the skin. 
This study assessed in vivo the immune response to allotransplanted CSG and SCTT in 
a rat model using confocal microscopy. 
5.2 OVERVIEW OF EXPERIMENT 
The experiment is summarized in figure 5.1. In vivo confocal microscopy was used to 
observe cell trafficking into and targeting within the skin.  This non-invasive in vivo 
technique avoids artefacts associated with histological fixation of biopsies, and   71
facilitates attainment of sufficient data at multiple timepoints and locations to make 
statistically significant quantitative observations.  PCR was used to track cellular efflux 
from allografts.  
 
 
 
 
 
 
 
 
 
Figure 5.1 Experimental overview   
 
 
Skin was transplanted from non-fluorescent donor rats to recipient rats that were 
transgenic for GFP so that all cells within the animal fluoresced.  This allowed for 
selective imaging of fluorescent recipient cells infiltrating the non-fluorescent 
transplanted skin using confocal microscopy.  A total of 18 rats were used in this study.  
Donor animals (n=9) were Lewis (LEW; RT-1
l) and Wistar Furth (WF; RT-1
u) rats.   
Recipient animals (n=9) were Lewis GFP transgenic rats.   
 
To compare SCTT and CSG transplanted across isogeneic and allogeneic barriers, 
animals were divided into four experimental groups (see table 5.1).   
 
Table 5.1 Experimental groups 
 
 
GROUP  No. of rats  No. of images 
acquired 
SCTT/CSG  Transplant Barrier 
 I  3 1012  SCTT  LewÆ Lew-GFP 
II  2 962  SCTT  WFÆ Lew-GFP 
 III  2 717  CSG  LewÆ Lew-GFP 
 IV  2 732  CSG  WFÆ Lew-GFP 
Skin 
graft/flap 
(Allo/Iso) 
Confocal 
Skin 
graft/flap 
biopsy 
Endpoint 
u-GFP   72
Group 1 (n=3) received a SCTT across an isogeneic barrier (LewÆLew-GFP).  Group 2 
(n=2) received a SCTT across a full MHC mismatched allogeneic barrier (WFÆLew-
GFP).  Group 3 (n=2) received a CSG across an isogeneic barrier (LewÆLew-GFP). 
Group 4 (n=2) received a CSG across a full MHC mismatched barrier (WFÆLew-
GFP).  A key strength of this study was the use of non-invasive imaging.  This allowed 
for multiple images to be obtained from the same animal, controlling for variability 
between animals.  Each animal was imaged in multiple areas and depths in each 
imaging session, with multiple imaging sessions over consecutive days. To obtain an 
equivalent data-set with invasive imaging techniques (e.g. biopsies and histology), 50-
100 times more animals would be required, introducing a significant source of 
variability into the experiment. 
 
Images were obtained at multiple timepoints after allotransplantation.  Evans Blue Dye 
(detectable on confocal microscopy at a different wavelength to GFP) was injected 
intravascularly into some animals to visualize the blood vessels within the flap.  
 
5.3 RESULTS 
The influx of cells into transplanted skin, the target of the infiltrating cells and the efflux 
of donor cells was examined.   73
 
5.3.1 Influx of infiltrating cells 
 
 
 
Figure 5.2 Representative examples of recipient cell influx into skin grafts and skin flaps 
transplanted across isogeneic and allogeneic barriers   
 
 
5.3.1.1 More recipient cells infiltrate SCTT than CSG due to immediate 
vascularisation  
There were up to twice as many cells infiltrating the centre of each isogeneic and 
allogeneic SCTT than the respective isogeneic (figs 5.2a cf.5.2c; p<0.03) and allogeneic 
(5.2b cf.5.2d; p<0.01) CSG at each timepoint. 
 
To investigate why there was more cellular influx in SCTT compared to CSG, the influx 
at the centre and edge of each CSG and SCTT were compared. CSG, in which there is 
no blood supply initially, showed no significant difference in recipient cell numbers at 
the centre compared to the edge at all timepoints (figs. 5.2a & 5.2b; p<0.1). In contrast, 
all SCTT had significantly more infiltrating recipient cells at the centre (solid line) than 
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the edge (dotted line) from day 1 onwards (figs 5.2c & 5.2d; p<0.05) indicating that the 
vasculature (which supplies the centre more richly than the edge) was a major route for 
recipient cellular influx. 
 
5.3.1.2 There is greater cellular trafficking into allografts than isografts 
Greater numbers of recipient cells infiltrated allografts compared to isografts.  In SCTT 
there were greater number of recipient cells in all allotransplants compared to 
isotransplants from two days after transplantation (p<0.01).  In contrast, in CSG there 
were only greater numbers of recipient cells in allotransplants compared to 
isotransplants by three days after transplantation (p<0.02; fig 5.2).   
  a.              b. 
 
 
 
 
 
 
 
   
Figure 5.3 Endothelial class II expression on vasculature of rejecting skin.  MHC Class II expression 
was observed on immunohistochemical staining of biopsies taken from allogeneic SCTT taken 4 days 
after transplantation (a), but not on isogeneic SCTT (b) (x40 magnification). 
 
 
5.3.1.3 MHC II was only expressed on rejecting SCTT dermal vascular endothelium 
Endothelial MHC class II expression was examined to investigate reasons for greater 
infiltrate in allogeneic SCTT compared to isogeneic SCTT.  Staining revealed Class II 
MHC was expressed on the endothelium of all allogeneic SCTT but not on isogeneic 
SCTT or CSG four days after transplantation (fig 5.3).    
 
The immune cell types infiltrating the graft were characterised by immunohistochemical 
staining of biopsy samples.The cells infiltrating isogeneic and allogeneic CSG and 
SCTT included MHC class II positive and CD8 positive lymphocytes (fig 5.4 a & b). 
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Figure 5.4 Recipient cell types within transplanted skin.  Infiltrating cells included both CD8+ (a) and 
Class II positive (b) lymphocytes, which were identified in allogeneic and isogeneic CSG and SCTT on 
immunohistochemical staining (x40 magnification).  Infiltrating recipient cells included dendritic cells (# 
- cell body; * - dendrite), which were observable on confocal microscopy in allogeneic flaps from two 
days after transplantation (c), but not observable at any timepoint in CSG (d).  
 
 
 5.3.1.4 Recipient dendritic cells are present in allogeneic SCTT, but not allogeneic 
CSG  
Recipient cells infiltrating the transplanted skin could also be identified and 
characterised in vivo with confocal microscopy by virtue of their fluorescence.  
Recipient dendritic cells (rDCs) were observed in the dermis in allogeneic SCTT two 
days after transplantation (fig 5.4a), but not in allogeneic CSG at any timepoint (fig 
c.  d. 
 
CD8+
 
Cl 2+
 
a. b. 
*
*
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5.4b).   In contrast, rDCs were observable in both isogeneic SCTT from seven days after 
transplantation, and isogeneic CSG from eight days after transplantation
2.  
 
5.3.2 Target of infiltrating cells 
5.3.2.1 Infiltrating cells cluster around vessels and hair follicles in the superficial 
dermis of allotransplants 
Rat epidermal thickness was determined to be ~40µm from measurements of biopsy 
samples.  In vivo imaging revealed minimal cellular infiltrate within 50µm of the 
surface of the skin in all animals at all timepoints compared to the dermis (p<0.01). 
 
Hair follicles and blood vessels were identified in vivo within the skin using confocal 
microscopy. Hair follicles could be localized by auto-fluorescence of the hair within the 
follicle, and blood vessels could be identified by injection of Evans blue dye.   
 
SCTT were examined four days after transplantation for evidence of clustering of 
infiltrating cells.  There was clustering of infiltrating cells around both hair follicles (fig 
5a; p<0.01) and blood vessels (fig 5b; p<0.01) in allogeneic SCTT, but no significant 
clustering around either structure in isogeneic SCTT (p>0.1).  
 
There was clustering of infiltrating cells around hair follicles in allogeneic CSG 
(p<0.01; fig 5c), but no significant clustering in isogeneic CSG (p>0.1).  Only scattered 
blood vessels were visible in skin grafts at four days after transplantation following 
injection of Evans blue dye.  Confirmation that sufficient dye had been injected was 
provided by imaging blood vessels in the ear (fig 5d).  Due to the limited number of 
blood vessels visible in CSG, clustering of infiltrating cells was only examined around 
hair follicles.   
 
 
 
                                                 
2 There is no immunohistochemical stain that is specific for dendritic cells.  A standard method to 
distinguish DCs by their unique morphology (from which they derive their name) was used to identify 
DC.   77
 
Figure 5.5 Clustering of infiltrating cells observed around blood vessels and hair follicles in 
allogeneic skin transplants.  Clustering of infiltrating cells was observed around blood vessels (a; 
vessels coloured red, arrows indicating perivascular cell clustering; p<0.01) and hair follicles (b; arrows 
indicating cells pallisading around hair base; * indicating a hair ; p<0.01) in allogeneic SCTT, and around 
hair follicles in allogeneic CSG (c; arrows indicating cells pallisading around hair base; p<0.01), but not 
in isogeneic SCTT (p>0.1) and CSG (p>0.1), 4 days after transplantation. Adequate Evans blue dye 
injection to image CSG vessels was confirmed by good vessel detection in the ear (d; vessels coloured 
red). However, few vessels were visible in CSG 4 days after transplantation, preventing assessment of 
cell clustering around CSG vessels.  
 
 
5.3.3 Efflux of donor cells 
The efflux of donor cells from the skin to recipient tissues was assessed by PCR 
analysis of characteristic donor microsatellite repeats at day 4 following transplantation.  
a.  b. 
 
c.
  a
d.
a
** 
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There was no evidence of donor cells in the bone marrow, thymus, draining lymph 
nodes, spleen or peripheral blood in recipients of either allogeneic CSG or SCTT. 
 
5.4 DISCUSSION 
Much of our knowledge about the mechanism of skin rejection has been gathered from 
in vitro observations of fixed histological specimens taken from rejecting CSG.  
However, this may not accurately represent the in vivo clinical situation for SCTT. This 
study indicates there are significant differences between SCTT rejection and CSG 
rejection, limiting the relevance of much of the historical data on skin graft rejection 
when applied to composite tissue allotransplantation.  Furthermore, using novel in vivo 
techniques, this study identifies characteristics of the immune response to skin not 
previously described, which may be useful in directing future approaches to overcoming 
skin rejection.  
 
5.4.1 Influx includes the vascular route, and is earlier and more intense in skin 
flaps compared to skin grafts 
This study indicates that, in contrast to CSG, the vascular route of cellular influx is 
important for primarily vascularised SCTT, accounting for up to half of the recipient 
cells found within the skin over the first four days after transplantation.  Consequently 
there are significantly more infiltrating cells within allogeneic SCTT than CSG.  
Furthermore, there was an earlier observable rejection response with increased cellular 
infiltration of allogeneic SCTT from day two post-transplantation compared to day three 
for CSG.   
 
The earlier, more intense rejection response seen in SCTT compared to CSG at first 
seems to contrast with previous reports that allogeneic primarily vascularised skin 
transplants may have a slight survival advantage over CSG (Bushell, A. et al. 1995; 
Steinmuller, D. 1998).  One explanation may be that many of the infiltrating cells in 
SCTT are not involved in the rejection response.  This is supported by the observation 
of large numbers of cells infiltrating isogeneic SCTT, which are not involved in 
rejection.  Additionally, SCTT may be more resistant to the effects of rejection than 
CSG due to SCTT having more extensive vasculature initially. This possibility is 
supported by the observations that the rejection response in CSG is primarily due to 
infarction of the microvasculature (Dvorak, H. F. et al. 1979), whereas vessel infarction   79
has only been seen in cases of severe rejection in human composite tissue 
allotransplants (Cendales, L. C. et al. 2006). 
 
5.4.2 MHC class II was expressed only on SCTT, not CSG dermal vascular 
endothelium 
MHC class II was expressed only on the dermal vascular endothelium of SCTT, not 
CSG.  This difference may be a function of the later vascularisation of CSG compared 
to SCTT.  
 
This is the first time that MHC class II has been observed on endothelium in rat dermis.  
However, it is consistent with previous studies indicating that rat endothelium does not 
express MHC class II constitutively (Choo, J. K. et al. 1997), but expression can be 
induced in retina, brain, liver, kidney (Ustinov, J. et al. 1994; Wang, Y. et al. 1995) and 
on heart allotransplants (Forbes, R. D. et al. 1991).  
 
It is possible that the induced expression of MHC class II observed on the endothelium 
during rejection of allogeneic SCTT is a reason for more cellular infiltrate in allogeneic 
SCTT compared to isogeneic SCTT.  This is supported by the observation that human 
dermal endothelial cells can present antigen for effector T cells homing to skin (Pober, 
J. S. et al. 2001).   
 
5.4.3 Presence of rDCs in SCTT, but not CSG 
A major difference between allogeneic SCTT and CSG was that rDCs were observed by 
day 2 in SCTT but not at any timepoint in allogeneic CSG.   This has not been 
previously reported.  It is possible that the early presence of rDC in rejecting SCTT may 
be able to be exploited to achieve skin tolerance in SCTT.  In murine bone marrow 
transplant tolerance induction models recipient dendritic cells have been used to achieve 
skin tolerance (Beriou, G. et al. 2005), whereas only prolonged skin survival has been 
achieved with donor dendritic cells (Markees, T. G. et al. 1999), indicating that recipient 
dendritic cells can also have a crucial role in preventing the rejection process.    
 
5.4.4 The target of the rejection response is the vasculature and adnexae 
There was clustering of infiltrating cells in allogeneic transplants around vasculature 
and hair follicles, but not the epidermis.  Previous explanations for the susceptibility of 
skin to reject have often focused on skin specific antigens. Skin specific antigens have   80
been described in mouse allotransplantation (Boyse, E. A. et al. 1968) and rat to mouse 
xenotransplantation (Silverman, M. S. et al. 1962) models.  However, skin specific 
antigens have only been identified on epidermal cells in the skin, not around adnexal 
structures or blood vessels in the dermis.   The observation of no epidermal clustering 
suggests that skin specific antigens may not be a complete explanation for skin’s 
susceptibility to rejection.  The observation of statistically significant clustering around 
hair follicles and blood vessels also objectively confirms previous subjective 
observations that skin rejection may be focused in the superficial dermis, around 
adnexal glands and the vasculature (Cendales, L. C. et al. 2006; Bhan, A. K. et al. 1982; 
Dvorak, H. F. et al. 1980).    
 
5.4.5 Donor immune cell efflux is below the limits of detection using microsatellite 
repeat PCR   
No efflux of donor cells was detected in the lymph node, spleen, bone marrow, thymus 
or peripheral blood in this study with an assay sensitivity of 1% donor chimerism. The 
inability to detect donor chimerism is in line with previous studies.  Ozmen could not 
detect donor chimerism in the peripheral blood (sensitivity 0.5%) in rats receiving an 
SCTT across a MHC barrier without treatment (Ozmen, S. et al. 2006). Therefore, it is 
very likely that there was low-level efflux of donor cells into the recipient, but the 
resultant level of donor chimerism was below the level of detection.   
 
Donor chimerism has been at detectable levels in composite tissue allotransplantation 
models incorporating immunosuppression. In a hemifacial allotransplant chronic 
immunosuppression model Siemionow demonstrated chimerism with dendritic cell 
morphology donor-derived cells in the lymph nodes and spleen of the recipient 
(Siemionow, M. et al. 2005).  
 
It is likely that recipient cells as well as donor cells will efflux from the composite tissue 
allotransplant.  Effluxing donor dendritic cells (dDCs) and rDCs are likely to have 
different functions, possibly due to their activation status (Fiorina, P. et al. 2007).  
Previous work indicates that the initial efflux of dDC from CSG probably occurs via the 
lymphatics (Larsen, C. P. et al. 1990b).  Once in the lymphatics dDCs have been shown 
to migrate to the spleen (Fossum, S. 1988) and lymph nodes (Austyn, J. M. et al. 1988) 
leading to sensitisation and rejection.  Intravascular efflux from CSG occurs only later, 
as demonstrated by the prolonged survival of secondarily vascularised alymphatic CSG   81
(Barker, C. F. et al. 1968; Tilney, N. L. et al. 1971).   There is little direct data 
pertaining to immune cell efflux from primarily vascularised SCTT.  In murine 
primarily vascularised heart allografts, both dDCs and rDCs preferentially migrate via 
the bloodstream to the spleen and regional lymph nodes stimulating sensitisation (Saiki, 
T. et al. 2001).    
 
5.5 CONCLUSIONS 
In conclusion, this study identifies differences in cell trafficking into and within CSG in 
comparison to SCTT.  In contrast to CSG, the vascular route is important for initial 
cellular influx, there is trafficking in of rDCs, and there is an earlier and more intense 
cellular infiltrate seen in SCTT.  In addition, there is an early presence of rDC in 
rejecting SCTT but not CSG.  Finally, the rejection response has dermal targets rather 
than the epidermis as has been often assumed previously.  These observations challenge 
previous dictums that have directed skin transplant rejection research, and also give 
direction to future research into ways to avoid skin rejection in CTA. 
 
This study, and the previous study (Chapter 4), analysed the mechanism and 
consequences of skin rejection using rat models.   Small animal models are very useful 
in examining issues related to rejection.  However, as outlined in Chapter 2, there is 
difficultly in translating success in achieving skin allotransplant survival in small animal 
studies to the large animal.  Consequently, in Part B, attempts to achieve skin survival 
across a MHC barrier will be examined in a large animal model.   82
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CHAPTER 6 
 
The aim of this study is develop a hypothesis of how to achieve skin tolerance in a large 
animal model.  In Chapter 6a the more extensive experience with organ 
allotransplantation is examined to identify variables that predict subsequent organ 
allograft tolerance; then in Chapter 6b these predictors of tolerance induction are used to 
interpret the results from a smaller series of animals that previously underwent 
chimerism induction with CTA with identification of reasons why tolerance to skin was 
not achieved.  On the basis of these findings a hypothesis of how to achieve skin 
tolerance is formed. 
 
CHAPTER 6A:  PREDICTORS OF TOLERANCE IN ORGAN 
TRANSPLANTATION 
 
6.1 INTRODUCTION 
Based on Ray Owen’s initial observations that naturally occurring chimeric twin calves 
were tolerant to reciprocal skin grafts (Owen, R. D. 1945) and the early work of other 
researchers (Billingham, R. E. et al. 1953), it was thought that ‘chimerism leads to 
transplant tolerance’.  More recently this simple paradigm has been challenged.  
Although full haematocytic chimerism always leads to tolerance (Sayegh, M. H. et al. 
1991), the relationship between chimerism and tolerance in mixed chimeras has been 
variable, with reported cases of long-lasting T cell chimerism being possible without 
tolerance (Umemura, A. et al. 2001), and stable tolerance achievable after only transient 
chimerism (Buhler, L. H. et al. 2002).   
 
Some, in the most extreme hypothesis relating to this phenomena, have proposed low-
level chimerism (‘microchimerism’) as the basis of all cases of long-term organ 
allograft survival, including those induced by chronic immunosuppression (Bonilla, W. 
V. et al. 2006; Starzl, T. E. et al. 1992; Starzl, T. E. 2004).  However, this relationship 
has been disputed (Elwood, E. T. et al. 1997; Fuchimoto, Y. et al. 1999b; Wood, K. et 
al. 1996).    
 
Previously Gleit et al. observed variability in the association of peripheral blood 
chimerism and tolerance following non-myeloablative chimerism induction protocols in   84
the MGH miniature swine pre-clinical model of haematopoietic cell transplantation 
(Gleit, Z. L. et al. 2002b).   
 
This study aims to determine whether this variability of tolerance induction in the 
presence of peripheral blood chimerism might be the result of differences between 
engraftment status of haematopoietic cells in tolerant versus non-tolerant animals.  For 
this purpose, the possible relationship between donor organ acceptance and the presence 
of donor-derived cells in the bone marrow, thymus and peripheral blood at the time of 
solid organ transplantation is examined in a series of haematopoietic cell transplant 
(HCT) recipients. 
   
6.2 OVERVIEW OF EXPERIMENT 
This is a combined retrospective and prospective analysis of animals from different 
protocols all directed toward induction of tolerance through mixed chimerism.  All 
miniature swine from the Transplant Biology Research Center (TBRC) that had 
received HCT between 1998 and 2004 and then a delayed organ transplant were 
analysed.  Animals were excluded if it was not possible to assess organ transplant 
tolerance due to technical problems, early animal death, or copathology.  
 
Peripheral blood and bone marrow chimerism, as well as in vivo and in vitro (by CML 
and MLR) assessments of tolerance, were all assessed prospectively by the particular 
researcher using that animal.  Thymic microchimerism, antibody cytotoxicity, collation 
and analysis of all data were performed retrospectively as part of this study. 
 
Engraftment can be strictly defined as the long-term presence of donor haematopoietic 
stem cells in the bone marrow.  However, there are not any specific markers for stem 
cells in pigs yet.  Mouse data indicates that detection of donor bone marrow colony 
forming units (BM-CFUs) longer than 12 weeks after haematopoietic cell 
transplantation (HCT) correlates with engraftment of HSCs (Christensen, J. L. et al. 
2001).  Consequently, presence of donor-derived bone marrow colony forming units 
(BM-CFUs; detected by PCR analysis) greater than 12 weeks after PBMC 
transplantation, was used to indicate the presence of haematopoietic stem cells. 
 
Chimerism was assessed in the peripheral blood, and in the bone marrow progenitors 
and thymus.  Peripheral blood chimerism was assessed in the lymphocyte, monocyte   85
and granulocyte lineages individually by FACS analysis.  Bone marrow progenitor 
chimerism was assessed by detection of donor-derived BM-CFUs, as described above.  
Thymic macrochimerism was assessed by FACS, and microchimerism by PCR with 
Southern Blot confirmation. 
 
Tolerance was assessed in vivo by acceptance or rejection of an organ allograft, and in 
vitro by CML, MLR and antibody cytotoxicity assays.  Organ transplants were 
performed from the PBMC donor (n=15) or donor-matched animal (n=7).  All animals 
received a kidney transplant, except for animal 14980, which received a heterotopic 
heart transplant.  The surgical procedures were performed, without immunosuppression, 
at least one month after cessation of cyclosporine.  
 
6.3 RESULTS  
Twenty-two animals that had undergone the mixed chimerism protocol and then 
received a MHC-mismatched organ allograft were analysed (10 retrospectively and 12 
prospectively) (table 1).  Four animals were excluded because allograft tolerance was 
indeterminate due to early death (animals 13810, 14224),  technical failure (14529), and 
an unrecognized lymphocoele obstructing the ureter (animal 13635
3). 
 
6.3.1 Presence of donor-derived bone marrow CFUs at the time of organ 
transplantation correlate with tolerance 
Presence of donor-derived progenitor cells in the bone marrow at the time of organ 
transplant was determined by measuring CFUs in 14 animals.  This finding correlated 
precisely with organ tolerance (p<0.001) as all animals with detectable donor-derived 
BM-CFUs at 90 days or more after HCT accepted delayed donor matched organ 
allografts (n= 9; PPV = 100%).   In one animal (15401) CFUs became undetectable by 
day 512 despite being detectable at day 90 after HCT.  All animals with undetectable 
donor-derived BM-CFUs at 90 days after HCT (or the nearest timepoint after this) 
rejected their organ (n= 8; NPV = 100%) (table 6.1).  
 
                                                 
3 This animal was previously reported as rejecting its organ (Gleit, Z. L. et al. 2002a; Gleit, Z. L. et al. 
2002b)   86
6.3.2 Presence of thymic chimerism at the time of organ transplantation correlates 
with tolerance 
Thymic microchimerism (detectable by PCR/Southern Blot; n=15) was assessed as well 
as macrochimerism (detectable by FACS; n=19) so that any cases with low-level thymic 
chimerism would still be identified.  Thymic chimerism (micro- or macro-) at the time 
of organ transplantation correlated precisely with allograft acceptance (p<0.001; 
n=9;PPV=100%). Only one animal (14040) had detectable thymic microchimerism 
without macrochimerism
4.  All animals with undetectable thymic microchimerism 
rejected their allograft (n=13; NPV = 100%) (table 6.1).  
                                                 
4 Animal 14040 had thymic microchimerism without macrochimerism 49 days before kidney 
transplantation (61 days after PBMC transplant); it was not possible to ascertain the status of thymic 
microchimerism at the time of transplantation from the samples obtained.   87
 
Key:   
Bold animal no.  Prospectively analysed 
a  Day of assay in relation to organ transplantation (transplantation day= 0; pre-transplantation= Pre Tx) 
b  Peripheral blood chimerism: recorded as Multilineage (‘M’), Lymphoid (‘L’) or Not detectable (‘N’) 
c  In vitro responses: recorded as responsive (‘Y’), hyporesponsive (‘H’) or unresponsive (‘N’)    
d  ‘SB’=Southern Blot    Animal number prefix = Induction Protocol (see table 3.1)     
Ø  Thymic biopsy at kidney transplant         
*  Pretransplant DLI  
Є  Value not ascertained at the relevant time point 
  
Table 6.1 Summary of chimerism induction and delayed organ transplant animals 
Chimerism In  Vitro  Response
c 
Thymus  BM-CFU 
(Day
a) 
Ab Cytotoxicity 
 
Animal 
Number 
 
 
 
 
SLA 
Barrier 
(Donor-
Host) 
Days 
between 
PBMCs 
and  
Organ 
Protocol 
Periph 
Blood
b 
(Day
a)   FACS 
(Day
a) 
PCR/SB
d 
(Day
a) 
 
MLR 
(Day
a)  
CML 
 (Day
a) 
 
 
Post 
PBMC 
 
Post 
Organ 
 
 
Accepted Organ 
              
A13101
Ø AC-AD  190  A  M 
(0) 
Y 
(0) 
Y 
 (0) 
Y 
(519) 
N 
 (-110) 
N  
(-50) 
N N 
B 13272  AC-AD  156  B  M 
(6) 
Y 
(57) 
Y 
 (7) 
Y 
(875) 
N  
(53) 
N 
 (53) 
N N 
A13476
 Ø CD-AD  98  A  L 
(7) 
Y 
(0) 
Y 
 (0) 
Y  
(482) 
N 
(-28) 
N 
(-28) 
N N 
C14225
 Ø AC-AD  85  C  L 
(180) 
Y  
(21) 
Є  Y 
 (180) 
N 
 (-23) 
N 
 (-23) 
N N 
F14980*
     AC-AD  693  F  M 
(87) 
Y 
(104) 
Є  Y 
(608) 
N 
(3) 
N 
(3) 
N N 
E15401  AC-AD 212  E  M 
(110) 
Y 
 (301) 
Y 
 (184) 
Y 
(90) 
N 
 (0) 
N 
(0) 
N N 
F15403  AC-AD 212  F  M 
(110) 
Y 
(186) 
Y 
(186) 
Y 
(90) 
N 
(0) 
N 
(0) 
N N 
F15641  AC-AD 203  F  L 
 (86) 
Y 
 (-107) 
Y 
 (44) 
Y  
(0) 
N  
(155) 
N 
(144) 
N N 
                
B14040 AC-AD  115  B  N   
(-80) 
N 
(-49) 
(Y) 
(-49) 
Y 
(0) 
Y 
(0) 
Y→H 
(0)  (32) 
Y  Є 
 
Rejected Organ 
              
B13583
 Ø CC-AD  119  B  N 
 (-109) 
N 
(0) 
N 
 (0) 
Є Y   
(Pre Tx) 
Y  
(Pre Tx) 
N  Є 
B13584
 Ø CC-AD  119  B  N 
 (-109) 
N 
(0) 
N 
 (0) 
Є Y   
(Pre Tx) 
Y 
 (Pre Tx) 
Y  Є 
D14041*
 Ø AC-AD  110  D  L 
(2) 
N 
(0) 
Є  Є  Є  Є Y  Y 
C14143
 Ø CC-DD  131  D  L 
(0) 
N  
(0) 
N  
(0) 
N  
(0) 
Є H 
 (0) 
Y Y 
A14145
 Ø CC-DD  131  B  N 
(-118) 
N 
(-98) 
N  
(0) 
Є  Є H 
 (-54) 
Y  Є 
C14682
 Ø   CC-DD  203  A  N 
(-141) 
N 
 (-169) 
N  
(-132) 
N  
(-169) 
Y 
 (-132) 
Y 
 (-132) 
Y  Є 
C14683
    CC-DD 204  C  N 
(-143) 
N  
(-69) 
N  
(-33) 
N 
 (0) 
Y 
 (-33) 
Y 
 (-33) 
N  Є 
C14805
    AC-AD 104  C  N 
 (-1) 
N 
(-34) 
Є  N 
 (-34) 
Y 
 (-49) 
Y 
 (-49) 
Є  Є 
C14833
   AC-AA 204  C  L 
(39) 
Є  Є  N 
 (-141) 
Є Y 
 (-99) 
Є  Є 
C14917
 Ø   AC-AA  55  C  L 
(1) 
Є  Є  Є  Є N 
(0) 
N  Є 
E15638  AC-AD 203  E  L 
(15) 
Є  Є  N 
 (-31) 
Є N 
(-24) 
N Y 
E15704  AC-AD 125  E  N 
 (0) 
N  
(-36) 
N  
(-30) 
N 
 (0) 
Y  
(0) 
H 
 (0) 
N Y 
F15770  AC-AD 125  F  N 
(-46) 
N  
(-66) 
N  
(-54) 
N 
 (-54) 
Y 
(0) 
Y 
(0) 
N  Є   88
6.3.3 Multilineage peripheral blood chimerism correlates with organ tolerance  
Previously we have noted that there was a variable relationship between peripheral 
blood lymphoid chimerism and tolerance (Gleit, Z. L. et al. 2002b).  In this study, we 
separately analysed animals with donor-derived peripheral blood lymphoid and myeloid 
cells versus animals with donor-derived lymphoid cells only. 
 
Multilineage chimerism, when present at the time of organ transplantation (n=5), always 
correlated with tolerance (p<0.005; PPV=  100%).  As in previous studies, isolated 
lymphoid chimerism, at the time of organ transplantation (n=8) correlated poorly with 
tolerance (p<0.3; PPV=38%).  One animal had no detectable peripheral blood 
chimerism at the time of organ transplantation but was tolerant (animal 14040).  
Analysis of the donor-derived cell populations contributing to chimerism revealed that 
isolated lymphoid chimerism consisted of only T lymphocytes (Gleit, Z. L. et al. 2002b) 
whereas multilineage chimerism included B and T lymphocytes, granulocytes, 
monocytes and natural killer (NK) cells (chimerism levels in representative animals are 
outlined in table 6.2).   89
 
Key: 
NK  Natural Killer 
ND  ‘Not detectable’; taken as <0.5% above background staining on FACS assessment.  
 
Table 6.2 Chimerism in each peripheral blood lineage at organ transplantation 
 
 
6.3.4 Organ tolerance 
6.3.4.1 In vivo assessment: organ T cell infiltrate in mixed chimeras but no T cell 
infiltrate in full chimeras 
Nine of 22 animals (41%) were tolerant to their organ as assessed by biopsy histology 
and functional assessments (creatinine level for kidney allografts and 
electrocardiography for heart allografts).  Histological analysis of transplant biopsies 
taken from acceptor animals revealed normal structure of the transplanted organ.  
However, there was significant cellular infiltrate (fig 6.1a) in all but two animals (14980 
and 15403, the only near full chimeras at organ transplantation): these two had 
histological appearances identical to that of a naïve organ following transplantation (fig 
6.1b).   
Peripheral Blood Chimerism on Day of Organ Allograft Transplantation   
T cell  
(%) 
B Cell  
(%) 
Granulocyte 
(%) 
Monocyte 
(%) 
NK Cell 
(%) 
High Multilineage 
Chimera             
(15403) 
 
41.6 
 
49.5 
 
84.6 
 
97.1 
 
95.7 
Low Multilineage 
Chimera             
(15401) 
 
3.1 
 
0.8 
 
0.6 
 
1.1 
 
1.9 
Isolated Lymphoid 
Chimera:  Acceptor 
(14225) 
 
10.0 
 
ND 
 
ND 
 
ND 
 
ND 
Isolated Lymphoid 
Chimera: Rejector 
(14833) 
 
5.5 
 
ND 
 
ND 
 
ND 
 
ND   90
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Histology of accepted organs.  Representative histology of accepted organs:  animals with 
mixed chimerism have graft infiltrating lymphocytes without evidence of inflammation or rejection (a; 
animal 13272).  These infiltrating cells may have a regulatory function. In contrast, animals with full 
chimerism have no infiltrate in their organ graft (b; animal 15403).  
 
 
6.3.4.2 In vitro assessment: assays do not always correlate with in vivo organ 
tolerance 
CML, MLR and antibody cytotoxicity assay results were close, but not exact, correlates 
of in vivo allograft tolerance  (p<0.002 for each).   CML and MLR both showed donor 
unresponsiveness whilst maintaining robust 3
rd party responses, and no antibody 
cytotoxicity was detected in any tolerant animal except animal 14040.   Prior to organ 
allografting animal 14040 had detectable cytotoxic antibody to donor (fig 6.2a), and at 
the time of organ placement had a normal alloresponse to donor on CML (fig 6.2b) and 
MLR.  However, on day 42 after organ transplantation the CML assay showed donor 
specific unresponsiveness at high ratios of effectors to target cells, tending towards 
hyporesponsiveness at increased effector to target cell dilution (fig 6.2c).  
 
CML was unresponsive in two animals which rejected their kidney transplants: 14917 
and 15638.  MLR was not assessed in these animals, but was found to be responsive in 
all non-tolerant animals where it was assessed at an appropriate time point (n=9). 
Graft Infiltrating 
Lymphocyte
a.   b.   91
 
 
Figure 6.2 Animal 14040’s immune alloresponse.  Prior to transplantation this animal had detectable 
cytotoxic antibody to donor (a) and was responsive on CML ((b) day 112: day of organ transplantation).  
Following organ transplantation the CML was unresponsive at high effector to target (E:T) ratios 
however this tended towards hyporesponsiveness with increasing E:T dilutions ((c) day 154: 42 days after 
organ transplantation). 
 
 
6.3.5 Minimal adverse effects 
No animal in this study had significant complications related to treatment except animal 
13101 which developed GvHD following HCT.  This was mild and resolved with 
steroid treatment. 
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6.4 DISCUSSION 
Presence of detectable levels of donor BM-CFUs (by PCR), thymic chimerism (by 
PCR/Southern Blot) and multilineage peripheral blood chimerism at time of delayed 
organ allograft placement are consistent markers of stable organ allograft tolerance in 
this chimerism induction protocol.  The strong relationship of each of these three 
markers to tolerance in a clinically relevant large animal tolerance model has not been 
described previously.   This relationship is important, both for directing tolerance 
induction research using HCT, and as a marker of the achievement of tolerance prior to 
organ allografting in future clinical HCT tolerance induction protocols.   
 
6.4.1 Donor-derived bone marrow colony forming units are a reliable predictor of 
tolerance 
Presence of donor-derived BM-CFUs at 90 days were used as a marker for engrafted 
stem cells.  However, the detected BM-CFUs may also have originated from donor 
progenitor cells.  One of the animals (15401) in this study lost evidence of BM-CFUs 
greater than 90 days following HCT.  Other animals receiving the same HCT protocols 
without an organ allograft lost evidence of BM-CFUs up to 22 weeks after PBMC 
infusion in swine (data not shown).  This is much longer than the 10-12 weeks 
demonstrated by Weissman in mice (Christensen, J. L. et al. 2001).  
 
Rejector animals lost evidence of donor-derived BM-CFUs before 12 weeks.  Antibody 
cytotoxicity data (table 6.1) indicates that this was due to graft rejection in five cases.  
However, in the majority (six cases) there was no evidence of antibody cytotoxicity to 
donor implying that the graft was not lost due to rejection in these animals. 
 
Whatever the origin of the BM-CFUs, it is likely that they need to be present at least 
until the time of organ allografting.  In tolerant animals assayed at relevant timepoints 
(at the time, or after organ transplantation) BM-CFUs were detected; the exception to 
this was 15401, however it did not have a relevant CFU assessment until 12 months 
after organ transplantation. 
 
6.4.2 Donor thymic chimerism is an accurate predictor of tolerance 
Presence of thymic chimerism is as closely associated with organ tolerance as the 
presence of BM-CFUs.  This may be because both donor-derived BM-CFUs and cells in 
the thymus originated from haematopoietic stem and progenitor cells from the HCT.    93
The donor cell type in the thymus was not examined in this study.  However, previously 
the presence of donor cells expressing MHC class II, without epithelial surface markers, 
and showing the morphology of dendritic cells in the thymus have been identified in a 
tolerant animal that underwent this protocol (Fuchimoto, Y. et al. 2000).  The other 
possible source of these donor cells in the thymus is from the initial PBMC infusion.  
Tian found, in mice, that infusion of mature T cells into a conditioned host led to donor 
specific tolerance due to the T cells migrating to the thymus and mediating central 
deletion of alloreactive thymocytes (Tian, C. et al. 2004).  Peripheral blood 
contamination was not the likely source of the donor cells detected in the thymus as 
thymic chimerism was absent in the presence of 7% peripheral blood chimerism in 
animal 14143.  
 
The relationship between thymic chimerism and organ tolerance was unaffected by 
thymic biopsy on the day of transplantation: three animals had thymic biopsies on the 
day of organ transplantation with no adverse effects on tolerance (see table 2).  The 
neutral effect of thymic biopsy is in contrast to the effect of thymic biopsy during 
establishment of renal allograft tolerance by peripheral mechanisms (using a short 
course of FK506)  in which renal tolerance was not achieved if thymic biopsy is taken 
21 days prior, or on the day of organ transplantation (Vagefi, P. A. et al. 2004).  A likely 
reason for this is that tolerance is already established by the time of organ 
transplantation in this model whereas it is being induced following organ transplantation 
in the peripheral tolerance model. 
 
The association of thymic chimerism and organ tolerance has limited utility as a 
predictor of subsequent allograft acceptance in tolerance induction regimens because it 
is not practicable to perform a thymic biopsy in a clinical context.  However, a bone 
marrow aspirate for BM-CFUs would be relatively easy to obtain and both have equal 
positive predictive value.   
 
6.4.3 Multilineage peripheral blood chimerism is a reliable predictor of tolerance 
This study demonstrates that multilineage peripheral blood chimerism at the time of 
organ transplantation was predictive of organ tolerance.  Previously, a variable 
relationship between peripheral blood chimerism and tolerance was described (Gleit, Z. 
L. et al. 2002b).   However, this was in relation to simple peripheral blood chimerism 
(i.e. either lymphoid or multilineage).  Establishing a clear relationship between   94
chimerism and tolerance is helpful in understanding the mechanism of tolerance 
induction with HCT.  Whether the relationship of BM-CFU, thymic and multilineage 
peripheral blood chimerism with each other and with organ tolerance is causative or an 
epiphenomenon is the focus of ongoing research.  It is interesting to note that 
multilineage peripheral blood chimerism is not necessary for tolerance. 
 
The in vitro tolerance data did not correlate with organ tolerance in all animals.  BM-
CFU, thymic and multilineage peripheral blood chimerism are more reliable and 
consequently should be used in preference as predictors of tolerance.  One possible 
reason for the predictive limitations of in vitro assays is that they do not mirror the 
conditions in vivo, with limited cell populations in non-physiologic relative 
concentrations.  If a regulatory mechanism is involved in tolerance induction, then any 
regulatory cells may not be at the same relative concentration to effector cells as in vivo 
where they exert their physiologic effects.    
 
6.4.4 Regulatory and deletional tolerance mechanisms 
There was indirect evidence for the involvement of regulatory mechanism as well as a 
central deletional mechanism in organ allograft tolerance for some animals.  For 
example, allograft histology in the near full chimera acceptor animals (e.g. animals 
14980 and 15403) demonstrated a naïve looking organ, with no evidence of rejection or 
T cell infiltrate, as would be expected in a central deletional picture where there are no 
alloreactive T cells.  However, in animals with lower levels of chimerism there was a T 
cell infiltrate without evidence of rejection.  Previous analysis of these cells has 
indicated a likely regulatory function (Baron, C. et al. 2001a; Torrealba, J. R. et al. 
2004).   
 
Furthermore, the in vitro data from animal 14040 is consistent with a predominantly 
regulatory mechanism: following chimerism induction it became responsive to donor by 
in vitro assays.  It was not initially tolerant to its transplanted organ but recovered after 
an initial rejection crisis.  This pattern suggests that a deletional mechanism was not 
dominant.  The animal then went on to become unresponsive to donor type cells on 
CML, becoming hyporesponsive on reducing concentrations of effectors suggestive of 
dilution of regulatory cells (figs. 6.1 c & 6.1 d).  
   95
Different tolerance mechanisms may dominate, depending on chimerism levels.  In 
high-level chimeras, central deletional mechanisms are dominant, but with decreasing 
levels of chimerism there is decreased thymic deletion of the repertoire of developing T 
cells by donor-derived cells.  This results in the emergence of more alloreactive T cells, 
and so increasing importance of regulatory mechanisms to achieve tolerance (fig 6.3).  
This has been demonstrated in mice (Domenig, C. et al. 2005; Kurtz, J. et al. 2004), but 
has not been suggested in a large animal model before.   
 
 
 
 
 
 
 
 
 
Figure 6.3 Both central deletional and regulatory mechanisms involved in tolerance induction in 
chimeras 
 
 
6.5 CONCLUSIONS 
The aim of this study was to identify reliable predictors of tolerance.  Simple presence 
of peripheral blood chimerism and in vitro assays of responsiveness do not appear to 
predict tolerance with complete accuracy.  This study indicates that the presence of 
donor-derived BM-CFUs, thymic microchimerism and multilineage peripheral blood 
chimerism correlate with subsequent tolerance to an organ transplant.  Furthermore, this 
study suggests that high-level chimeras appear to have a predominantly central 
deletional mechanism of tolerance, with regulatory mechanisms becoming more 
important in lower level chimeras. These findings are applied retrospectively to a 
previous CTA allotransplant study in Chapter 6b to further understand why skin 
tolerance was not achieved and to formulate a hypothesis to induce skin tolerance.  
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CHAPTER 6B: APPLICATION OF ORGAN TOLERANCE FINDINGS TO CTA 
 
6.6 INTRODUCTION 
The aim of this part of the study was to develop a hypothesis to achieve skin tolerance 
in a preclinical swine model.  Previously, a swine chimerism induction with CTA 
transplant model achieved tolerance to the musculoskeletal element of a composite 
tissue allograft but only prolonged survival of the skin element.  This work is reviewed 
in the light of the findings gained from the more extensive experience of swine 
chimerism induction with an organ transplant model described in Chapter 6.  
 
6.7 SUMMARY OF PREVIOUS CHIMERISM INDUCTION AND LIMB 
ALLOTRANSPLANT STUDY  
 
6.7.1 Chimerism induction and limb allotransplant study outline 
A previous study attempted to induce tolerance to a limb transplant using chimerism 
induction in swine.  Tolerance was achieved to the musculoskeletal element but not to 
the skin (a state of split tolerance).   Seven animals (previously reported on by 
Hettiaratchy (Hettiaratchy, S. et al. 2004)) underwent chimerism induction with T-cell 
depletion with immunotoxin, and infusion of either bone marrow cells (BMC) or 
cytokine-mobilised PBMCs (CM PBMCs) from the donor, followed by a course of 
cyclosporine until day 30.  A limb transplant from either the donor or a donor matched 
animal was placed heterotopically in a subcutaneous abdominal pocket with a window 
to expose the donor skin (see fig 6.4) either on day 0 (n=6) or at day 52 (n=1).  A 
control animal received immunotoxin and cyclosporine with a limb transplant, but did 
not receive haematopoietic cells. 
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Figure 6.4 Chimerism induction and limb transplant study outline 
 
 
6.7.2 Results from chimerism induction and limb allotransplant study 
Two of the experimental animals died without rejecting their limb transplant but before 
tolerance could be formally assessed (i.e. before 90 days post transplant).  All of the 
remaining five animals were analysed for tolerance in vitro by CML and MLR.  They 
were also assessed for thymic and peripheral blood chimerism by FACS.  Some animals 
(n=3) were analysed for presence of engraftment as indicated by donor bone marrow 
CFUs; these results have not been reported previously (see table 6.3).  All animals 
rejected the epidermal portion of the skin on their limb allograft, with variable dermal 
involvement, but accepted the musculoskeletal elements (a state of split tolerance).  The 
control animal died on post operative day 17 with evidence of skin rejection but no 
rejection of the musculoskeletal elements. 
 
 
 
 
 
02   Days -2 -1
PBMCs/ 
BMCs 
1 
Heterotopic limb 
transplant 
T cell depletion 
Cyclosporine  
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Key: 
a  Day of assay in relation to limb transplantation (transplantation day= 0; pre-transplantation= Pre Tx) 
b  Peripheral blood chimerism: recorded as Multilineage (‘M’), Lymphoid (‘L’) or Not detectable (‘N’) 
c  Presence (‘Y’) or absence (‘N’) of thymic chimerism on FACS assessment (chimerism defined as 
>0.5% above background) 
d  In vitro responses: recorded as responsive (‘Y’), hyporesponsive (‘H’) or unresponsive (‘N’).  In some 
the limb was removed and in vitro responses were reassessed (indicated by: result before limb removal 
‘Æ’ result following limb removal). 
 
Table 6.3 Summary of the outcomes and assay results from chimerism induction and limb 
transplant study 
 
 
6.8 REVIEW OF THE RESULTS OF THE LIMB ALLOTRANSPLANT STUDY 
IN LIGHT OF THE ORGAN TRANSPLANT FINDINGS 
At the time of the limb allotransplantation study it was unclear precisely why tolerance 
to skin was not achieved in the limb allotransplants. In Chapter 6a predictive markers 
for delayed organ allograft tolerance following chimerism induction were identified. 
These are: 
 
(1)  Evidence of donor-derived bone marrow stem cell engraftment as measured by 
bone marrow CFUs at 14 weeks 
 
(2) Evidence of thymic chimerism at transplantation 
 
(3) Multilineage peripheral blood chimerism at transplantation 
In Vitro
d  Animal 
No. 
SLA 
Dis- 
parity 
HCT 
Source 
Limb 
Source 
(Day
a) 
PB 
Chim
b 
 
BM-
CFUs 
(Day
a) 
Thymic 
Chim
c 
MLR  CML 
Day of 
Skin 
Rejectn
a 
 (FT/PT) 
14831  AC-
AA 
CM 
PBMC 
Donor 
Matched 
(0) 
L  Y 
(30) 
Y 
(78) 
N  N  42 
(PT) 
14918  AC-
AA 
CM 
PBMC 
Donor 
Matched 
(52) 
L  Y → N 
(30)  (60) 
Y 
(150) 
N →Y  N→Y  70 
(FT) 
15024  AC-
AD 
CM 
PBMC 
Donor 
(0) 
L  -  Y 
(148) 
N  N  60 
(PT) 
15067  AC-
AA 
BMC Donor 
(0) 
N  -  N  Y  Y  60 
(FT) 
15022  CC-AD BMC  Donor 
(0) 
N  N 
(180) 
N  N →Y  N→Y  60 
(PT)   99
  
Furthermore there was indirect evidence that with decreasing levels of chimerism, 
regulatory mechanisms are more dominant and central deletional mechanisms less 
dominant in maintaining tolerance.   
 
6.8.1 Predictors of tolerance 
The following observations were made when the predictors of tolerance from the organ 
allotransplant study were applied to the limb allotransplant study: 
 
(1) There is no evidence of engraftment of donor-derived bone marrow stem cells in 
either bone marrow cell or CM-PBMC recipients 
 
(2) There is no thymic chimerism in the bone marrow recipients, and only low level 
(<2%) thymic chimerism in the CM-PBMC recipients beyond 14 weeks 
 
(3) There is no peripheral blood chimerism in the bone marrow recipients, and falling 
isolated lymphoid chimerism in the CM-PBMC recipients 
 
These results would predict that the limb transplant would be rejected.  In the bone 
marrow recipients there were no predictors of tolerance, and even in the CM-PBMC 
recipients not all the essential predictors (presence of donor-derived BM-CFUs and 
thymic chimerism) were fulfilled.  Interestingly, although the skin was eventually 
rejected,  the musculoskeletal element was accepted in all animals, which would not be 
predicted with these criteria; there was evidence this may have been due to regulatory 
mechanisms. 
 
6.8.2 Evidence of regulatory mechanisms maintaining musculoskeletal tolerance 
and prolonging skin survival  
There is indirect evidence both from the histological findings and in vitro data 
indicating active regulatory mechanisms in the limb allotransplants.  Histology revealed 
a non-inflammatory perivascular lymphocytic infiltrate within the musculoskeletal 
element of the limb transplants.  This type of infiltrate has previously been 
demonstrated to have a regulatory phenotype in organ transplants  (Baron, C. et al. 
2001a; Torrealba, J. R. et al. 2004).   
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The MLR results also indicated the presence of a regulatory mechanism that was 
maintained within the limb allograft itself. Following allografting, animals showed 
donor specific unresponsiveness to the limb allograft 
5.  Two animals subsequently had 
the limb removed with return of responsiveness to donor-type cells. 
 
6.8.3. Reasons for failure to achieve engraftment but still attainment of 
musculoskeletal tolerance 
This study used the same general approach to induce chimerism as in the animals 
receiving organ transplants outlined in Chapter 6a.  However, there were several 
elements that were specific to this protocol which may have contributed to the outcome 
in this study: 
 
(1) No irradiation was given to the recipients.  The rationale for this was to attempt to 
reduce the regimen’s toxicity and so make it more widely applicable. Irradiation is 
thought to create an “immunological space” to allow engraftment of the donor 
haematopoietic stem cells.  It has been possible to omit this element from chimerism 
induction protocols in small animals (see Chapter 2).  However, this has required 
profound T-cell depletion or disablement, which is not currently possible in large 
animal models.  This may have been a key factor in the failure to engraft and the low to 
non-existent peripheral blood and tissue chimerism levels.  
 
(2) Bone marrow cells were given to some of the recipients (n=2).  It is not possible to 
attain as high a number of cells for transplantation with bone marrow so only 7.5x10
6 
cells/kg were administered compared to 1.5x10
9 CM-PBMC.  A lower number of donor 
cells could decrease the likelihood of achieving engraftment, and this may have been the 
reason that no chimerism was observed in the bone marrow recipients. 
 
(3) The animals received a limb instead of an organ transplant.  This may have had 
several consequences.  Firstly, the predictors of organ tolerance may not apply to the 
tissue in a limb: skin is generally considered more difficult to induce tolerance to than 
other tissues, and the musculoskeletal tissue in a limb may actually be more tolerogenic 
than many organs.  Secondly, the donor marrow in the transplanted limb could be an 
ongoing source of donor cell chimerism.  However, there was no chimerism in the bone 
                                                 
5 One animal was responsive on MLR despite being tolerant to the musculoskeletal element of the limb.  
There was evidence that this was due to sensitisation to non-MHC minor antigens.    101
marrow recipients indicating that any donor bone marrow in the transplanted limb was 
not particularly active. Finally, the bone marrow in the transplanted limb could be a 
target for engraftment of the infused HSCs at chimerism induction.  This may facilitate 
engraftment of donor HSCs even with less stringent conditioning of the recipient, and is 
a possible location of engraftment in the animals receiving CM-PBMC. 
 
These factors may explain why there was no clear evidence of HSC engraftment with 
rejection of the donor skin, but acceptance of the musculoskeletal element of the 
allograft.  There is no evidence that the timing of progenitor cell infusion had any effect 
on tolerance.  In four cases the limb was transplanted on the day of bone marrow cell/ 
PBMC infusion, and in one case the limb transplant was delayed by 52 days.  Despite 
this difference, all animals had the same outcome of split tolerance. 
 
6.9 HYPOTHESIS FOR ACHIEVEMENT OF SKIN TOLERANCE 
 
 
 
 
 
 
 
 
Figure 6.5 Likely mechanism of tolerance induction for limb allografts 
 
 
The findings in the chimerism induction and limb allograft model are consistent with a 
predominantly regulatory mechanism of tolerance, which was strong enough to achieve 
tolerance to the musculoskeletal element of the limb allograft but did not induce 
tolerance to skin (see fig 6.5).   
 
Central deletional tolerance is considered more robust than regulatory tolerance, which 
may explain why skin was rejected in this model.  However, a purely central deletional 
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mechanism may not achieve skin tolerance because it may not be able to prevent skin 
rejection via skin specific antigens. There is evidence that skin specific antigens can 
cause skin rejection.  These skin specific antigens may not be represented in the 
repertoire of the dendritic cells originating from the donor bone marrow that migrate to 
the thymus to take part in negative selection of thymocytes.  In a purely central 
deletional model it is possible that lymphocytes specific for those skin specific antigens 
could be produced despite full chimerism.  A moderate-level engrafted chimera may 
combine the advantages of both a robust central deletional mechanism with significant 
skewing of the T cell repertoire away from a rejection, and a strong regulatory 
mechanism that may prevent rejection due to skin specific antigens. 
 
  
 
 
 
 
 
 
 
 
Figure 6.6 Hypothesis to achieve tolerance to skin  
 
 
Based on these findings, the following hypothesis can be formulated: tolerance can be 
achieved to primarily vascularised skin transplanted across a single haplotype MHC 
barrier in a preclinical swine model, by induction of haematopoietic stem cell 
engraftment with moderate levels of mixed chimerism as measured in the thymus and 
peripheral blood.  This will achieve a mixture of both central deletional and regulatory 
tolerance (see fig 6.6). 
 
6.9.1 Conditions to be fulfilled to test hypothesis  
To be able to test this hypothesis in an ideal model two conditions need to be fulfilled: 
 
Chimerism
Tolerance 
Mechanism
Central Deletional
Regulatory
High-level Low-level
Vascularized Skin Allotransplant Tolerance
Chimerism
Tolerance 
Mechanism
Central Deletional
Regulatory
Central Deletional
Regulatory
High-level Low-level
Vascularized Skin Allotransplant Tolerance  103
(1) Engraftment with a moderate level of chimerism needs to be achieved.  Two 
methods of achieving a moderate level engrafted chimera are explored: adult and in 
utero chimerism induction. The reliable achievement of moderate chimerism is difficult 
with adult chimerism regimens, since most animals in previous chimerism   induction 
experiments only achieved low levels of chimerism (thymic chimerism<10%). 
Consequently, a method to boost chimerism using donor leukocyte infusions is 
examined in Chapter 7.  An alternative to adult chimerism induction that has been 
successful in achieving moderate-to-high levels of chimerism is in utero chimerism 
induction.  Therefore, in Chapter 9 in utero chimerism induction protocols are used to 
attempt to induce moderate level chimeras. 
 
(2) A vascularised skin allograft model is required. The previous study used a 
composite tissue allograft containing musculoskeletal elements as well as skin.  
However, the other elements in the allograft may affect tolerance to skin making the 
data difficult to interpret.  Furthermore, this is not a good model for many  CTAs that do 
not necessarily contain bone marrow (e.g. face or abdominal wall).  A non-vascularised 
skin graft would not be a good model for CTA (as described in Chapters 2 and 5).  
Therefore, in Chapter 8 a vascularised skin allograft is developed in swine. 
 
6.10 CONCLUSIONS 
Analysis of the more extensive experience gained with organ transplantation in 
chimerism induction demonstrated three predictors of organ tolerance, as well as 
indicating that both central deletional and regulatory mechanisms can be involved in the 
achievement of tolerance.  The application of these findings to the chimerism induction 
with limb allotransplant data indicates that not all the predictors were met.  
Furthermore, the data suggests that active regulatory mechanisms enabled acceptance of 
the musculoskeletal element.   The hypothesis developed for the achievement of skin 
tolerance requires the induction of moderate levels of mixed chimerism (i.e. thymic 
chimerism of 10-80%).  However, this level of chimerism is not reliably achieved in the 
adult chimerism induction model.  Furthermore, a vascularised skin allograft transplant 
is required to test this hypothesis in an easily interpretable model.  Chapter 7 will 
examine the use of donor leukocyte infusion to boost chimerism following adult 
chimerism induction, and Chapter 8 will describe the development of a vascularised 
skin allotransplant model in swine.   104
CHAPTER 7: BOOSTING CHIMERISM WITH DONOR LEUKOCYTE 
INFUSION 
 
7.1 INTRODUCTION 
The hypothesis laid out in Chapter 6 is that engraftment with at least a moderate level of 
thymic and peripheral blood chimerism is required to achieve tolerance to skin 
allotransplanted across a full MHC barrier in a swine model.  The most reliable 
chimerism induction regimen outlined in Chapter 6a achieved engraftment in all long-
term surviving animals, however only low-level chimerism was achieved in half of the 
animals (Cina, R. A. et al. 2006). One method used to increase donor cell chimerism in 
low-level chimeras is to perform a donor leukocyte infusion (DLI) following HCT, an 
approach that has been promising both in animal models (Baron, F. et al. 2006b; Billiau, 
A. D. et al. 2002; Georges, G. E. et al. 2000) and in clinical settings (Spitzer, T. R. et al. 
2000).  Unfortunately, overall results from DLI studies remain variable and GvHD often 
develops in patients receiving DLI.   
 
This study reviews the previous experience with DLI in this model. Mechanisms 
controlling the effectiveness of DLI at boosting chimerism are investigated. Finally a 
strategy for improving the effectiveness of DLI is developed.  This strategy is then 
tested in Chapter 11.  
 
7.2 OVERVIEW OF EXPERIMENT 
All miniature swine from the Transplant Biology Research Center (TBRC) that had 
received a non-myeloablative HCT across a single haplotype major MHC barrier 
between 1998 and 2006 were analysed.  Animals were excluded if the HCT protocol 
was not completed.  Forty-seven animals that had undergone HCT, including 15 
chimeric animals that received DLI, were analysed.  All animals had detectable levels of 
peripheral blood chimerism by flow cytometry at the time of DLI. 
 
DLI was defined as ineffective if there was no sustained increase in peripheral blood 
chimerism so as to exclude the small rise in lymphocyte chimerism seen immediately 
after DLI infusion due to the donor cells within the infusion. 
 
The engraftment status (presence of donor haematopoietic stem cells) was assessed in 
the animals included in the study.  Engraftment was indirectly assessed by the presence   105
of donor-derived bone marrow colony forming units (BM-CFUs; detected by PCR 
analysis), thymic chimerism or multilineage peripheral blood chimerism beyond 12 
weeks after PBMC transplantation, as previously described in Chapter 6a.  
 
Animals were monitored for symptoms of GvHD indicated by the presence of a skin 
rash, abnormal liver function tests and/or gastrointestinal disturbances as well as the 
clonal expansion of alloreactive donor T cells. 
 
7.3 RESULTS 
7.3.1 Donor leukocyte infusion failed to increase chimerism in the majority of 
chimeric recipients  
Fifteen chimeric animals received one or more DLIs, either from the original donor or 
from an animal MHC-matched to the original donor (summarized in table 7.1).  Twelve 
of these recipients (80%) showed no response to DLI as measured by increase in 
peripheral blood chimerism.   
 
Only three animals showed a sustained increase in peripheral blood chimerism 
following DLI.  Animal 14980 converted to full chimerism (i.e. 100% donor cells) 
without GvHD.  This animal had high-level multilineage chimerism (Lymphocyte (L): 
50%; Monocyte(M): 60%; Granulocyte (G): 74%) prior to receiving DLI.  The two 
other animals, 13101 and 15204, had low-level chimerism
6 (13101 L:49; M:1; G:2, 
15204 L:25; M:0; G:3) prior to DLI and developed GvHD following DLI leading to 
their subsequent sacrifice.  All three animals had evidence of haematopoietic stem cell 
engraftment in the bone marrow and multilineage peripheral blood chimerism at the 
time of DLI.  Donor stem cell engraftment in the bone marrow was detected in 6 of the 
12 animals that did not respond to DLI, with engraftment not present (n=2) or not 
assessed (n=4) in the others.  
 
 
                                                 
6 Lymphoid chimerism is not a time-sensitive measure of haaematopoietic chimerism due to the long life-
span of lymphoid cells.  Chimerism in the shorter surviving myeloid lineages (monocyte and granulocyte) 
provides a more accurate measure.   106
 
ANIMAL  HAPLOTYPE MISMATCH  DLI Day
a  Donor 
Stem Cell 
BM 
Engraft-
ment
d 
PB CHIMERISM AT DLI 
% 
e (Day
a) 
GvHD
f  PB 
CHIMERISM 
~4WK POST 
–DLI (Day) 
%
f 
 
Chimerism Boost 
        
13101 
 
AC-AD 709 
 
Y  L:49 M:1 G:2 (709)  Y 
 
L:95 M:79 
G:99  
(742) 
14980 AC-AD  219 
 
Y  L:50 M:62 G:74  (217)  N  L:57 M:85 
G:79 (246) 
15204 AC-AD  111  Y  L:25 M:0 G:3 (104)  Y  L:9 M:41 G:1 
(134) 
 
No Chimerism Boost 
        
13272 AC-AD  745
b 
 
Y 
 
L:13  
(745) 
N  
   984
b Y  L:7 
(984) 
N  
13476 CD-AD  482
b 
 
Y  10  
(469) 
N  
13810 
 
AC-AD 82 
 
U  L:14 
(82) 
N  
14225 AC-AD  110  Y  L:10 M:0 G:0.5 (110)   N   
14375 
 
AC-AD 35    U  L:59 M:25 G:40 
(34)  
N  
14376 AC-AD  35 
 
N  L:33 M:18 G:25 
(35) 
N  
   252
c N  L:10 
 (252) 
N  
14529 AC-AA  35 
 
N  L:35 M:24 G:31 
(34) 
N  
14547 AC-AD  35 
 
U  L:30 M:11 G:20 (34)  N   
14548 AC-AD  35 
 
U  L:34 M:10 G:18 (34)  N   
16558 AC-AD  152 
 
Y  L:10 M:0 G:1 
(151) 
N  
16626 AC-AD  153 
 
Y  L:6 M:3 G:4 
(153)  
N  
   566
b Y  L:3 M:3 G:2 
(566) 
N  
17017 
  
AC-AD 
  
150 
  
Y  L:17 M:8 G:13 (153)  N  
Key 
a  Day in relation to original PBMC infusion to induce chimerism  
b  Donor Matched Leukocyte infusion 
c  Sensitised DLI   
d  ‘Y’=Engrafted, ‘N’=Not engrafted, ‘U’=Engraftment undetermined at time of DLI 
e  Percentage of peripheral blood donor chimerism in each lineage (L-lymphocyte; M-monocyte;  
    G-granulocyte).  Monocyte and granulocyte levels not given if only lymphoid chimerism present 
f  ‘Y’=presence, ‘N’=absence of GvHD 
 
Table 7.1 Donor leukocyte infusion outcomes 
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7.3.2 Evidence of suppression of the DLI donor-vs.-chimera effect by CD25+ cells 
 
 
Figure 7.1 Suppression of graft versus host alloresponses following DLI in chimeric recipients
7.  
Suppression of donor T cell alloresponses by two chimeric recipients (16626 and 14376) were assessed 
by MLR before (a & b) and after DLI (c, d & e).   
 
 
                                                 
7 Mean background count for 16626 pre-DLI MLR= 305 counts per minute (cpm); 2 weeks post-DLI 
MLR =136 cpm, 2 weeks post-DLI coculture MLR=335. Mean background count for 14376 pre-DLI 
MLR=149 and 2 weeks post DLI MLR=136. 
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Suppression of the donor-vs.-chimera effect of DLI is one possible reason that DLI 
failed to increase chimerism in the majority of animals.  Donor-vs.-chimera suppression 
was assessed in two chimeric animals before and after DLI treatment (14376 was 
assessed at day 35 and 16626 at day 566 following chimerism induction). Prior to DLI 
there was no donor-vs.-chimera (AC vs. AC/AD)
8 suppression in either animal, with 
strong donor-vs.-chimera responses (fig 7.1a and 7.1b: “AC@Chimera”).  In contrast, 
following DLI these donor-vs.-chimera responses were no longer detected (fig 7.1c and 
d), indicating donor-vs.-chimera suppression.   
 
Confirmation of active donor-vs.-chimera suppression in a chimera following DLI was 
obtained by co-culture MLR. PBMC taken from chimera 16626 post-DLI were added to 
naïve donor-type (AC) PBMC being stimulated by naïve host-type (AD) PBMC.  There 
was significant suppression of the donor-vs.-host (AC vs. AD) alloresponse (fig 7.1e: 
“AC/-@AD” - unsuppressed alloresponse; “AC/Chimera@AD” - suppression of 
alloresponse by the addition of cells from chimeric animal 16626).   
 
To determine if CD25+ cells (a population containing CD4+CD25+FoxP3+ Treg cells), 
contribute to the suppressive effect post DLI.  Cells taken from chimera 16626 post-DLI 
were depleted of over 90% of the CD25+ subset by magnetic activated cell sorting 
(MACS). The cells were then irradiated and used as stimulators in MLR for naïve 
donor-type cells (AC).   There was a strong donor(AC) -vs.-chimera response to CD25 
depleted chimera cells (fig 2: “AC@Chimera CD25 Depleted”).  In contrast, there was 
no donor-vs.-chimera response when undepleted chimera cells were used as stimulators 
(fig 7.2: “AC@Chimera”).  To ensure that the gain of reactivity observed after CD25 
depletion was not due to the staining process for MACS, recipient cells from 16626 
were coated with CD25 antibody and magnetic beads without passage through the 
MACS column prior to being used as stimulators with no alloresponse detected (fig 7.2: 
“AC@Chimera Stained”).   
 
 
 
 
                                                 
8 the majority of their leukocytes in these mixed haaematopoietic chimeras were AC (i.e. host) phenotype 
(>66% in 14376 and >94% in 16626), with the remainder AD (i.e. donor) phenotype.    109
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Suppression of donor-vs.-chimera response may be mediated by CD25+ cells in chimeric 
recipients
9 
 
 
A further indication that CD4+CD25+FoxP3+ Treg have a role in donor-vs.-chimera 
suppression post DLI was provided by observation of the change in the absolute number 
of Treg before and after DLI in animal 16626.  There was a 74% increase in the number 
of Treg 2 weeks after DLI compared to the day of DLI (96.5 Æ 168 Treg/µm
3), this 
increase was sustained at 4 weeks (172 Treg/µm
3) (fig 7.3).  
 
 
                                                 
9 Mean background count = 84.  
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Figure 7.3 Absolute levels of CD4+CD25+FoxP3+ cells increase post DLI 
Prior to DLI the level of CD4+CD25+FoxP3+ T cells in the animal 16626’s blood was 96.5/um
3 (‘Pre-
DLI’ left-hand column).  Following DLI the level of CD4+CD25+FoxP3+ T cells increased to 168/um
3 
(middle column), an increase of 74%.  The level remained raised at 4 weeks following DLI at 172/um
3 
(right-hand column).  NOTE: It is possible that up to 30% of this increase was due to donor 
CD4+CD25+FoxP3+ T cells within the DLI. 
 
 
7.4 DISCUSSION 
The non-myeloablative chimerism induction regimen used in this model results in a low 
incidence of GvHD, but does not reliably achieve high enough levels of chimerism to 
test the hypothesis that a moderate level engrafted chimera will be tolerant to a 
vascularised skin allotransplant.  DLI is able to boost chimerism in chimeras, but is 
largely ineffective in this model.  The low incidence of GvHD in this model may be due 
to donor-vs.-chimera suppression.  However, donor-vs.-chimera suppression may also 
make DLI ineffective at increasing chimerism.   
 
7.4.1 DLI is rarely effective due to donor-vs.-chimera suppression 
DLI was not effective at increasing donor chimerism in the peripheral blood of most 
chimeric animals studied.  These findings are in agreement with those of the Storb 
group who showed that repeated DLI neither facilitated conversion to full donor 
chimerism after HCT nor prevented rejection in dogs receiving a non-myeloablative 
single-haplotype mismatch HCT (Fukuda, T. et al. 2006).  They had previously   111
demonstrated success with DLI in MHC-matched minor antigen-mismatched transplants 
following sensitisation of the DLI donor (Georges, G. E. et al. 2000) and even some 
success without prior donor sensitisation (Baron, F. et al. 2006b).  It is possible that the 
difference in the DLI effects between donor/host combinations that differed by minor 
antigen versus single MHC haplotypes may be because there is greater immunological 
similarity in minor mismatched animals and so not as much donor-vs.-chimera down-
modulation is stimulated. 
  
One possible weakness in this study is that a donor-matched DLI was used in two of the 
animals that did not respond to DLI opening up the possibility that minor antigen 
differences could stimulate anti-donor responses from the original donor cells in the 
chimera.   
 
In this study in vitro evidence of donor-vs.-chimera suppression was only obvious 
within 4 weeks following DLI.  The origin of the regulatory cells mediating donor-vs.-
chimera regulation is unclear. These regulatory cells were either present in the recipient 
prior to DLI and their numbers and/or activity were boosted by the DLI, or were donor-
derived and were infused with the DLI.  It has been previously demonstrated that 
regulation is present in animals prior to DLI (Kunisaki, S. M. et al. 2001), indicating 
that these regulatory cells were not infused with the DLI, rather the DLI actually boosts 
the activity of the regulatory cells.  Whether these donor-vs.-chimera regulatory cells 
are of recipient or donor origin (i.e. from donor PBMCs given for initial chimerism 
induction) has not been determined.  Johnson et al. attributed the donor-vs.-chimera 
suppressive effect to donor cells (Johnson, B. D. et al. 1999);  however, Blazar et al 
demonstrated that recipient cells can also mediate the donor-vs.-chimera suppressive 
effect (Blazar, B. R. et al. 2000).   
 
In this non-myelablative model, recipient cells are exposed to donor T cells following 
HCT induction.  It is therefore possible that recipient T cells are then stimulated to 
contribute, at least in part, to the suppressive effect. This is supported by the fact that 
one of the animals (14376) analysed for evidence of donor-vs.-chimera regulation of 
DLI was not engrafted, and so would have had limited capacity to produce any donor 
origin regulatory cells following chimerism induction.  However, this animal still had a 
donor-vs.-chimera regulatory mechanism that was boosted by DLI.    
   112
In this model the cell type mediating the suppression appeared to be CD25+ cells.  This 
finding correlates with rodent data demonstrating that regulatory T cells can suppress 
GvHD (Cohen, J. L. et al. 2002; Hoffmann, P. et al. 2002; Taylor, P. A. et al. 2002; 
Trenado, A. et al. 2006; Zeng, D. et al. 2004).  It is possible that there are other cells 
which contribute to suppression, and that these were removed by non-specific binding 
to the column during magnetic bead depletion.  CD4+ T cells (Johnson, B. D. et al. 
1999), veto cells (Weiss, L. et al. 1999) and NK cells (Asai, O. et al. 1998; Sykes, M. et 
al. 1990a) have all been shown to suppress donor-vs.-chimera responses in mouse 
models.  However, the coincident increase in T cells with a regulatory phenotype in the 
peripheral blood of recipients following DLI provides in vivo evidence supporting the 
hypothesis that CD25+ cells contribute to the regulatory mechanism. 
 
7.4.2 Possible approaches to make DLI effective 
DLI appears not to be effective at increasing chimerism in this model due to donor-vs.-
chimera suppression.  An approach to achieving increased chimerism following DLI 
would be to prevent donor-vs.-chimera suppression.  This could be achieved by either 
preventing the development of donor-vs.-chimera suppression or removing donor-vs.-
chimera suppression. 
 
Prevention of the development of donor-vs.-chimera suppression has been achieved in 
murine models by complete long-lasting T-cell depletion that continues until after the 
HCT thereby achieving a donor-vs.-chimera and chimera-vs.-donor free platform, has 
been use to prevent donor-vs.-chimera suppression and make DLI more effective.  This 
allows engraftment without inflammation, which can be subsequently boosted by DLI 
(Pelot M.R. et al. 1999).  However, the success in rodents has not been replicated in 
large animals or the clinic.  Reasons for this may be that, in contrast to rodent models, it 
is not possible to achieve complete T-cell depletion without significant toxicity, nor can 
such high T cell doses be administered in the DLI in large animals and the clinic. 
 
A second approach to prevent donor-vs.-chimera suppression and make DLI more 
effective is to remove the suppression.  This study demonstrates that this is possible in 
vitro.  It may also be possible to achieve this in vivo by either global T-cell depletion or 
by selective depletion of CD25+ cells with specific reagents.  
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A possible limitation of both approaches for removal of donor-vs.-chimera suppression 
(prevention or depletion) is that in addition to the increased chimerism (due to donor-
vs.-chimera response), GvHD may develop. Separation of donor-vs.-chimera response 
from GvHD is central to the achievement of high-level chimerism without significant 
morbidity and death.  Donor-vs.-chimera response without GvHD was achieved in only 
one of the three animals that responded to DLI in this study.   In mouse models it has 
been possible to consistently separate lympho-haematopoietic donor-vs.-chimera 
response and GvHD effects for the treatment of leukaemia (Bortin, M. M. et al. 1979; 
Sykes, M. et al. 1989; Sykes, M. et al. 1990b).  However, it has not been possible to 
reliably replicate this in the clinic in either HLA mismatched (Sykes, M. et al. 1999) or 
HLA matched transplants (Dey, B. R. et al. 2003; Spitzer, T. R. et al. 2000).   This may 
indicate that this large animal model provides a closer clinical representation than 
rodent models for studies separating donor-vs.-chimera response and GvHD.   
 
The mechanism for separation of donor-vs.-chimera response and GvHD has not been 
fully elucidated.  However, it is likely that the T cells mediating donor-vs.-chimera 
response also mediate GvHD (Horowitz, M. M. et al. 1990).  Donor-vs.-chimera 
regulation may provide a mechanism by which it is possible to isolate donor-vs.-
chimera response from GvHD.   Edinger et al. demonstrated that CD4+CD25+ 
regulatory T cells can suppress the expression of IL-2 receptor alpha chain by donor-
vs.-chimera alloreactive T cells as well as decrease their ability to mediate GvHD, 
without affecting donor-vs.-chimera response.  This occurs through the perforin lysis 
pathway (Edinger, M. et al. 2003).   
 
In addition to removing donor-vs.-chimera suppression, HSC engraftment may be 
necessary for DLI to be effective at increasing chimerism. In our model all three 
animals that responded to DLI with an increase in donor chimerism had evidence of 
HSC engraftment.  However, several animals that did not respond to DLI also had 
evidence of engraftment, so engraftment alone is not sufficient for DLI to be effective.  
The level of engraftment may also be of consequence: it is possible that with greater 
levels of engraftment, regulatory mechanisms play less of a role and deletional 
mechanisms are more important (Domenig, C. et al. 2005; Kurtz, J. et al. 2004). It is 
possible that DLI could facilitate engraftment; Baron found that an early DLI following 
non-myeloablative chimerism induction in a dog model correlated with increased 
incidence of long-term mixed peripheral blood chimerism (Baron, F. et al. 2006b).   114
7.5 STRATEGY TO INCREASE THE EFFECTIVENESS OF DLI IN THIS 
MODEL 
The model described is minimally toxic with a low incidence of GvHD but often 
achieves a level of chimerism too low to be useful for testing the hypothesis that a 
moderate level engrafted chimera will be tolerant to a vascularised skin allotransplant.  
DLI is one possible method to increase chimerism.  However, it only achieves boosting 
of chimerism in this model in a minority of cases.  This may be due to donor-vs.-
chimera suppression. 
 
Possible ways to achieve boosting of chimerism are either to prevent development of 
donor-vs.-chimera suppression, or to remove/reduce suppression once it has developed.  
Even if it is possible, it may not be desirable to prevent the development of donor-vs.-
chimera suppression in a large animal as this may result in a high incidence of GvHD.  
Another option is to remove or reduce donor-vs.-chimera suppression; there are several 
ways that donor-vs.-chimera suppression could be reduced: 
 
(1) Depletion of all white blood cells (WBCs), including the suppressor T cells. WBC 
depletion could be achieved by leukapheresing the animal immediately before 
administration of the DLI.  This approach has the added advantage that the leukoproduct 
can be frozen and saved.  If the animal subsequently develops GvHD following DLI the 
leukoproduct (containing donor-vs.-chimera suppressor cells) could be given back to 
treat the GvHD. 
 
(2) Depletion of all T cells including the suppressor T cells.  The only option for 
achieving this in swine would be with the anti-CD3 immunotoxin used in the chimerism 
induction protocol.  However, at the time of these experiments there is only enough 
immunotoxin available for chimerism induction when the animals are smaller, but not 
enough for the subsequent depletion T cells at the time of DLI when the animals have 
grown larger.   
 
(3) Selective depletion of the suppressor cells.  Removal of just one cell type is an 
attractive experimental approach because it allows the study of the effect of that cell 
type in isolation.  Options for achieving this are use of anti-CD25 or anti-CD8 
antibodies (swine Tregs are CD4/CD8 double positive).  However, these were not 
available in large enough quantities to deplete in vivo at the time of this study.  Another   115
option was to use Ontak®, a human IL2R-Diptheria toxin fusion protein.  Ontak® binds 
to the IL2R (which is CD25) on T cells and is internalized.  The dipheria toxin then 
blocks elongation factor 2 leading to cell death.  The IL2R is conserved between pigs 
and humans making it highly likely Ontak® would work in pigs.  Several routes were 
explored to acquire Ontak at an affordable price but all were unsuccessful. 
 
On the basis of these constraints, in Chapter 10 animals underwent a pre-DLI 
leukapheresis in an attempt to make DLI effective at boosting chimerism.   116
CHAPTER 8: PIG COMPOSITE TISSUE ALLOTRANSPLANTATION 
MODELS 
 
8.1 INTRODUCTION 
The aim of this study is to develop a swine vascularised skin transplant model to test the 
hypothesis that an engrafted moderate-level chimera will be tolerant to a vascularised 
skin allotransplant.  A secondary aim that would be useful for future research is to 
incorporate the possibility of testing allograft functional recovery following 
allotransplantation.   
 
The two elements required for a useful vascularised skin flap model to test the skin 
tolerance hypothesis is that it should contain no other tissues except skin, and that it is 
primarily vascularised.  There are several composite tissue allotransplant models 
already described.  Many of these CTA models contain vascularised bone and/or muscle 
(Eduardo Bermu, Dez L. et al. 2002; Lee, W. P. et al. 1991; Mathes, D. W. et al. 2003; 
Xudong, Z. et al. 2006; Yazici, I. et al. 2006).  The inclusion of other tissues in the 
allograft may affect tolerance to skin making the data difficult to interpret. For example 
in a rodent model, it has been observed that the presence of vascularised bone marrow 
extends allograft survival (Ozmen, S. et al. 2006).  An alternative to these CTA models 
are conventional skin grafts which do not contain other tissues.  However, conventional 
skin grafts would not be a good model for composite tissue allotransplantation due to 
the differences in the interaction with the immune system compared to primarily 
vascularised skin found in CTA (as described in Chapters 2 and 5).   
 
Functional recovery following allotransplantation can include both motor and sensory 
elements.  The ideal CTA model for testing the skin tolerance hypothesis would include 
only skin and so motor recovery could not be assessed.  However, identification of the 
sensory innervation of the skin and anastomosis to the donor in the transplant would 
allow assessment of sensory recovery.  A musculocutaneous allotransplant model would 
be required to assess both motor and sensory recovery.  There have been no previous 
models described in swine that allow for assessment of motor and/or sensory recovery. 
 
It was not possible to develop a single model to address all the limitations of previous 
models.  Consequently, both cutaneous and musculocutaneous vascularised CTA swine 
models that allow for assessment of functional recovery are developed in this study.      117
 
8.2 OVERVIEW OF EXPERIMENT  
Possible swine CTA models for orthotopic or heterotopic placement were explored on 
cadaveric swine (two animals per model).  These models were then developed in live 
animals, by either simple dissection to confirm cadaveric findings, or by isolating the 
CTA on its vascular pedicle to confirm reliability of the blood supply.  Finally, the most 
useful CTA models were transplanted, either orthotopically or heterotopically, to 
ascertain the best strategy technically for transplantation. 
 
8.3 RESULTS  
Five different CTA models were explored (as outlined in table 8.1): 
 
 
Table 8.1 Swine CTA models and outcomes 
 
 
 
Flap  Flap Type 
(Recipient 
site) 
Number 
performed
Technical 
Success 
n 
Technical failure 
n (Day; Reason) 
Facial   Pedicled   1  NA  NA 
 
Radial Artery   Pedicled 2  0  2 
(D0; not perfused) 
Groin   Pedicled 2  2  0 
 
Pedicled 
 
3 2 
 
1   
(D3; Infection) 
Free 
(orthotopic) 
1 1 
 
1   
(D4; Infection) 
Saphenous  
Free 
(heterotopic) 
4 3 
 
1  
(D1; thrombosis) 
Gastrocnemius   Free 
(heterotopic) 
1 1  0   118
8.3.1 Facial flap 
On cadaveric dissection the facial vein was easily identified lying in a similar location 
as in humans, originating at the medial canthus before descending obliquely across the 
face, crossing the inferior border of the mandible and terminating in the internal jugular 
vein.  However, it was not possible to identify a facial artery.  The motor and sensory 
innervation of the facial region was also examined.  The facial nerve was identified just 
postero-superior to the angle of the jaw, and the dorsal buccal branch was easily 
followed to the snout.  In addition, the auriculotemporal nerve was also identified 
running superiorly behind the posterior ramus of the mandible.  
 
To confirm the findings on cadaveric dissection, a dissection of the facial vasculature 
was performed on a live animal.  The facial veins were again easily identified 
bilaterally.  However, no facial artery was identified.  Consequently, this model was not 
developed further. 
 
8.3.2 Radial artery flap 
 The radial vessels were easily identified on cadaveric dissection running along the 
interosseus membrane.  The overlying skin flap was isolated on distal branches from 
these vessels on live dissection (fig 8.1a).  However, only a small area of skin was 
viable by 48 hours following operation (fig 8.1b).  In addition, no single sensory nerve 
supplying the skin within the flap could be easily identified.  Consequently, this model 
was not developed further. 
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Figure 8.1 Radial artery flap.  A radial artery flap was raised on a pedicle in two live dissections (a).  
However, by 48 hours it was apparent that only a small area of the flap was actually supplied by the 
pedicle (b). 
 
 
8.3.3 Groin flap 
A groin flap based on the superficial epigastic artery was developed.  An elliptical skin 
incision, based over the lateral half of the groin crease, was made (fig 8.2). The 
abdominal cavity was not opened.  The superior edge of the skin flap was raised deep to 
Scarpa’s fascia.  The superficial epigastric vessels were identified and isolated 
retrograde to the femoral vessels.  Two pedicled groin flaps were raised.  Although both 
flaps survived, the dissection of the inferior epigastric vessels was difficult: the vessels 
in the pedicle were small (1-2mm diameter) with a pedicle length of over 12 cm.  
Consequently, the flap was not developed further. 
 
a.  b.
Area of viable skin 
at 72 hours post op. 
Vascular pedicle   120
 
 
 
 
 
 
 
 
Figure 8.2 Groin flap: technically possible, but long pedicle with narrow calibre vessels.  A groin 
flap 1 week post operatively indicating the position of the skin paddle centred over a line running from 
the anterior-superior iliac spine to the pubic tubercle. 
 
 
8.3.4 Saphenous fasciocutaneous flap 
A flap based on the saphenous vessels was developed.  The medial saphenous artery 
was palpated and marked.  An elliptical skin incision, based around the medial 
saphenous artery, was made on the medial aspect of the knee and extending inferiorly 
(fig 8.3a).  The flap was raised deep to fascia lata with identification of the 
neurovascular pedicle (fig 8.3b). Isolation was straightforward, requiring minimal 
dissection of the recipient tissues. The saphenous vessels were divided inferiorly and 
then the neurovascular pedicle was dissected superiorly.   The neurovascular pedicle 
was larger in diameter than the groin flap (arterial diameter 3mm) with a vascular 
pedicle length of 8-10 cm.  The saphenous vessels (usually one artery and two veins) 
were isolated along the inferior edge of sartorius back to the femoral vessels.   
 
The saphenous fasciocutaneous flap receives cutaneous innervation from the saphenous 
nerve.  This was easily identified and preserved as it separated from the vessels 
approximately 6-8cm proximal to the skin flap.  Identification of this nerve indicates 
that functional assessment of return of cutaneous sensation is possible in this model if 
the nerve is anastomosed to a cutaneous nerve on the recipient (e.g. the 
auriculotemporal nerve). 
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The initial live dissections of the saphenous flap indicated that this model fulfilled the 
criteria of being composed of just skin (and associated connective tissue), and having an 
identifiable sensory innervation. To develop this model further, the flap was 
transplanted orthotopically.   In these free flaps the vessels were divided including a 
2cm cuff of the femoral vessels superiorly.  Following removal of the flap it was 
possible to close the donor site directly without a drain (fig 8.3c) and recover the 
animal. The recipient femoral vessels were isolated and divided just proximal to the 
saphenous vessels.  The femoral vessels in the cuff on the flap were anastomosed end-
to-end to the recipient femoral vessels.  A suction drain was placed.   
 
Two orthotopic flaps (one isolated on the neurovascular pedicle and one orthotopic 
transplant) underwent thrombosis.  In both cases, at necropsy, the vein was found to be 
thrombosed, with significant of inflammation in the flap and surrounding tissues, and an 
infected seroma underlying the flap.   
 
Due to the complications with the orthotopically transplanted flaps, further flaps were 
transplanted heterotopically in a cervicofacial position.  The vessels of the flap femoral 
vessel cuff were anastomosed, end-to-end, to the recipient common carotid artery and 
internal jugular vein.   An ellipse of skin was excised from the angle of the jaw and 
superior cervical area and the flap secured in place (fig 8.3d).   These heterotopically 
placed flaps had a lower complication rate compared to the orthotopic flaps.     122
a.   
           
 
                  
 
Figure 8.3 Saphenous flap: identifiable sensory nerve, with minimal dissection allowing recovery of 
the donor.   a: The flap was marked out (marked in black) overlying the course of saphenous artery 
(marked in red).  b: The flap was then isolated on its neurovascular pedicle with minimal dissection of the 
surrounding tissues.  c: In flaps that were transplanted the donor site was closed directly with good 
healing (picture shows donor site at one week post op) allowing for post operative recovery of the donor 
and use in follow-up immunological assays.  d: Due to complications on orthotopic placement of the flap, 
later flaps were transplanted to the cervicofacial region.  
 
 
8.3.5 Gastrocnemius musculocutaneous flap 
The saphenous flap contained no muscle for assessment of return of motor innervation 
and function.  Therefore, a myocutaneous flap based on the gastrocnemius muscle was 
developed.   This included muscle, with its identified motor nerve (tibial nerve), as well 
as skin with the identified sensory nerve (saphenous nerve) to allow for assessment of 
functional recovery on transplantation. An elliptical skin incision was made centred 
over the gastrocnemius muscle, extending from the popliteal fossa to the tendo-achilles 
(fig 8.4a).  The medial sural vessels were dominant, branching with the lateral sural 
b.
c. 
d.   123
vessels from the popliteal vessels approximately 2cm below the knee joint before they 
both almost immediately entered the muscle.  The popliteal vessels were both 4-5mm in 
diameter and were isolated for 5cm proximally before passing through the adductor 
hiatus.  The branch of the tibial nerve to gastrocnemius (fig 8.4b) and the saphenous 
nerve was identified, isolated, and divided. The tendo-achilles was divided and the 
gastrocnemius was separated from the underlying muscles. The medial and lateral sural 
vessels were isolated, followed back to the popliteal vessels overlying the knee joint 
capsule and divided just distal to the adductor hiatus.   
The flap was transplanted across a MHC Class 1 barrier with histologically confirmed 
rejection of the flap at 8 days.   124
 
 
                           
 
 
 
 
 
 
 
 
 
Figure 8.4 Gastrocnemius myocutaneous flap: identifiable motor and sensory nerves, with utility 
for functional recovery assessment.  a: The flap was raised centred over the gastrocnemius muscle.  b: 
The flap was isolated on the popliteal vessels with identification of the tibial and sural nerves.  c: The flap 
was then transplanted to a heterotopic cervicofacial position overlying the jaw (outline marked in blue) 
and cheek. 
 
 
8.4 DISCUSSION 
This study has developed a skin allotransplantation model in swine based on the 
saphenous vessels which can be used to assess the hypothesis developed in Chapter 6 
for the attainment of skin tolerance by creating an engrafted moderate level chimera.  
This saphenous skin flap model is particularly useful because skin is the only major 
tissue type, thereby avoiding effects from other tissues. In addition, the saphenous flap 
is harvested with minimal morbidity allowing for recovery of the donor animal, which 
Motor 
innervation 
(branch of 
tibial nerve) 
b. 
c.  
a.   125
can then be used in follow-up immunological assays.  Consequently the saphenous flap 
is used to test the hypotheses in Chapters 10 and 11.  
 
As well as preventing rejection, functional recovery is of central importance for a good 
outcome in CTA.  Functional recovery in most composite tissue allotransplants require 
at least moderate sensory recovery, however not all require good motor recovery.  In 
hand allotransplants the transplanted long flexor and extensor tendons attach proximally 
to innervated recipient muscles, and only intrinsic muscle function is dependent on 
motor nerve growth into the transplant.  In contrast, motor function may be essential in 
some face allotransplants for perioral musculature to maintain oral continence and for 
communication, and for periorbital musculature to achieve eyelid closure.   
 
The models described here allow for function assessment of either just sensory recovery 
(saphenous flap) with recovery of the donor for further immunological assays, or motor 
and sensory functional recovery (gastrocnemius flap).  It is important to be able to study 
both motor and sensory recovery as unfortunately, motor nerve recovery is not always 
as good as sensory recovery in allotransplants (Lanzetta, M. et al. 2005). There has been 
a previous description of bilateral orthotopic replantation of the rectus femoris muscles 
including the motor nerve and vascular pedicles in dogs (Hua, J. et al. 1996).  However, 
this did not involve skin, limiting the relevance of it as a CTA model due to reduced 
immunogenicity. 
 
The facial allograft models described here are heterotopic, which is a possible limitation 
as they could not be used to study the technical aspects of a face transplant.  Our 
findings indicate that it would be difficult to develop an orthotopic model in swine 
based on the vascular pedicle that would be commonly used clinically.  Previously, 
orthotopic facial transplant animal models have been described (Ulusal, B. G. et al. 
2003; Zhang, X. D. et al. 2006); however, these have differing anatomy from humans 
and so will have limited utility in further improving clinical operative technique.  
Furthermore, the initial successes of the facial transplants, and previous facial replants, 
have demonstrated that technical difficulty is not a limitation.  
 
8.5 CONCLUSIONS 
The saphenous flap achieves the primary aim of this study: defining a vascularised skin 
flap, not containing other tissues, to be used to test the skin tolerance hypothesis   126
developed in Chapter 6. Consequently, the saphenous flap is used to test the hypothesis 
that skin tolerance can be achieved in an engrafted moderate level chimera in Chapter 
10 and to examine site-specific therapy in Chapter 11. 
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 CHAPTER 9: IN UTERO INDUCTION OF CHIMERISM 
9.1 INTRODUCTION 
The primary aim of this study was to obtain an engrafted moderate-level chimera in 
which to test tolerance of vascularised skin allografts transplanted across a full 
mismatch barrier.  The in utero chimerism induction model has previously proven to be 
a robust model for achieving moderate-level chimerism in swine (Lee, P. W. et al. 
2005b; Mathes, D. W. et al. 2001; Rubin, J. P. et al. 2001) and was therefore selected 
for this study.   
 
In previous studies SLA
cc MGH miniature swine were used as bone marrow donors and 
Yorkshire outbred swine as recipients.  SLA
cc MGH miniature swine were selected 
because, at the time, more reagents were available to phenotypically type immune cells 
in SLA
cc cells than other SLA subtypes.  Yorkshire swine were chosen as recipients 
because they are large, which is helpful in correctly locating the in utero inoculation, 
and also they are robust with low abortion rates. 
 
In this study two modifications were made from previous experiments.  Firstly, the 
MGH miniature swine inbred line of SLA
dd animals are used as bone marrow donors, 
instead of partially inbred SLA
cc miniature swine.  This eliminates minor antigen 
differences between the bone marrow donor and the skin donor. The bone marrow 
donor is sacrificed to harvest bone marrow for in utero injection, then an animal from 
the same line is used for donation of the skin flap allotransplant. One of the mechanisms 
of skin rejection may be via skin specific minor antigens. Partially inbred SLA
cc 
miniature swine are identical at the MHC but may have non-MHC minor antigen 
mismatches making these animals unsuitable donors. The “inbred” SLA
dd line is not 
fully inbred and so still may have some minor antigen differences. However, previous 
studies have demonstrated that they accept reciprocal skin grafts from animals in the 
same line (Mezrich, J. D. et al. 2003) making these animals suitable donors. 
 
The second modification from previous studies was the use of Hanford mini-swine 
instead of Yorkshire swine as recipients.  The rationale for this was that some of the 
resultant chimeras would later have received renal allotransplants as well to assess 
tolerance to organ allografts in the event of vascularised skin allograft rejection.  
Previous studies have demonstrated initial tolerance to renal transplants (Lee, P. W. et 
al. 2005a; Mathes, D. W. et al. 2005); however,  the kidneys eventually failed.  The   128
reason for the kidney allograft failure is unclear but one possibility is that the size 
mismatch between the donor kidney (from a miniature swine) and the recipient (a full-
sized swine) eventually became too great for the kidney to be life-supporting.  This size 
mismatch issue would not be a problem with mini-swine and so Hanford mini-swine 
were selected because of their large litter sizes and robustness in pregnancy in 
comparison to the MGH mini-swine. 
 
It was noted in the previous studies that better chimerism was achieved when 
unmanipulated bone marrow was added back to the T cell depleted fraction to achieve 
the desired percentage of  T cells (Rubin, J. P. et al. 2001).  The secondary aim of the 
current study was to further understand the effect of bone marrow manipulation and T-
cell depletion on progenitor cell function using cobblestone area forming cell (CAFC) 
assay and bone marrow colony forming unit (CFU) assays. 
 
9.2 OVERVIEW OF EXPERIMENT  
The experiment is summarized in figure 9.1.  Potential recipient animals were screened 
by MLR to confirm alloreactivity to donor MHC, and by PCR and FACS to confirm 
that donor and recipient could be phenotypically distinguished.  An inbred SLA
dd donor 
animal was sacrificed and bone marrow was harvested.  Some of the bone marrow was 
T cell depleted by magnetic bead cell sorting (MACS).  Unmanipulated bone marrow 
was then added back to the depleted marrow to bring the T cell count up to 1.5 -1.9%.  
The bone marrow harvest was timed to coincide with day 55 or 56 of gestation for the 
foetuses within the pregnant recipient.  The bone marrow was then injected into the 
foetuses at a dose of 2x10
9 cells/kg. The recipient sow received daily progestin 
(Regumate®) until day 100 of pregnancy in an attempt to prevent spontaneous abortion.  
The chimeric animals were then to receive a donor-type skin allotransplant after birth. 
 
 
Figure 9.1 Summary of in utero experimental outline 
Pregnant 
Sow 
Day  55-56
Birth
IU Injection 
of donor bone marrow
Day  55-56 115
Donor-type skin 
allotransplant   129
 
9.3 RESULTS 
Four rounds of in utero injections were performed 
 
9.3.1 Near full viability of bone marrow cells at injection following manipulation 
To assess the viability of the bone marrow injected in utero an extra syringe was 
prepared in rounds 2, 3 and 4 at the time of in utero injection with the ‘Add back’ bone 
marrow in exactly the same way as for the actual injections.  The bone marrow from 
this syringe was then analysed for cell viability using trypan blue exclusion method.  
There was >99% cell viability for each round. 
 
9.3.2 Bone marrow progenitor cell growth decreased following T-cell depletion by 
MACS 
To assess the effect of T-cell depletion and subsequent adding back of T cell replete 
unmanipulated bone marrow on the growth potential of the bone marrow progenitor 
cells in utero samples were saved during bone marrow processing and then tested in 
vitro.  
 
The growth potential of bone marrow progenitors used in the first round of in utero 
injections was assessed using cobblestone area forming cell assay.  ‘Add back’ bone 
marrow had significantly better CAFC growth at 10 weeks (fig 9.2 ‘Add back’; cream 
column) than either the unmanipulated bone marrow or the T cell depleted bone 
marrow; there was no significant difference between the CAFC growth in 
unmanipulated and T cell depleted bone marrow.   130
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2 CAFC growth after 10 weeks in unmanipulated, T-cell Depleted and T-cell ‘Add back’ 
bone marrow from round 1 
 
 
The growth potential of bone marrow progenitors used in rounds 2, 3 and 4 of in utero 
injections were assessed by the growth of bone marrow colony forming units (BM-
CFU) in the granulocyte erythrocyte monocyte megakaryocyte (GEMM), granulocyte 
monocyte (GM) and blast forming unit erythrocyte (BFU-E) lines (fig 9.3).  Following 
removal of T cells there was significantly worse growth in T cell depleted bone marrow 
(p<0.01; paired t-test) with restoration of growth on adding back of unmanipulated bone 
marrow to a reach a T cell level of 1.5% (p<0.02).  There was no significant difference 
in growth between unmanipulated BM-CFUs and add back BM-CFUs (p<0.08, paired t-
test). 
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Figure 9.3 CFU growth in unmanipulated, T-cell depleted and T-cell ‘Add back’ bone marrow.  
There was reduced growth of CFUs in T-cell depleted bone marrow in round 2 (a), round 3 (b) and round 
4 (c). 
a. 
b. 
c.   132
 
Key: 
a  ‘GA’ Gestational Age 
b  Number of bone marrow cells injected per foetus.  
c  Bone marrow was either freshly prepared for injection (‘Fresh’) or was frozen, stored and then thawed 
before injection 
d  Foetus too decayed to obtain tissue for analysis 
e  Swine can resorb foetuses during gestation so all foetuses may not be accounted for at birth 
 
Table 9.1 Outcomes from in utero injections 
 
Round  Sow 
No. 
Day of 
injection 
(GA
a) 
No. of 
foetuses 
injected/ 
Total 
foetuses 
No. of 
cells 
injected
b 
(Donor 
animal
 c) 
T cell 
content 
(%) 
Outcome
(Live 
Births/ 
Foetuses 
injected) 
Comments 
1688 
 
 
55 10/11 
(11
th had 
hydrops) 
0/10  GA 58 Spontaneous 
abortion:  
4 decaying foetuses 1688-
1, 1688-3
d, 1688-4, 1688-
5  
1 fresh foetus 1688-2 
(82g) 
1 
14-1 55 
 
 
6/6 
5x10
8 
 (17042 
Fresh) 
 
 
4.5 
 
0/6  GA 120 C-section: 6 
mummified foetuses
d 
2406 55  8/8  1/8  GA 93: Transabdominal 
doppler US probe: 2 
foetal heart-beats detected 
GA 117: 1 live birth 
2406-1; 6 mummified 
foetuses
d,e 
22-2 
 
56 
 
 
5/5 0/5  GA 96 Spontaneous 
abortion: 1 still-born 22-
2-1, 4 mummified 
foetuses
d 
2 
2252 
 
56 
 
 
5/5 
1.3x10
8 
(17139 
Fresh) 
1.50 
 
1/5  GA 108: 1 live birth 
2252-1, 3 mummified 
foetuses
d,e  
3  263 55  11/11  5x10
8 
 (17141 
Fresh) 
 
1.50 
 
1/11  GA 90:  Transabdominal 
USS: 7 foetuses, all with 
heart beats 
GA 103 Farrowed: one 
live foetus 263-1, 9 
mummified foetuses
d,e 
4  368 56  4/4  5x10
8 
 (17141 
Frozen) 
 
1.60 
 
0/4  GA 62 Transuterine USS: 
Heart beats in all 4 
foetuses 
GA 68 Transabdominal 
USS: Heart beats in all 4 
foetuses 
GA 99 Vaginal Discharge 
GA103 C-section: 4 
mummified foetuses
d    133
9.3.3 The majority of foetuses died in utero 
Forty-nine foetuses were injected with bone marrow in utero (reviewed in table 9.1).  
Only three piglets (6%) were born alive at full-term.  Modifications were made in each 
round with the aim of improving the survival rate.  In the first round, due to a technical 
error, the T cell percentage in the add-back bone marrow was 4.5% instead of the 
planned 1.5-1.9%; there were no survivors.  Furthermore, the abortion of sow 1688 
three days after injection revealed that the foetuses were only a third of the estimated 
size pre-injection (82g vs. estimated 250g).   
 
The T cell percentage in the bone marrow injection and the smaller than expected size 
of Hanford foetuses were taken into account in the second round of injections:  the T 
cell percentage was kept to 1.50% and the total number of cells injected per foetus was 
only 1.3 x10
8 cells (i.e. an estimated 2x10
9 cells/kg).  Additionally, in an attempt to 
monitor the foetuses in utero one of the sows underwent trans-abdominal Doppler 
ultrasound assessment at gestational age day (GA) 93, which was 38 days after in utero 
injection.   Two foetal heart-beats were detected on Doppler ultrasound, but this was at 
the limit of detection for the probe and so no conclusions could be made about the status 
of the other foetuses. Even with the modifications made in round 2 only two piglets 
from the 18 injected foetuses were born alive (survival rate: 11%).    
 
The two live piglets from round 2 (2252-1 and 2406-1) were born prematurely and 
despite maximal supportive therapy both animals died at five days old.  Piglet 2252-1 
succumbed to sepsis secondary to Klebsiella and E.Coli gastrointestinal infection. Piglet 
2406-1 died from sepsis due to segmental necrosis of the distal small bowel, presumably 
secondary to a volvulus that resolved before death.   
 
It was hypothesized that the low live birth rate in round 2 may have been because the 
Hanford breed is less robust than the larger Yorkshire pigs that had been used by others 
in previous experiments. So, in the third round, the breed of pig was changed from 
Hanford to Yorkshire. The foetuses were monitored at GA 90 using trans-abdominal 
Doppler ultrasound scanning; 7 foetal heart-beats were detected before the mother 
became non-compliant preventing further examination.  However, at term there was 
only one live birth from the 11 foetuses injected in round 3 (survival rate: 9%).  This 
piglet (263-1) was assessed not to be chimeric and so was sacrificed at 7 days old. 
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As there were no significant differences between the methods used in round 3 and 
previous experiments it was planned to use the same conditions in round 4 that had been 
used in round 3.  The bone marrow for the in utero injection was harvested from the 
donor (animal 17302). Unfortunately, the bone marrow was then irretrievably 
contaminated.  As an alternative, bone marrow from round 3 that had been frozen was 
defrosted and used. The viable cell yield after defrosting was 31.4%. The foetuses were 
monitored with transuterine ultrasound one week after injection, and trans-abdominal 
ultrasound two weeks after injection with heart-beats detected in all foetuses. However, 
at term there were no live births. 
 
9.3.4 Chimerism was achieved both in utero and perinatally 
Microchimerism (via PCR) was assessed in foetuses, and both macrochimerism (via 
FACS) and microchimerism was assessed in piglets within one week of birth. 
 
In utero assessment of microchimerism was facilitated by the spontaneous abortion of 
sow 1688 3 days after injection. Microchimerism was detected in the livers of four 
foetuses assessed using a PCR specific for the Class 1 MHC of SLA-D (fig 9.4).   135
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.4 Microchimerism in the liver of foetuses three days after in utero injection.  To achieve 
specificity of the PCR for MHC Class II of D, an aliquot of each PCR product (P) was digested (D).  Each 
digest was run on the gel adjacent to its originator product.  There was evidence of SLA-D DNA in all 
four foetuses examined (1688-1, 1688-2, 1688-4 and 1688-5) indicating presence of donor DNA 
originating from the bone marrow injection.  No SLA-D DNA was detected in either parent (1688 and 15-
7) indicating that the foetal findings were not due to cross-reactivity. 
 
 
Peripheral blood macrochimerism was assessed in the three live-born piglets.  Only 
piglet 2252-1 had detectable macrochimerism with lymphocyte/monocyte chimerism of 
3.14% and granulocyte chimerism of 1.02% (fig 9.5).  Blood from piglet 2406-1 did not 
stain with any antibody including the positive control (antibody 74-22-15 against 
myeloid cells), so it was not possible to determine if there was macrochimerism.  Piglet 
263-1 had no evidence of peripheral blood macrochimerism on FACS.  
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Key: 
a Percentage chimerism above isotype control 
 
Figure 9.5 Peripheral blood chimerism detectable by FACS perinatally in piglet 2252-1  
 
 
Microchimerism was assessed in all four piglets available for perinatal assessment (the 
three live-born piglets and one still-born piglet) using a PCR specific for class II MHC 
of SLA-D (fig 9.6).   
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Figure 9.6 rt-PCR assessment of microchimerism in live- and still-born piglets using Class I D 
primers 
 
 
Microchimerism was detected in the tissues (bone marrow and/or thymus) of all piglets.  
To confirm that the microchimerism detected was due to presence of donor DNA and 
not due to cross-reactivity, peripheral blood samples from the parents of these piglets 
were also tested.   Parents of two piglets were cross-reactive. The mother of piglet 2406-
1 was weakly positive (fig 9.6: Sow 2406).  However piglet 2406-1 was strongly 
positive in bone marrow, thymus and peripheral blood making it likely that the 
chimerism detected was real. The father of piglet 263-1 was weakly positive (fig 9.6; 
Boar 643) with only piglet 263-1 also being only weakly positive in the bone marrow 
(fig 9.6: 263-1 BM) indicating possible cross-reactivity of host DNA to MHC class II 
SLA-D PCR.  To investigate this further quantitative PCR (qPCR) was performed (fig 
9.7).  The level of amplification of DNA extracted from the peripheral blood of 263-1 
and her parents was compared.  DNA from the peripheral blood of an SLA
dd animal was 
used to define 100% amplification.  There was 0% amplification of DNA from the 
mother sow and 3.7% non-specific amplification of DNA from the father boar.  The 
amplification in the father was greater than the 0.82% amplification seen in piglet 263-1 
indicating that the microchimerism detected was likely to be due to cross-reactivity 
inherited from the father.  
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Figure 9.7 q-PCR assessment of chimerism in piglet 263-1 using Class II D primers/probe 
 
 
9.4 DISCUSSION 
The primary aim of this study was to achieve robust chimerism with engraftment in a 
swine model for the purpose of testing tolerance to a vascularised skin allotransplant:  
this was not achieved.  Chimerism was achieved both in utero and in the perinatal 
period.  However, no animal survived long enough to receive a vascularised skin 
allotransplant.  Despite lack of success to achieve the primary aim, useful data was 
acquired regarding the influence of MACS depletion of T cells on progenitor cell 
growth. 
 
9.4.1 Decreased in vitro growth of bone marrow progenitors following MACS 
depletion of T cells 
This study identified reduced growth in both CAFC and CFU assays of bone marrow 
progenitor cells following bone marrow T-cell depletion by MACS.  This is in contrast 
to a previous report on in vitro growth potential of swine bone marrow progenitor cells, 
which found no difference in growth potential in either CAFC or CFU assays (Lee, P. 
W. et al. 2005b).  A reason for this difference is was that growth was assessed until 10 
SLA-D
Boar 
Piglet 
263-1 
Sow   139
weeks in this study compared to only 6 weeks in the previous study (in this experiment, 
the growth difference had not yet reached statistical significance at 6 weeks). 
 
The CAFC assay identified the best progenitor cell growth potential in the ‘Add back’ 
bone marrow, whereas in the CFU assay both unmanipulated bone marrow and ‘Add 
Back’ bone marrow had similarly improved growth potential compared to ‘T Cell 
Depleted’ bone marrow.  This difference between the CAFC and CFU assays may be 
because of a differential growth rate of the more primitive progentiors in the CAFC 
assay compared to later progenitors in the CFU assay.  An alternative possibility for the 
difference in growth potential seen between the CAFC assay and the CFU assays is the 
much higher T cell percentage in the ‘Add Back’ bone marrow in the CAFC assay 
(4.5%), which used marrow from round 1 of the injections, compared to the CFU assays 
(1.5%), that used marrow from rounds 2, 3 and 4.  It would have been useful to compare 
CAFC and CFU growth from the same inoculum.  Unfortunately, the CAFC assay set 
up for round 2 became contaminated, and there was not enough time to set up the assay 
for rounds 3 and 4 (up to 4 weeks are required).   
 
These results indicate that there is a decrease in growth in vitro following T-cell 
depletion by MACS.  The relatively poor growth of bone marrow progenitor cells 
following MACS T-cell depletion correlates with previous in vivo findings indicating 
that in utero injection of T cell depleted bone marrow does not achieve chimerism 
(Crombleholme, T. M. et al. 1990; Rubin, J. P. et al. 2001). This decreased growth 
potential following T-cell depletion by MACS may be due to depletion of the T cells.  
Support for this possibility comes from previous murine studies, which indicate that the 
resistance to engraftment induced by T-cell depletion may be due to a direct role T cells 
have in haematopoiesis (Sharkis, S. J. et al. 1978; Wiktor-Jedrzejczak, W. et al. 1977).  
However, it is also possible that the effect of MACS on progenitor cell growth may not 
just be due to T-cell depletion; other cell populations could be removed, activated or 
down-regulated during the staining or on passaging through the magnetic column. 
 
9.4.2 Chimerism achieved 
Chimerism was achieved in this model.  Macrochimerism (detectable by FACS) was 
only able to be assessed in one animal (2252-1).  However, donor derived DNA was 
detected by PCR in one other piglet (2406-1) and in four foetuses three days after 
injection. Detection of chimerism by PCR in isolation is referred to as microchimerism.    140
The literature is unclear whether microchimerism has significance for tolerance in 
several models (as discussed in chapter 2); this is also true for in utero induction of 
chimerism (Donahue, J. et al. 2001; Hedrick, M. H. et al. 1994).  It is possible that there 
was also macrochimerism present in these animals but this could not be analysed, either 
because it was not possible to obtain live cells (from the foetuses), or because the 
animal’s cells did not stain with the control antibodies (piglet 2406-1).   
 
The foetuses in which microchimerism was detected were obtained only 3 days after in 
utero injection. The detection of donor DNA in these animals may not necessarily 
indicate that these animals were chimeric.  The donor bone marrow cells may have died 
leaving behind donor DNA that had not yet been degraded, and this was detected on 
PCR.  Analysis of RNA would have circumvented this problem as it degrades much 
faster.  The detection of donor DNA by PCR in piglet 2406-1 is likely to represent true 
chimerism: any residual DNA from dead cells would have been degraded by this 
timepoint (67 days after injection). 
 
9.4.3 Reason for low survival: 
A 15-40% embryonic mortality is to be expected even in a normal swine pregnancy 
(Legault, C. 1985).  However, there was a 94% mortality rate in the injected foetuses.  
The reasons for the low survival seen in this model are unclear; possibilities include (1) 
trauma at the time of injection, (2) contamination of the bone marrow, and (3) Graft-
versus-Host Disease. 
 
9.4.3.1 Trauma at the time of injection   
It is possible that the high mortality rate was due to the injection procedure itself.  All 
injections in this experiment were performed by the same person (Injector C); this was a 
different person to previous experiments in this model.  The method used to inject cells 
in this model is technically more difficult than the intra-peritoneal route used in most 
other models (Carrier, E. et al. 1997; Crombleholme, T. M. et al. 1990; Hedrick, M. H. 
et al. 1994; Kim, H. B. et al. 1998; Mychaliska, G. B. et al. 1997; Pallavicini, M. G. et 
al. 1992; Rice, H. E. et al. 1994; Shields, L. E. et al. 2003).  The intravenous injection 
involves insertion of a needle trans-abdominally through the liver parenchyma to the 
hepatic vein. Additionally, the needle entry point depends on the orientation of the 
foetus in the uterus, so adjacent organs (e.g. spleen, kidney, bowel, etc.) can also be 
punctured.  It is possible that the process of injecting the foetuses in utero caused fatal   141
trauma to the foetus.  Depending on the nature of the damage, this could have resulted 
in immediate death or caused damage to a vital organ with death occurring at a later 
timepoint.   
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Figure 9.8 Relationship between mortality and T cell percentage in the inoculum for injections 
performed by different operators in previous experiments 
 
 
The best way to assess whether the injection procedure itself was a factor in the high 
mortality in this experiment is to perform saline injections into the foetuses of a 
pregnant sow as has been done previously (Rubin, J. P. et al. 2001). However, a saline 
injection was not performed in this case. An indirect method to assess the effect of the 
injection procedure is to compare the outcomes of the person performing the injection 
(Injector C) to previous injectors in the same model.  There have been two previous 
operators (Injector A and Injector B).  Data from previous published (Lee, P. W. et al. 
2005b; Mathes, D. W. et al. 2001; Rubin, J. P. et al. 2001) and unpublished (Mathes et 
al.) swine in utero experiments in this laboratory were reviewed. The T cell percentage 
at the time of injection was also included in the analysis as previous studies have 
indicated that this can also have a significant impact on mortality due to GvHD 
(Crombleholme, T. M. et al. 1990; Shields, L. E. et al. 2003).  There was a very close 
correlation between mortality rate and T cell percentage for Injector A (r
2=0.978; fig 
9.8, blue dots).  There was a significantly lower mortality in the pigs injected by Injector 
A than either Injector B (p<0.04; paired t-test) or Injector C (p<0.04; paired t-test).    142
There was an increased mortality in pigs injected by Injector C compared to Injector B, 
but this did not reach statistical significance (p>0.1; paired t-test).   
 
This data suggests that the injection procedure may have been one factor in the high 
mortality rate. It is likely that four of the foetuses of sow 1688 were fatally injured at the 
time of injection with abortion of the already decaying foetuses three days after 
injection. The only intact foetus (#1688-2) in sow 1688 was consequently aborted along 
with its dead siblings.  In several of the other sows there was ultrasound evidence of 
foetal survival to near full-term.  This does not exclude an injury to the foetus that was 
not initially fatal but eventually caused foetal death. 
 
9.4.3.2 Contamination of the bone marrow  
Another potential cause for the high foetal mortality rate is bone marrow contamination.  
There was no evidence of bacterial or mould contamination on the bone marrow plated 
for CAFCs or CFUs making this an unlikely cause of foetal death.  
 
9.4.3.3 Graft versus Host Disease (GvHD) 
A third possibility is that the foetuses developed GvHD in utero causing foetal death.  It 
was impossible to analyse the mummified foetal tissue for GvHD so this cannot be 
excluded.  GvHD was cited as the likely cause for foetal loss in a previous in utero 
experiment (Rubin, J. P. et al. 2001), but no evidence was provided.  In previously 
described models GvHD correlates to T cell dose.  In round 1 the T cell percentage was 
4.5% and the bone marrow cell dose was three times as high as planned (due to over-
estimation of foetal weight) with a resulting absolute T cell dose 6 times higher than 
considered optimal.  Therefore it is possible that the foetuses of sow 14-1 in round 1 
succumbed to GvHD.  However, it is less likely that GvHD was the cause of the high 
mortality in rounds 2, 3 and 4 because the T cell dose was comparable to previous 
studies that achieved much lower mortality (Mathes, D. W. et al. 2005).   
 
9.5 CONCLUSIONS 
This study did not achieve its primary objective of providing a robust large animal 
model for achieving high-level chimerism with engraftment in which to test skin 
tolerance. However, useful data was obtained indicating that the process of MACS 
depletion of T cells results in poorer growth of bone marrow progenitors.  Furthermore, 
a direction for future studies has been outlined: (1) Sham injection of saline instead of   143
bone marrow to assess the injection procedure; (2) plan foetal sacrifice at various times 
throughout pregnancy to obtain live tissue samples for assessment to exclude GvHD; 
and (3) plating of both CAFCs and CFUs  from the same inoculum to further define the 
role of T cells in progenitor cell growth, as well as experimenting with different levels 
of T cells. 
 
In Chapter 10 adult induction of chimerism is explored as an alternative model to 
achieve a moderate level engraftment chimera to test the skin tolerance hypothesis.   144
CHAPTER 10: INDUCTION OF SKIN TOLERANCE 
 
10.1 INTRODUCTION 
The primary aim of this study is to test the hypothesis developed in Chapter 6.  The 
hypothesis states that an engrafted moderate-level chimera will be tolerant to 
vascularised skin transplanted from the HCT donor across a single haplotype MHC 
barrier.  The secondary aim of this study is to assess the effectiveness of DLI with prior 
leukapheresis to boost chimerism. 
 
In Chapter 9 an in utero model was used in an attempt to obtain an engrafted moderate-
level chimera to test the skin tolerance hypothesis.  However, this experiment was not 
successful in attaining long-living chimeras.  Consequently, the approach of adult 
induction of chimerism was used in this experiment.  The experiment required two 
separate phases: induction of an engrafted moderate level chimera, and then 
performance of vascularised skin flap allotransplantation. 
 
10.1.1 Induction of an engrafted moderate level chimera 
The method used successfully by Cina (Cina, R. A. et al. 2006) to non-myeloblatively 
induce chimerism with engraftment across a single haplotype MHC barrier in pigs is 
used in this study.  This involves low-dose whole body irradiation, T-cell depletion with 
immunotoxin, haematopoietic cell transplantation (HCT) of cells from a single-
haplotype MHC mismatched donor mobilised with SCF and IL3, and cyclosporine 
cover until day 45.  
 
Previously, this protocol achieved engraftment in all surviving animals, but only fifty 
percent had high enough levels of chimerism to test the skin tolerance hypothesis.  
Consequently, in this study animals that do not achieve high enough levels of chimerism 
with the protocol will receive a DLI with a prior leukapheresis. The use of leukapheresis 
prior to DLI is based on the hypothesis developed in Chapter 7: leukapheresis will 
deplete suppressor cells (along with all other white cells) in the chimera which normally 
prevent DLI from being effective. 
 
10.1.2 Vascularised skin flap allotransplantation  
Once a moderate level of chimerism is achieved in an engrafted chimera, the animals 
receive a vascularised skin flap from the HCT donor.  Engraftment has been previously   145
defined as presence of donor bone marrow colony forming units (BM-CFUs) beyond 
week 14 after HCT.  However, it has previously been observed with this chimerism 
induction protocol that moderate and high-level multilineage peripheral blood 
chimerism (i.e. myeloid lineages >10% chimerism) at day 60 correlates with presence of 
donor-derived BM-CFUs beyond week 12, so this was used as a marker of engraftment 
as well.  The use of the actual HCT donor aims to avoid a non-MHC minor antigen 
mismatch between the HCT donor and a MHC matched skin donor. This non-MHC 
minor antigen mismatch has not been a problem in previous organ allotransplants but 
may be significant in skin allotransplantation due to skin’s susceptibility to rejection. 
 
10.2 OVERVIEW OF EXPERIMENT  
.  
  
 
 
 
 
 
 
 
Figure 10.1 Summary of experimental plan 
 
 
The experimental is summarized in figure 10.1.  Three sibling SLA
ad animals (17467, 
17468 and 17469) underwent HCT with non-myeloablative chimerism induction 
(summarized in table 3.1 protocol F). 
 
Sixty days after HCT (which is two weeks after completion of the 45 day initial 
induction period) animals were allocated to receive a leukapheresis and DLI, if required, 
to achieve moderate level of chimerism needed to test the skin tolerance hypothesis. To 
allow for possible later downward drift of chimerism, even moderate level chimeras that 
were not approaching near full chimerism were allocated for a leukapheresis and DLI.  
The application of leukapheresis and DLI was staggered between animals so that an 
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animal receiving a delayed leukapheresis and DLI could act as a control for an animal 
receiving immediate leukapheresis and DLI.  Following achievement of engraftment 
and moderate level chimerism a vascularised saphenous skin flap was allotransplanted 
from the HCT donor.   A control animal was included that did not undergo chimerism 
induction but received a vascularised saphenous skin flap across a single-haplotype 
barrier. 
 
10.3 RESULTS 
The results from the study are in two parts.  Firstly, the findings following leukapheresis 
and DLI; and secondly, the outcome following vascularised skin allotransplantation. 
 
10.3.1: Leukapheresis and Donor Leukocyte Infusion 
 
10.3.1.1 Moderate to high levels of peripheral blood chimerism were achieved at day 
60 following chimerism induction 
Following completion of the non-myeloablative chimerism induction protocol all three 
animals had multilineage peripheral blood chimerism (fig 10.2).   
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Figure 10.2 Peripheral blood chimerism following chimerism induction protocol 
 
0 20 40 60
0
20
40
60
80
100
Day
%
 
C
h
i
m
e
r
i
s
m
 
0 20 40 60
0
20
40
60
80
100
Day
%
 
C
h
i
m
e
r
i
s
m
 
0 20 40 60
0
20
40
60
80
100 Lymphocytes
Monocytes
Granulocytes
Day
%
 
C
h
i
m
e
r
i
s
m
   147
The presence of multilineage peripheral blood chimerism indicated haematopoietic stem 
cell engraftment in all three animals.  This was confirmed at week 14 with evidence of 
donor-derived BM-CFUs and thymic chimerism.   
 
The level of multilineage chimerism was then assessed for allocation of animals to 
receive a leukapheresis and DLI to achieve moderate level chimerism if required. 
Animal 17468 had 70-80% chimerism in the myeloid (monocyte and granulocyte) 
lineages, with chimerism still rising.  The lymphocyte lineage was lower at 40%.  
However, lymphocyte chimerism is not as sensitive a marker of production of donor 
cells in the recipient due to the long-life of lymphocytes.  Due to the high and rising 
myeloid levels of peripheral blood chimerism in 17468 it was decided not to perform a 
leukapheresis and DLI on this animal. 
 
Animals 17467 and 17469 had similarly moderate levels of peripheral blood 
multilineage chimerism.  To protect against possible later downward drift to low-level 
chimerism both animals were allocated to undergo leukapheresis and DLI.  Animal 
17469 underwent leukapheresis and DLI immediately with 17467 initially used as a 
control animal for comparison.  Animal 17467 subsequently underwent a DLI 5 weeks 
later. 
 
10.3.1.2 Leukapheresis prior to DLI resulted in the temporary depletion of Tregs 
Animals 17467 and 17469 both underwent leukapheresis for a 7-hour period prior to 
DLI. The leukapheresis on 17469 was interrupted and then had to proceed at a slower 
flow rate (20ml/min) for the last 4 hours due to technical problems; leukapheresis on 
17467 was unimpeded running at >30 ml/min for the 7 hours. The number of white 
blood cells removed from 17467 was much greater than from 17469 (see table 10.1), 
with a more profound subsequent lymphopenia (see fig 10.4)    148
 
  Total WBCs (x10
10) 
  17469 (22kg)  17467 (16kg) 
WBC in peripheral blood 
pre-leukapheresis 
0.98 1.19 
WBCs in leukoproduct 
 
1.11 4.57 
WBC in peripheral blood 
post-leukapheresis 
Not measured  1.74 
 
Table 10.1 White blood cells removed by DLI, and in the peripheral blood before and after DLI  
 
 
The number of circulating peripheral white blood cells prior to leukapheresis was 
similar in 17469 and 17467 despite the difference in animal weights (22kg vs.16kg).  
Leukapheresis was technically better in 17467 with removal of approximately four 
times as many white cells as 17469.  Despite the large numbers of white cells removed, 
the peripheral blood white cell count actually rose in 17467 by the end of leukapheresis. 
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Figure 10.3 Lymphocytes in the peripheral blood before and after DLI.  Measurement of the absolute 
concentration of lymphocytes before and after leukapheresis and DLI revealed that there was a significant 
decrease in lymphocyte count in both 17469 and 17467. The decrease was larger in 17467 than 17469 
(62% vs. 42%).  There was only a minimal resolution of post leukapheresis relative lymphopenia by 3 
weeks in 17467, and it took 6 weeks for the lymphocyte count to rise to pre-DLI levels in 17469.   149
Despite the larger number of cells removed from 17467 compared to 17469, there was a 
similar decrease in CD4+CD25+FoxP3+ T cells (Tregs) from pre leukapheresis/DLI to 
afterwards.  This depletion of Tregs was only temporary, with return to pre-
leukapheresis levels in 17469 within 4 weeks (fig 10.3). 
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Figure 10.3 CD4+ CD25+ FoxP3+ cell levels pre and post leukapheresis and DLI.  Graphs of 
CD4+CD25+FoxP3+ cell (Treg) levels over the same time period in 17469 and 17467 aligned for 
comparison of contemporaneous timepoints. Treg levels fell by 30% following leukapheresis and DLI in 
17469, with no decrease over the same time period in 17467.  Similarly, Treg levels fell by 32% in 17467 
following leukapheresis and DLI with no decrease over the same time period in 17469.   
 
 
10.3.1.3 Increased chimerism at 4 weeks following DLI  
Chimerism levels following leukapheresis and DLI were monitored in the thymus at 4 
weeks after DLI and in the peripheral blood several times a week.  Both 17467 and 
17469 demonstrated increased thymic chimerism at 4 weeks after DLI compared to the 
immediate pre-DLI level (fig 10.4).  17467 received its leukapheresis and DLI at week 
14, later than 17469. 17467 demonstrated no increase in thymic chimerism over the 
 30%Treg Depletion  
 32%Treg Depletion    150
time-period (weeks 8-12 post HCT) that 17469’s thymic chimerism increased.  
Similarly, no historical control animals (n=5) that had undergone the same chimerism 
induction protocol but no DLI at this time point, showed an increase in thymic 
chimerism over the same period.  
 
 
Figure 10.4 Increase in thymic chimerism following leukapheresis and DLI  
Four weeks following leukapheresis and DLI, 17469 had a 12.4% increase in thymic chimerism, and 
17467 had a 12.2% increase in thymic chimerism.  
 
 
17467 also demonstrated an increase in peripheral blood chimerism, particularly in the 
myeloid lineages following leukapheresis and DLI.  In contrast, 17469’s peripheral 
blood chimerism was stable (fig 10.5). 
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Figure 10.5 Peripheral blood chimerism following leukapheresis and DLI. Peripheral blood 
chimerism was unchanged in 17469 following leukapheresis and DLI.  In contrast peripheral blood 
chimerism increased in 17467 over the 4 weeks following leukapheresis and DLI (lymphocytes ↑14%, 
monocytes ↑19% and granulocytes ↑2%). 
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10.3.1.4 Evidence for increased donor-vs.-chimera suppression by 4 weeks post DLI 
Animals 17467 and 17469 underwent in vitro assessment of donor-vs.-chimera 
suppression prior to leukapheresis and DLI.  17469 also underwent in vitro assessment 4 
weeks after DLI (see fig 10.6) (17467 unfortunately died before post DLI in vitro 
assessment could be performed).  Prior to DLI, in both 17467 and 17469, PBMCs from 
the donor (SLA
ac; marked ‘nAC’) showed a normal alloresponse to recipient type 
PBMCs (SLA
ad; marked ‘nAD’), even when cocultured with PBMCs from the chimera.  
However, following DLI there was significant suppression of the donor PBMC 
alloresponse to recipient-type PBMCs when cocultured with chimera PBMCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.6 In vitro assessments of donor-vs.-chimera suppression pre and post leukapheresis and 
DLI.   Animal 17469 was assessed both just prior (a), and 4 weeks following DLI (b), for evidence of 
active donor-vs.-chimera suppression by primary coculture MLR. Prior to leukapheresis and DLI, 
addition of non-irradiated peripheral blood mononuclear cells (PBMCs) from 17469 to the donor (‘nAC’) 
did not inhibit the donor’s normal alloresponse (a; normal alloresponse: ‘nAC@nAD’ cf. alloresponse 
with addition of  PBMCs from 17469: ‘nAC/469@nAD’).  However, following DLI there was significant 
suppression of the donor alloresponse on addition of PBMCs from 17469 (b).  Animal 17467 
demonstrated no evidence of donor-vs.-chimera suppression at the same timepoints (data not shown), 
which were both pre-leukapheresis and DLI for this animal. 
 
 
10.3.2 Vascularised skin flap allotransplantation 
Only two of the three chimeras (17468 and 17469) survived long enough to receive a 
vascularised skin flap allotransplant from the HCT donor. One control animal (17519) 
was included, which underwent skin flap allotransplantation across a single haplotype 
MHC barrier without prior chimerism induction.  The chimeras were tolerant to the 
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MHC on in vitro assessment by MLR prior to skin flap allotransplantation; in contrast 
the control animal was responsive. (fig 10.7).  
 
 
Figure 10.7 Assessment of in vitro responsiveness to the donor prior to skin flap allotransplantation.  
MLRs performed prior to skin flap transplant demonstrating tolerance to the MHC in both chimeric 
animals (a, b), but alloresponsiveness in the control animal (c). 
 
 
Both chimeras and the control animal received a vascularised saphenous skin flap 
allotransplant across a single haplotype barrier without immunosuppression.  The results 
of skin flap allotransplantation are summarized in Table 10.2. 
 
Animal  Immune Barrier  Engrafted 
Chimera 
Skin Survival 
17519 (Control)  ACÆAD No  6  Days 
17468 ACÆAD Yes >46  Days 
17469 ACÆAD Yes  >130  Days 
 
Table 10.2 Summary of results of vascularised skin flap allotransplantation 
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10.3.2.1 Tolerance is achieved to vascularised skin in a moderate level chimera 
The control animal rejected the allotransplanted skin flap by day 6 (fig 10.8 a & b).  In 
contrast, both animals 17468 and 17469 showed no signs of rejection of their 
allotransplanted flaps at any timepoint. Animal 17468 died 46 days after skin 
transplantation from an unrelated cause
10 with no evidence of skin flap rejection (fig 
10.8 c & d).  Animal 17469 survived long-term with no evidence of skin flap rejection 
(fig 10.8 e & f).   Tolerance (i.e. donor-specific unresponsiveness) was confirmed in 
animal 17469 with in vitro assays (fig 10.9). 
a .      c      e .  
                  
       17519 (Control)           17468             17469 
              Day 6           Day 46            Day 113 
b.         d.               f. 
                                      
 
 
Figure 10.8 Skin survival outcomes: photographs and histology.  Photographs and incisional biopsies 
from the allograft skin flap allografts were taken. Histological examination of the biopsies was performed 
(haematoxylin and eosin stain, x80 magnification shown).  Animal 17519 (control animal) had visible 
skin necrosis of its flap at 6 days after transplantation with histological evidence of epidermal necrosis 
and dermal mononuclear cell infiltrate.  Animals 17468 and 17469 had viable skin flaps with no visual or 
histological evidence of skin rejection at any timepoint (17468 died at day 46, 17469 survived to >130 
days). 
                                                 
10 Animal 17468 caught a multi-drug resistant bowel infection from an animal in an adjacent cage.  This 
infection became systemic and eventually caused formation of an infected thrombus around a central line, 
from which the animal subsequently died. 
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Figure 10.9 Animal 17469 had donor (AC) specific unresponsiveness 91 days after skin flap 
allotransplantation 
 
 
10.3.2.2 No cellular infiltrate into the skin flaps in tolerant animals 
In contrast to previous swine composite tissue allotransplantation models, there was no 
T cell infiltrate of the skin flaps of animals 17468 and 17469 on histological 
examination.  
 
10.4 DISCUSSION 
This study consisted of two parts: (1) induction of a moderate level chimera by HCT 
and subsequent leukapheresis and DLI, in which to test the skin tolerance hypothesis; 
and (2) skin allotransplantation across a single haplotype MHC barrier from the HCT 
donor with the aim of achieving tolerance.   
 
Both elements of the study were successful.  Chimerism was achieved following HCT 
with subsequent boosting of chimerism to moderate levels by leukapheresis and DLI.  In 
addition, tolerance to skin transplanted across a single haplotype MHC barrier was 
achieved.  
 
10.4.1 Leukapheresis and DLI is effective at increasing chimerism 
In this study, the strategy developed in Chapter 7 was tested:  DLI with prior 
leukapheresis will be effective at boosting chimerism.  Both animals that underwent 
leukapheresis and DLI showed increased thymic chimerism by 4 weeks after the 
procedure, and one had increasing levels of peripheral blood chimerism.  The aim of   155
leukapheresis was to reduce all white blood cell populations, including any causing 
donor-vs.-chimera suppression thereby preventing the DLI from being effective. Simple 
measurement of the total number of white blood cells in the peripheral blood did not 
give a good estimate of the proportion of total white blood cells removed by 
leukapheresis, with the actual number increasing after removal of four times the number 
of white blood cells initially present in the peripheral blood in animal 17467.  The rapid 
replenishment of peripheral blood white blood cells by the completion of leukapheresis 
is likely to be largely due to release of large numbers of leukocytes from lymphoid 
tissues,  with expansion of residual leukocytes as well as production of new white blood 
cells in the bone marrow.   
 
Measurement of the peripheral blood lymphocyte count over time indicated that the 
leukapheresis procedure was effective at temporarily depleting up to almost two-thirds 
of the lymphocyte population.  This is consistent with clinical studies that have found 
that leukapheresis can result in a reduction of peripheral blood lymphocytes (Nicolini, 
F. E. et al. 2004; Prior, C. R. et al. 1991; Strauss, R. G. et al. 1980).  
 
Recovery of both the lymphocyte and the Treg population to pre-leukapheresis and DLI 
levels took six weeks in 17469.  The time required for replenishment of the lymphocyte 
blood count has not been directly examined in the pig before.  Huang followed T cell 
recovery following profound depletion with anti-CD3 immunotoxin (Huang, C. A. et al. 
1999b), noting return of peripheral T cell levels by 6-11 days.  However, this was only 
partial recovery and the levels appeared to be already plateauing in the two animals 
followed to 11 days indicating that return to pre-depletion levels may have taken a lot 
longer.   In contrast, Suzuki found that depletion using anti-CD8 antibody resulted in the 
return of CD8+ cells to pre-depletion levels in the peripheral blood within 8 to 12 days 
(Suzuki, T. et al. 1990).   However, it is not clear that this was due to replenishment 
with new CD8+ cells. This study did not exclude the possibility that CD8+ cells in 
lymphoid tissues were not fully depleted.  Furthermore, it is possible that many of the 
CD8+ cells were not actually depleted but just temporarily down-regulated CD8 from 
their cell surface.    
 
There have been few relevant clinical studies analysing replenishment of the 
lymphocyte pool after depletion.  In patients donating at least one DLI following a 
previous bone marrow or cytokine mobilised progenitor cell donation Nicolini found   156
that 22% of donors became leukopenic following their first DLI.  Furthermore, donors 
stayed leukapenic for a median of 3.7 months (range 1.6 to 43 months) following DLI 
(Nicolini, F. E. et al. 2004).  However, these patients already had depleted levels of 
lymphocytes prior to DLI due to the previous bone marrow or progenitor cell donation. 
 
Following leukapheresis and DLI there was an initial reduction of 30-32% in the 
number of CD4+CD25+FoxP3+ cells in the peripheral blood.  This was associated with 
an increase in thymic chimerism (and peripheral blood chimerism in 17467) by 4 weeks 
after DLI.  It was hypothesized that leukapheresis would deplete cells mediating Donor-
vs.-chimera suppression thereby making DLI effective.  It is possible that 
CD4+CD25+FoxP3+ cells are mediating the suppression and their temporary depletion 
provides a window of opportunity for the DLI to be effective.  However, depletion of 
CD4+CD25+FoxP3+ cells may not be relevant for the effectiveness of DLI following 
leukapheresis because there may be other cell types mediating suppression.  
Additionally, it is possible that this approach is effective because global depletion of the 
white blood cell population by leukapheresis renders the recipient partly immuno-
incompetent thereby creating “immunological space” in which donor bone marrow 
progenitor cells can expand.  
 
The absolute number of CD4+CD25+FoxP3+ cells increased to greater than pre- 
leukapheresis/DLI levels in 17469 by five weeks after the procedure.  This was 
associated with donor-vs.-chimera suppression in vitro, which was not evident prior to 
leukapheresis and DLI.  This correlation suggests that the increase in 
CD4+CD25+FoxP3+ cells may have this boosted donor-vs.-chimera suppression.  
However, this was not confirmed.   Furthermore, previous work indicates that increase 
suppression is not just due to CD4+CD25+FoxP3+ cell expansion (Koenen, H. J. et al. 
2005), but also to changes in their activation status (Yates, J. et al. 2007). 
 
10.4.2 Skin tolerance is achieved in a moderate-level engrafted chimera 
Composite tissue allotransplantation techniques are the best reconstructive option for 
many severe defects.  Induction of tolerance to skin and other tissues in composite 
tissue allotransplants would remove many of risks associated with composite tissue 
allotransplantation techniques, further widening their applicability.   Several methods 
have been successful in achieving tolerance to skin in rodents, as outlined in Chapter 2.  
However, this success has not been translated to the large animal or the clinic.    157
Tolerance to musculoskeletal elements of a CTA has already been achieved across a 
MHC mismatch in large animal models (Hettiaratchy, S. et al. 2004);  however, 
tolerance to skin has only previously been achieved across non-MHC minor mismatch 
barriers (Mathes, D. W. et al. 2003; Tillson, M. et al. 2006; Yunusov, M. Y. et al. 2006).  
This study confirms the hypothesis that a moderate-level engrafted chimera will be 
tolerant to skin allotransplanted from the HCT donor across a single-haplotype MHC 
barrier.  This is the first time that tolerance to skin transplanted across a MHC barrier 
has been achieved in a large animal model. 
 
The achievement of tolerance to allotransplanted skin in a large animal model indicates 
that it may be also possible to achieve skin tolerance clinically.  However, there are 
limitations to this experimental protocol, which may affect the application of this 
approach to clinical composite transplantation.   
 
A limitation in the design of this experiment is that transplantation was performed 
across just a single haplotype MHC barrier; this is equivalent to transplantation between 
siblings or between parent and child. Until now, due to a lack of donors, there has been 
no deliberate matching between donors and recipients, limiting the use of this technique 
to fortuitous HLA matching.  However, as composite tissue allotransplantation becomes 
more common-place, people may be more willing to be donors. So, it may be possible 
to get at least single haplotype HLA matching. 
 
There are also several other elements of the induction protocol which would not be 
directly transferable to the clinical situation.  For example, the delay following 
chimerism induction before skin allotransplantation would not be possible clinically 
because the donor would be brain dead and so could not be kept alive for an extended 
period of time. The barriers to the clinical application of each element of the protocol, 
and approaches to overcome these barriers are discussed further in Chapter 12.  
 
Another limitation in this experiment is that only two animals (17468 and 17469) 
underwent chimerism induction and vascularised skin allotransplantation.  Although 
both animals accepted their skin flap transplant, this is still a small number.  
Furthermore, animal 17468 died 46 days after skin allotransplantation.  So, it is possible 
that this animal would have gone on to reject its transplant.  However, even survival to 
day 46 without immunosuppression is longer than any previous vascularised skin   158
allotransplant.  Hettiaratchy (Hettiaratchy S. et al 2004) achieved limb allotransplant 
(which included vascularised skin) survival of 46-70 days.  However, these animals 
were given high-level systemic cyclosporine for the first 30 days following 
transplantation.  Consequently, survival without immunosuppression only ranged 
between 16-40 days.  Despite the long survival of 17468’s flap, it is still possible that it 
could have been rejected.      
 
Animal 17469 demonstrated long-term acceptance of the allotransplanted skin flap to 
greater than 100 days. This is significant because it is far beyond the time period when 
rejection due to non-MHC minor antigens usually occurs (10-50 days (Huang C. A et al 
2000; Fuchimoto Y et al. 2001)), indicating tolerance.  Skin has been considered one of 
the most difficult tissues to achieve tolerance to, and it was not known whether it would 
be even possible to achieve tolerance in a large animal model across a MHC mismatch.  
This experiment demonstrates that it is possible. 
 
10.4.3 Mechanism of skin tolerance 
This study confirmed the hypothesis that an engrafted moderate level chimera would be 
tolerant to a vascularised skin allograft.  The assumption underlying this hypothesis was 
that a moderate level chimera would achieve tolerance by combined central deletional 
and regulatory mechanisms. The central deletional mechanism provides robust tolerance 
to the MHC.  The central deletional mechanism is supplemented by regulatory 
mechanisms which provide tolerance to any skin specific antigens which are are not 
covered by the central deletional mechanism because they are not represented on bone 
marrow derived cells.   
 
The role of central deletional mechanisms was not directly examined in this model.  
However, the animals had evidence of haematopoietic stem cell engraftment.  
Engraftment has previously been associated with evidence of the presence of central 
deletional mechanisms achieving donor specific transplant tolerance (Fuchimoto Y. et 
al. 2000), and so it is likely that deletional mechanisms contributed to the achievement 
of skin tolerance in this study.   
 
The presence of regulatory mechanisms involved in the achievement of skin tolerance 
was only indirectly examined.  There was no regulatory T cell infiltrate into the skin 
flap.  This finding contrasts with the previous split tolerance composite tissue   159
allotransplant models, as well as the kidney transplant model described in Chapter 6.  In 
these models there was a perivascular non-inflammatory T cell infiltrate which was 
likely to have a regulatory function.  One reason for this difference is that the previous 
models achieved tolerance by almost entirely peripheral regulatory mechanisms (see 
Chapters 6a and 6b), whereas in this model a central deletional mechanism is likely to 
have made a significant contribution to the achievement of tolerance. 
 
If regulation is important in the achievement of skin tolerance, the mechanisms involved 
may only function across a single haplotype MHC mismatch between donor and 
recipient.  There is evidence that the induction of Treg cells involves the presentation of 
antigenic peptide on a self MHC class II molecule (LeGuern, C. 2003).  This would 
occur in transplantation across a single haplotype MHC barrier because of the shared 
MHC on the second haplotype.  In contrast, a full double-haplotype MHC mismatch 
would not have a shared MHC and so tolerance may not be able to be achievable.  
However, there are peripheral tolerance models that achieve organ tolerance across a 
full double-haplotype mismatch barrier (Utsugi 2001), indicating there are mechanisms 
not limited to the sharing of MHC class II. 
 
10.5 CONCLUSIONS  
Billingham, Brent and Medwar were the first to describe a method of skin tolerance 
induction in a small animal model (Billingham, R. E. et al. 1953).  Fifty-five years later 
this experiment finally takes the next step towards clinical skin tolerance induction, 
achieving tolerance to a vascularised skin allotransplant in a preclinical large animal 
model. The achievement of clinical skin tolerance could significantly lower the risks of 
composite tissue allotransplantation techniques, facilitating their widespread use, and 
also allow expansion into new applications; for example, CTA techniques could replace 
many current reconstructive techniques, thereby removing the problem of donor site 
morbidity. 
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CHAPTER 11:  THE USE OF SITE-SPECIFIC THERAPY TO PREVENT SKIN 
REJECTION 
 
11.1 INTRODUCTION 
The aim of this study is to examine the ability of topical FK506 to prevent skin rejection 
in skin transplant recipients both with normal and reduced alloreactivity. 
 
The main goal of CTA transplantation immunology research is to achieve widespread 
application of CTA techniques.  To achieve this goal there needs to be long-term 
survival of skin and other tissues transplanted across MHC barriers while avoiding the 
toxicity of systemic immunosuppression. As discussed in Chapter 2, there are several 
strategies that can be used to achieve this: 
 
(A) Tolerance induction: this would obviate the requirement of chronic 
immunosuppression 
 
(B) Reduction of the toxicity of chronic immunosuppression 
 
(C) Induction of a less alloreactive state with consequent reduction in 
immunosuppression  
 
The induction of skin tolerance (option A) has been investigated in previous chapters. 
However, skin tolerance is not necessarily required.  A reduction of immunosuppression 
toxicity (option B) or induction of a less alloreactive state (option C) could also achieve 
the goal of long-term survival of skin without immunosuppression toxicity.  Site-
specific therapy is one modality that could be used in the accomplishment of options B 
and C.  The use of site-specific treatment could facilitate a decrease in the levels of 
systemic immunosuppression required in a recipient with normal alloreactivity, with 
consequent reduction in medication toxicity.  Alternatively, site-specific monotherapy 
may prevent skin allotransplant rejection following induction of a less alloreactive state.   
 
The use of topical FK506 has been demonstrated to double the length of skin survival in 
a rat model (Fujita, T. et al. 1997; Yuzawa, K. et al. 1996).  Furthermore, topical 
steroids have been used to achieve prolonged limb allotransplant survival in a rat model 
(Inceoglu et al. 1994).   There has also been some success using site-specific treatments   161
to treat acute rejection episodes clinically.  The Louisville group achieved clinical 
resolution of grade 3 histological skin rejection in a hand transplant by alternating 
topical tacrolimus and topical steroid treatment with change to the systemic 
immunosuppressive regimen.  However, topical tacrolimus was not sufficient to reverse 
rejection responses in either an Austrian hand transplant (Lanzetta, M. et al. 2007) or 
the first French face transplant (Dubernard et al. 2007). 
 
The clinical use of site specific therapy has not been studied in a systematic way so it is 
not possible to draw firm conclusions about its effect.  This study aims to examine the 
effect of site-specific therapy in a clinically relevant large animal model.   FK506 was 
selected as the topical therapy because it is very effective in treating several immune 
mediated dermatological complaints, has minimal systemic toxicity (Munzenberger et 
al. 2007), and avoids the local side effects of topical steroids (e.g. skin atrophy, striae, 
telangectasia) that limit its prolonged use. 
 
11.2 OVERVIEW OF EXPERIMENT 
This is a combined prospective and retrospective study examining the effect of topical 
FK506 on allogeneic skin transplant survival.  The effect of topical FK506 in animals 
both with normal alloreactivity and reduced alloreactivity is examined.   
 
11.2.1 The effect of FK506 in animals with normal alloreactivity  
To ascertain if topical FK506 could be used as a substitute for systemic 
immunosuppression, the effect of FK506 on survival of both conventional skin grafts 
and vascularised saphenous skin flaps transplanted across a MHC barrier in naïve 
animals was examined (table 11.1; Groups I and II).  Experimental animals received 
FK506 daily starting on the day of skin allotransplant.  Controls received either a 
conventional skin allograft or a vascularised saphenous skin flap transplanted across a 
MHC barrier without immunosuppressive treatment.   162
 
Group  Alloreactivity Conventional 
Skin Graft/ 
Vascularised 
Skin Flap 
Topical 
FK506 
Animal  Transplant
Barrier 
17476  DDÆAC  No 
17506  DDÆCC 
15129 AAÆDK 
 
I 
 
Graft 
Yes 
15132 AAÆDK 
No  17519
a  ACÆAD   
II 
 
 
 
Normal 
Alloreactivity
 
Flap 
 
  Yes  17520  ACÆAD 
No 13476
b 
 
CDÆAD   
III 
(Chimera) 
 
Reduced 
Alloreactivity
 
 
Graft 
  Yes  16626
b 
 
ACÆAD 
Key 
Prospectively studied animals are highlighted 
a. Animal 17519 was also used as a control animal in Chapter 10 
b. Animal received an organ transplant (to which it was tolerant prior to skin allograft) 
 
Table 11.1 Summary of experimental groups 
 
 
11.2.2 Effect of topical FK506 in animals with reduced alloreactivity  
It has been previously observed that induction of engrafted chimerism across MHC-
matched minor mismatched barriers achieves a state of reduced alloreactivity with 
prolonged survival of conventional donor type skin grafts (Huang, C. A. et al. 2000).  
This model of a less alloreactive state achieved through chimerism induction was used 
to assess the effectiveness of FK506 to attain long-term skin allograft survival across a 
MHC barrier (table 11.1; Group III). Following non-myeloablative chimerism induction 
with engraftment across a single haplotype MHC barrier, experimental animal 16626 
received the following conventional skin grafts:  cryopreserved donor skin graft, fresh 
and cryopreserved donor-matched skin graft (from the same donor animal), and an 
autograft
11.  These skin grafts were then treated with daily topical FK506.  The control 
animal underwent chimerism induction with engraftment, and subsequent application of 
                                                 
11 It was not possible to use fresh donor skin as the PBMC donor had been sacrificed previously.  
Therefore, in addition to a cryopreserved donor skin graft, both fresh and cryopreserved donor-matched 
skin grafts were applied so that any possible effect of cyropreservation could be ascertained.   163
a fresh donor-matched skin allograft without application of topical FK506. The effect of 
topical FK506 on vascularised skin flaps in chimeras was not examined as tolerance can 
be achieved without topical FK506 in this model (see Chapter 10). 
 
Animals were followed daily for evidence of skin rejection.  Skin biopsies for 
histological assessment were taken at regular intervals and at the first signs of erythema 
possibly indicating skin rejection.  
 
11.3 RESULTS 
 
11.3.1 Conventional skin grafts, but not vascularised skin flaps, show prolonged 
survival with the application of topical FK506 in animals with normal 
alloreactivity 
Alloreactivity to the MHC of the donor was confirmed by MLR prior to skin 
allotransplantation (not shown).  The effect of FK506 on skin allotransplant survival is 
summarized in table 11.2 
 
 
Table 11.2 Summary of skin allotransplant survival in animals with normal alloreactivity 
 
 
Group  Conventional Skin 
Graft vs. 
Vascularised Skin 
Flap 
Topical 
FK506 
Animal  Skin 
Survival 
(Days) 
17476 8  No 
17506 7 
15129 18 
 
I 
 
Graft 
Yes 
15132 17 
No 17519  6   
II 
 
Flap 
 
 
Yes 17520  6   164
Daily topical FK506 ointment prolonged skin graft survival by 10 days in animals 
receiving conventional skin allografts (17.5 vs. 7.5 days).  In contrast, there was no 
prolongation of vascularised skin flap survival by the application of topical FK506 (6 
days vs. 7.5 days).  
 
11.3.2 Topical FK506 prolongs survival of conventional skin allografts in animals 
with a reduced alloreactive state 
  
Reduced activity to the MHC of the donor was confirmed by MLR prior to skin 
allotransplantation (see fig 11.1).  The outcomes following skin allografting are 
summarized in table 11.3. 
 
In animals in a reduced alloreactive state, the daily application of topical FK506 
ointment prolonged the survival of skin by 9 days of both donor and donor-matched 
skin, with rejection occurring 64 vs. 55 days after transplantation (see fig 11.2). There 
was no difference in the rejection times between fresh and frozen donor-matched skin. 
 
Figure 11.1 Unresponsiveness to donor MHC demonstrated in animals prior to skin grafting 
 
 
 
 
 
 
 
Table 11.3 Summary of skin allograft survival in animals with reduced alloreactivity 
Group  Topical FK506  Animal  Skin Survival 
(Days) 
No 13476 55  III 
Yes 16626  64 
16626
@ Self @AC @CC @YUC
0
5000
10000
15000
20000
1 2.9 1.6
376
@Stimulator
C
P
M
@Self @Donor @CC @YUC
0
50
100
150
200
11 . 21 . 4
193
S
t
i
m
u
l
a
t
i
o
n
 
I
n
d
e
x
@Stimulator
13476
   165
 
 
 
 
                           
Key 
* Only part of the frozen donor graft became vascularised following grafting and survived to rejection 
(outlined). 
 
Figure 11.2 Evidence of skin allograft rejection in animal 16626: photograph and histology. (a) 
Sixty-four days following grafting the self graft had normal appearance.  However, there was generalized 
erythema of the donor (frozen) and donor matched (frozen and fresh) skin allografts, indicating rejection.  
Visual findings were confirmed on histological examination of punch biopsies: (b) Rejecting grafts 
demonstrated generalized inflammation with degeneration of rete pegs and epidermal necrosis. (c) In 
contrast, the self graft was viable with no inflammation. 
 
 
In vitro assessment of animal 16626 was performed following skin graft rejection (fig 
11.3).  Animal 16626 was alloreactive against donor-type (AC) cells despite still 
receiving site-specific therapy.  However, this may have been responsiveness to minor 
antigens as animal 16626 had a greater response against the single donor haplotype 
(AC) than the full donor haplotype (CC). 
Representative rejecting graft 
(donor matched; frozen) 
(H&E x160) 
 Histology 
Non-rejecting graft  
(self; fresh) 
(H&E x160) 
b.  c. 
a. Photograph 
(D64) 
Donor           Donor Matched            Self 
Frozen*      Frozen          Fresh        Fresh   166
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.3 Responsiveness to donor MHC following skin rejection.  MLR following skin rejection 
demonstrated that peripheral blood lymphocytes (PBLs) from 16626 had a stronger alloreactive response 
to PBLs with a single donor haplotype (AC; Stimulation Index (SI)=6.3)) than a double donor haplotype 
(CC; SI=2.5).  This suggests that 16626 PBLs were reacting to non-MHC minor antigens rather than 
MHC antigens.  There was a strong alloreactive response against the 3
rd party YUC control. 
 
 
11.3.3 Systemic effects of topical FK506 
Systemic absorption of FK506 was measured weekly.  The systemic levels of FK506 in 
skin grafts was greatest in the first two weeks following allotransplantation (maximum 
7ng/ml), subsequently declining to a lower levels (consistently <2ng/ml from one month 
following grafting).  Skin flaps did not survive to later timepoints; the early levels of 
FK506 in skin flaps did not reach as high a level as skin grafts (maximum 3ng/ml).  No 
adverse local or systemic effects of FK506 were observed. 
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11.4 DISCUSSION 
The use of site-specific therapies offers the hope of an effective way of reducing the 
systemic toxicity of current immunosuppressive regimens in a way that may be more 
immediately achievable than tolerance induction. Topical FK506 has been considered a 
particularly attractive site-specific therapy both because of its effectiveness in immune-
mediated skin disorders and because it has minimal side-effects.  This study indicates 
that topical FK506 did not prolong the survival of a vascularised skin flap transplanted 
across a MHC barrier. However, topical FK506 has some efficacy in prolonging 
conventional skin allograft survival transplanted across a MHC barrier both in animals 
with normal and reduced alloreactivity.   
 
11.4.1 Topical FK506 has previously been demonstrated to be an effective inhibitor 
of the immune response to antigens in the skin 
Topical FK506 is clinically proven in non-transplant scenarios to be an effective 
inhibitor of immune mediated inflammatory skin disorders without causing significant 
side-effects.  Topical FK506 exerts its effects by acting on both the priming and the 
effector phases of the immune response.  
The priming phase of the immune response to antigens in the skin is mediated by 
antigen presenting cells. These antigen presenting cells include dermal dendritic cells 
and epidermal Langerhans cells which migrate from the skin to activate naïve T cells in 
draining lymph nodes. Studies have indicated that topical FK506 affects several stages 
of the priming phase.  In vitro studies demonstrated that FK506 significantly decreased 
the expression of MHC class I and II, CD25 and costimulatory molecules on human 
cultured Langerhans cells (Panhans-Gross, A. et al. 2001).  Ex vivo studies have 
demonstrated that FK506 inhibits DC migration from murine skin (Bäumer, W. et al. 
2005). Topical FK506 has also been shown to inhibit dendritic cell-lymphocyte synapse 
formation (Mijal, J. et al. 2002).  This may explain why dendritic cells isolated from 
patients treated with topical FK506 for atopic dermatitis have reduced stimulatory 
capacity by skin MLR (Wollenberg, A. et al. 2001). 
 
The effector phase of the immune response to antigens in the skin is mediated by T-
lymphocytes that have been activated in the draining lymph nodes.  These T cells 
migrate to the area of the antigenic stimulus due to a combination of expression of 
tissue-specific homing receptors, cytokines and adhesion molecules. Once they have 
infiltrated the area of the antigenic stimulus they secrete cytokines that potentiate the   168
immune response.  Topical FK506 has been demonstrated to inhibit adhesion molecules 
involved in cutaneous lymphocyte migration (Caproni, M. et al. 2006) and reduce 
inflammatory cytokine production of infiltrating T cells in patients with atopic 
dermatitis (Simon, D et al. 2004). 
 
11.4.2 Utility of topical FK506 for CTA recipients with normal alloreactivity 
Despite achieving prolonged conventional skin allograft survival in naïve recipients in 
this study, daily topical FK506 application did not prolong vascularised skin allograft 
survival.  This indicates that topical FK506 would be an ineffective monotherapy to 
prevent rejection of composite tissue allotransplants which include just skin.   
 
Topical FK506 is more likely to be used in conjunction with systemic 
immunosuppression rather than as a monotherapy.  The application of topical FK506 
might allow reduction of the systemic medication to a less toxic level, while still 
preventing skin rejection.  This study indicates that topical FK506 can delay skin 
rejection, so it is possible that FK506 ointment would achieve the goal of reduction in 
the amount of immunosuppression taken systemically in CTA.  However, it is unclear 
whether the effect of FK506 is due to its systemic absorption or a loco-regional effect.   
 
Topical FK506 may actually exert its main effects systemically.  There were detectable 
levels of FK506 in all animals, indicating that FK506 is being absorbed systemically. 
These levels were in the clinical therapeutic range initially (i.e.>5ng/ml) in some skin 
allograft recipients.  If prolonged skin survival is due to systemic absorption then the 
overall systemic levels of immunosuppression may not actually be reduced even though 
the oral dose will be less.  However, even in this scenario, topical FK506 may still 
reduce systemic toxicity: the topically administered FK506 may be absorbed at a 
constant rate over a period of time thereby avoiding the more toxic peak levels 
associated with bolus dosaging.   
 
Alternatively, topical FK506 may exert its primary effects at a loco-regional level.  If 
much of the topically applied FK506 enters the lymphatics, it will lead to a higher 
concentration in the regional lymph node basin for a given systemic level than FK506 
taken orally.  This relatively higher level of FK506 in the draining lymph node system 
may lead to more effective prevention of the initiation of the rejection response. 
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The systemic absorption of topically applied FK506 was highest immediately after skin 
transplantation, and then decreased.  Systemic FK506 levels were also higher when 
applied to conventional skin grafts rather than vascularised skin flaps. The difference in 
systemic absorption of FK506 seen in this model early after skin transplantation may be 
a reason for the differential effect of FK506 on conventional skin grafts compared to 
vascularised skin flaps.  The inflammation in the period immediately after skin grafting 
may be the reason for the higher systemic levels of FK506 seen early after skin grafting, 
or in skin flaps.  It has been observed clinically that there is greater absorption of topical 
FK506 through inflamed skin compared to normal skin (Reitamo, S. et al. 2002).  
Following transplantation, a skin graft goes through a period of relative ischemia which 
may stimulate an inflammatory reaction.  This inflammatory reaction will settle down 
once revascularisation has occurred and will not be present in older skin grafts, possibly 
reducing FK506 absorption.  Likewise, skin flaps are primarily vascularised and so do 
not pass through a pro-inflammatory period of relative ischaemia, which may reduce 
FK506 absorption.   
 
11.4.3 Utility of topical FK506 for CTA recipients with reduced alloreactivity 
In this study, topical FK506 prolonged skin allotransplant survival in a state of reduced 
alloreactivity. This has the potential for clinical relevance if the state of reduced 
alloreactivity that can already be achieved in organ transplants can be extended to CTA.   
 
Calne was the first to report on a state of “Prope (almost) tolerance”, in which low 
rejection rates of renal allografts were achieved with a low dose of cyclosporine after 
peri-transplant T-cell depletion with alemtuzumab (Calne, R. et al. 1998). Furthermore, 
groups in both Pittsburgh and Miami have used donor bone marrow infusions following 
organ allografting with conventional immunosuppression achieving survival with a 
lower incidence of acute and chronic rejection (Shapiro, R. et al. 2001; Tryphonopoulos, 
P. et al. 2005).  T-cell depletion and bone marrow infusions have been used in some 
composite tissue allograft patients without measurable effect; however, this has been 
performed on an ad hoc basis and so it is difficult to draw any firm conclusions about 
the effectiveness of this approach. 
 
There are limitations to this model which may restrict the clinical significance of 
prolonged skin allgraft survival with topical FK506.  The conditioning regimen in this 
model does not correlate precisely with current clinical approaches to induce a state of   170
reduced alloreactivity, and so may involve different immunological mechanisms.  
Furthermore, conventional skin allografts were used in this model, not primarily 
vascularised skin, as used in clinical composite tissue allotransplantation.  
 
It is possible that the use of conventional skin allografts may not actually have been a 
limitation of this model, but rather, they may have made this model even more stringent 
than the clinical situation using primarily vascularised skin.  Skin rejection appeared to 
be mediated by non-MHC minor antigens in this model.  It is likely that these minor 
antigens were tissue specific skin antigens.  Skin specific antigens have been thought to 
be the cause of rejection in previous chimeras receiving a non-vascularised skin 
allograft (Fuchimoto, Y., et al. 2001).  However, skin specific antigens do not cause 
vascularised skin allograft rejection, as described in Chapter 10.  Consequently, site-
specific therapies may be effective in indefinitely prolonging primarily vascularised 
skin survival under conditions of reduced alloreactivity, even if they only have a limited 
effect in prolonging secondarily-vascularised skin allograft survival. 
 
11.5 CONCLUSIONS 
Site-specific therapies have been used in several of the clinical composite tissue 
allotransplants because they offer the possibility of counter-acting rejection in 
composite tissue allotransplantation whilst avoiding significant systemic side-effects. 
However, the clinical benefits of using site-specific therapy have not yet been clearly 
demonstrated.  This study indicates that there are minimal systemic side-effects from 
the topical FK506 in a large animal pre-clinical model.  However, there is no 
measurable benefit in using topical FK506 on a vascularised skin allotransplant in a 
state of normal alloreactivity, and only marginal benefit in a state of reduced 
alloreactivity.  These findings indicate that, under the conditions investigated here, 
topical FK506 is unlikely to have a central role in preventing clinical composite tissue 
allotransplant rejection.  
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CHAPTER 12: DISCUSSION 
 
12.1 INTRODUCTION 
The outcomes from clinical composite tissue allotransplantations have been much better 
than many predicted.  It has been 10 years since the first successful clinical hand 
transplant was performed.  Since then, allotransplantation techniques have been 
successfully used to reconstruct defects on many areas of the body. The greatest 
experience has been gained with hand allotransplantation.  In the Western world, there 
have been 24 reported hand allotransplants, with loss of only one due to patient non-
compliance with medication.  The knee transplantation programme is the only 
application to date in which CTA outcomes have been suboptimal.  It has been 
suggested that the high rates of rejection of this essentially musculoskeletal transplant 
may have been triggered by the sentinel skin flap included in the transplant for 
monitoring purposes.  This may be another indication of the crucial role skin plays in 
the achievement of long-term survival of composite tissue allotransplants. 
 
Skin forms a key element of many composite tissue allotransplants.  Skin is more 
susceptible to immune rejection than other tissue within composite allografts, with more 
than two-thirds of recipients having at least one acute rejection episode within the first 
year.  These skin rejection episodes have so far been overcome with increased levels of 
immunosuppression, but this has prevented tapering of the immunosuppressant dose to 
lower, less toxic levels.  Consequently, significant side-effects are being observed: two 
hand recipients have already required hip replacements for avascular necrosis due to 
steroid medications, and the first face transplant recipient has suffered from renal 
toxicity.    
 
The experiments described in this thesis aim to address many of the questions 
surrounding the process of skin rejection and ways to overcome it.  This discussion is in 
two parts.  Firstly, the implications of these experimental findings for clinical CTA are 
examined.  Secondly, the possible future avenues of research will be discussed.  The 
order followed in each section is as follows: 
 
PART A: Skin rejection 
(1) The consequences of skin rejection 
(2) Cell trafficking in skin rejection   172
 
PART B: Prevention of skin rejection 
(3) Tolerance induction to skin  
(4) Reducing immunosuppressant toxicity 
 
12.2 PART A: SKIN REJECTION 
This thesis examined both the consequences of skin rejection in CTA, and cell 
trafficking in skin transplant rejection.    
 
12.2.1 The consequences of skin rejection 
There will be both social and biological consequences to skin rejection and composite 
tissue allograft failure.  The support of the wider scientific community and the public is 
crucial for the expansion of CTA.  
 
12.2.1.1 Social consequences of CTA allograft failures 
Initial difficulties with the first heart allotransplants led to the whole programme being 
suspended.  In the current hand allograft programme, there has been only one failure in 
the Western world, and much of the criticism of this case focused on inappropriate 
initial patient selection.  In contrast, 15 of the 16 hands that have been transplanted so 
far in China have now failed. The Chinese experience has been largely ignored in the 
Western media because this was due to lack of funding leading to cessation of patient 
medications and so has limited relevance to the experience in the rest of the world.  
However, it is likely that more composite tissue allografts will fail in the West, and an 
open, self-critical approach will be important for a fair assessment of the benefits from 
CTA by society. 
 
12.2.1.2 Consequences for the patient of CTA allograft failure 
In the event of a composite tissue allograft failure, the best reconstructive option is 
likely to be replacement of the failed allograft.  The findings in Chapter 4 suggest that in 
the event of a composite tissue allograft failure the recipient vessels would be intact 
making a retransplantation technically possible.  Obviously, graft survival is the most 
important factor for good outcome following retransplantation. The experience from 
organ retransplantation is that graft survival rates are poorer for retransplants than for 
first transplants.  It is likely that the experience in composite tissue retransplantation 
will mirror that of organ transplantation.  Factors that may contribute to poorer   173
outcomes following retransplantation include prior allosensitisation to the donor making 
it harder to find a suitable second transplant. 
 
12.2.1.3 Functional recovery of a retransplant is unknown 
In the event of graft survival the findings in Chapter 4 indicate that there will not be 
significant damage to recipient tissues underlying the allograft, which could otherwise 
limit the allograft function.  However, re-innervation is also essential for a good 
functional outcome.  Motor and sensory functional recovery in hand allografts has been 
comparable to that of hand replantation, and some have suggested that systemic FK506 
therapy may even promote nerve regrowth (Yang, R.K. et al. 2003).  However, there 
could be less functional recovery in a second transplant due to damage to the nerve from 
the rejection of the first transplant.   
 
12.2.2 Cell trafficking in skin rejection 
Chapter 5 raises several issues regarding cell trafficking in skin rejection including the 
susceptibility of skin to reject, the focus of the rejection response and the use of in vivo 
imaging in other models. 
 
12.2.2.1 Susceptibility of skin to reject 
Transplanted skin has a particular susceptibility to be rejected, compared to other 
tissues. This has been a focus of research for many years.  Several factors have 
previously been identified that may contribute to skin’s tendency to reject, including the 
mode of skin transplantation.  The findings in Chapter 5 indicate that recipient cell 
trafficking as part of the rejection response in secondarily vascularised conventional 
skin grafts is very different to primarily vascularised skin flaps.  These findings indicate 
that conventional skin allograft data has to be interpreted with caution when developing 
new strategies to prolong skin survival in composite tissue allotransplantation.    
 
12.2.2.2 Focus of the rejection response 
In Chapter 5 it is observed that the rejection response appeared to be focused in the 
superficial dermis with limited infiltration of the epidermis. This has implications both 
for the interpretation of some previous studies, and for the role of skin specific antigens.  
The focus of rejection within the skin in some previous studies appeared to be the 
epidermis: in the previously described split tolerance swine model there was acceptance 
of the dermal element of the allograft but rejection of the epidermis.  It is possible that   174
the findings in the rat rejection and the swine split tolerance models are not 
contradictory, and that it is the intense superficial dermal rejection response that leads to 
epidermal loss.  In addition, the finding of rejection focused on the dermis indicate that 
skin specific antigens may not be as important as sometimes thought in the rejection 
response to skin. 
 
12.2.2.3 The use of in vivo confocal imaging in other models 
Current clinical methods to prevent skin rejection include various chronic 
immunosuppression regimens, with attempts to reduce the alloreactivity of the recipient 
in some cases by T-cell depletion or bone marrow infusion.  The effects of these 
methods on immune cell entry, targeting and exit have not been fully examined. 
However, modifications to cell trafficking will be pertinent for the development of 
successful ways to improve the effectiveness of regimens to avoid skin rejection without 
toxicity.  Chapter 5 demonstrates the usefulness of in vivo imaging for studying cell 
trafficking.   
 
12.3 PART B: PREVENTION OF SKIN REJECTION 
Part B of the thesis explored two approaches to prevent skin rejection in a swine model: 
tolerance induction, and reduction of immunosuppressant toxicity by the induction of a 
less alloreactive state and/or site-specific therapy.  The swine model used, and both 
approaches to prevent skin rejection will be examined in turn: 
 
12.3.1 Limitations of the swine model 
This thesis uses a swine model to investigate methods to prevent skin rejection.   This is 
a useful model because of its greater clinical relavence compared to small animals, the 
ability to repeat transplants across the same immune barrier because the herd is 
immunologically defined, and the availability of immunological reagents for 
investigation of the immune mechanisms involved.  However, there are certain 
limitations to the swine model due to the use of the MGH miniature swine herd, and the 
use of young adult swine recipients. 
 
The MGH partially-inbred miniature swine herd is one of the only immunologically 
defined large animal models worldwide, and so it is not easy to corroborate findings in 
another large animal model. It is therefore difficult to know if any observations in this 
model have global relevance or are specific to this herd due to inbreeding.  Secondly, in   175
this thesis, skin tolerance was achieved across only a single haplotype MHC barrier.  
This is the equivalent of receiving a transplant from a parent or sibling.  In composite 
tissue allotransplantation it is likely that suitable donors will be in short supply, and so 
HLA matching to this extent may not be possible.  This model needs to be effective 
across a double-haplotype MHC barrier to maximize its clinical utility.  However, a 
double-haplotype mismatch in this swine model, equivalent to the clinical situation is 
not even possible, since there are only three lines of swine (SLA
aa, SLA
cc, and SLA
dd).  
Furthermore, there is some sharing of MHC Class II DR between SLA
aa and SLA
dd.  
The closest equivalent to a clinical double-haplotype mismatch transplant is to do a 
transplant from SLA
aa to SLA
cc; this is actually a double single haplotype mismatch. To 
achieve a mismatch equivalent to a clinical double-haplotype mismatch would require 
another subline; for example if the SLA
bb subline still existed it would be possible to 
perform a double-haplotype mismatch transplant from SLA
ab to SLA
cd. 
 
Young adult recipients were used in this thesis as recipients for haematopoietic cell 
transplantation.  It is likely that the mechanism of tolerance induction in this model is 
thymic dependent.  However, it has been observed in other thymic dependent tolerance 
induction protocols in this swine model, that tolerance can only be achieved in younger 
pigs.  Once the thymus has started to atrophy in adult pigs, it is no longer possible to 
achieve tolerance.  If this was true clinically, it would significantly limit the application 
of these techniques.  Consequently, methods to rejuvenate the thymus are currently 
being examined by others to extend the application of these techniques to older 
recipients. 
 
12.3.2 Tolerance induction 
The hypothesis developed in Chapter 6, and subsequently tested in Chapter 10, is that a 
moderate level engrafted chimera would be tolerant to a vascularised skin allograft 
transplanted across a single haplotype MHC barrier.  This hypothesis is correct, with the 
achievement of tolerance to MHC mismatched skin transplant for the first time in a 
large animal model.  The achievement of this in a large animal model represents an 
important step towards clinical CTA tolerance induction. 
 
12.3.3 Reducing immunosuppressant toxicity 
For many, clinical tolerance induction is too distant a goal for composite tissue 
allotransplantation.  Even if it were possible, the induction regimen might have to be   176
more aggressive than simple immunosuppression, increasing the risks in the initial 
perioperative period.  However, induction of a less alloreactive state may provide many 
of the benefits of tolerance induction, such as reduced treatment-related toxicity and 
decreased risk of chronic rejection, without the initial risks from the induction regimen.  
Consequently several composite allotransplant recipients have received T-cell depletion 
or post-transplant bone marrow infusion in an attempt to induce a state of reduced 
alloreactivity.  However, there is no evidence these approaches have worked.   
 
A less alloreactive state has been achieved clinically in organ transplant recipients.  
However, it may require stronger, more toxic treatment to induce a state of reduced 
alloreactivity to a composite tissue transplant due to the tendency of skin to reject.  It is 
possible that although this middle ground between high-dose chronic 
immunosuppression and true tolerance may exist, it may have little benefit, with only 
slightly less aggressive induction therapy required, but without the advantages of full 
tolerance. 
 
Even with the achievement of a less alloreactive state in composite tissue 
allotransplantation, the use of site specific therapy may not be worthwhile.  Topical 
FK506 only achieved prolongation of skin survival by a few days in a swine model; this 
would have little clinical use. 
 
12.4 FUTURE DIRECTIONS OF RESEARCH 
The findings of this thesis give the following direction to further possible research:  
 
12.4.1 Consequences of skin rejection 
In this study, the consequences of vascularised skin allograft failure while on 
immunosuppression were examined in a small animal model.  The findings indicate that 
there is minimal damage to the vasculature and recipient tissues with sub-therapeutic 
immunosuppression still having a protective effect on recipient tissues.   
 
To gain more clinically relevant information, there are two elements that could be added 
to the model.  Firstly, a large animal model may give a closer approximation of damage 
to recipient tissues caused by the rejection process.  Secondly, to assess fully the effect 
of allograft rejection on the function following retransplantation, a model is required 
that allows assessment of motor and sensory recovery.  A large animal model would be   177
most useful as it is not possible to apply all clinical sensori-motor assessment 
techniques to a small animal.  The gastrocnemius musculocutaneous allograft developed 
in Chapter 8 could be utilised to assess the effect of rejection on the functional outcome 
following retransplantation. 
 
One other avenue for future research is that rejection of a second CTA transplant may 
also cause more damage than rejection of the first transplant due to a more intense 
rejection response caused by the heterologous immunological memory.  The increased 
damage could have a significant impact on the outcome of any further transplants.  
 
12.4.2 Mechanism of skin rejection 
In this study, using in vivo confocal imaging, direct observations of recipient cell influx 
and targeting were performed; constituting the first steps in initiation of the immune 
response.   
 
12.4.2.1 Immune cell targeting  
In vivo imaging of antigen presentation, as well as cellular interactions within the 
allograft, has the potential to further characterise the elusive skin specific antigen(s). 
However, this would require a more complex model incorporating labelling of specific 
cell types.  At present, there are no transgenic rat models available that would facilitate 
this.   
 
Alternatives include in vivo use of fluorescent labelled antibodies in a rodent model, or 
transferring to a transgenic mouse model, but both these approaches have limitations.  
Relevant fluorescent antibodies are available that could be used in vivo.  However, it 
would be difficult to obtain global staining of all cells of a particular subtype, 
particularly over a sustained period.  Transgenic mouse models are another option with 
several available that have differential fluorescent labelling several relevant cell types.  
These models would make it possible to define the cellular interactions both within the 
allograft and lymphoid tissues in vivo.  However, reliable vascularised skin flap 
transplantation in mice is technically challenging; this has limited the use of mouse 
models to study vascularised skin allotransplantation. 
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12.4.2.2 Characterisation of immune cell efflux from allotransplanted skin 
The final element in the initiation of the immune response is cellular efflux and antigen 
presentation in lymphoid tissues. Donor cell efflux was examined via the more indirect 
method of PCR microchimerism analysis.  As in previous studies, the effluxing donor 
cells were below the level of detection.  To obtain a more complete picture of the 
mechanism of rejection, the efflux of donor and recipient cells from the allograft, 
precise trafficking patterns to lymphoid tissues, and antigen presentation to T cells all 
need to be examined.   
 
To image trafficking patterns of donor and recipient cells, simple modifications to the 
model used in this thesis could be introduced.  Efflux of donor cells could be imaged by 
performance of a vascularised skin allotransplant from a GFP positive rat to a GFP 
negative rat with in vivo imaging of target lymphoid tissues. Likewise, efflux of 
recipient cells targeting could be followed by injection of recipient type immature GFP 
labelled dendritic cells at the time of transplantation with in vivo imaging of the targeted 
lymphoid tissues.  
 
12.4.2.3 Design and direction of future experiments examining skin rejection and 
ways to overcome it 
Observations of significant differences in the rejection response to conventional skin 
allografts and vascularised skin allografts indicate that future CTA research should use 
vascularised skin allografts. 
 
In addition, the importance of recipient dendritic cells in the immune response to a 
vascularised skin allograft is supportive of research manipulating recipient dendritic 
cells to overcome skin rejection.  However, as the literature review in Chapter 2 
indicates, simple manipulation of dendritic cells has not been successful at achieving 
skin tolerance in a large animal model.  Consequently, it is possible recipient dendritic 
cell manipulation will only be successful at achieving large animal (and clinical) 
tolerance as part of a combination therapy regimen. 
 
12.4.3 Possible approaches to induce skin tolerance 
Chapter 10 contains the first description of the induction of tolerance to skin 
transplanted across a MHC barrier in a large animal model.  Several steps are required 
to further develop this finding for clinical application:   179
 
12.4.3.1 Confirmation of current findings  
In this thesis skin tolerance induction was performed in a small number of animals, with 
only one animal surviving long-term.  The first step would be to repeat the experiment 
to confirm the findings. 
 
12.4.3.2 Protocol schedule and immune barrier 
As previously described, the protocol is not directly clinically applicable because of the 
time taken to mobilise the donor haematopoietic progenitor cells and the delay between 
chimerism induction and transplantation.  Furthermore, transplantation was only 
performed across a single haplotype MHC barrier.  The modified protocol would need 
to address these constraints. 
 
12.4.3.3 Protocol medication  
Certain medications used in the progenitor cell mobilisation and chimerism induction 
protocol are not available for clinical use (e.g. stem cell factor and the T-cell depleting 
agent).  There are medications that have similar effects to those in clinical use.  
However, it is possible that these may significantly change the outcome necessitating 
the development of more closely correlating medications. 
 
12.4.4 Reduction of immunosuppressant toxicity 
Topical FK506 had minimal effect as a monotherapy to prolong skin flap survival in 
recipients with normal alloreactivity.  However, it prolonged survival of skin allografted 
across a MHC barrier in both recipients with normal, and reduced alloreactivity.  This 
has minimal direct clinical applicability because the effect was only seen in skin grafts, 
and also survival was only prolonged by a few days.  However, it indicates that this 
general approach may warrant further investigation.  There are several possible avenues 
for future research: 
 
12.4.4.1 Induction of a less alloreactive state   
Several methods have been used to induce reduced alloreactive states both in animal 
models and clinically (as described in Chapter 2).  However, the efficacy of many of 
these techniques has not been tested on composite tissue allotransplants.  It would be of 
particular interest to investigate some of these approaches in a clinically relevant model, 
particularly the ones that have had some efficacy in clinical organ transplant regimens.    180
 
12.4.4.2 Site-specific therapies   
Topical FK506 has efficacy compared to other medications in treating immune-
mediated skin disorders, with minimal side-effects.  For these reasons FK506 was 
assessed as having the highest likelihood of preventing skin allograft rejection and so 
was used in this study.  However, only marginal prolongation of skin allograft survival 
was achieved in this study.  It is possible that topical FK506 is not as efficacious as 
other medications in composite tissue allotransplantation, despite its utility in non-
transplant scenarios.  Topical steroids, cyclosporine, pimecrolimus, and combination 
therapy are possible alternative site-specific regimens that could be used instead.   
 
Topical steroids have been used for several decades and have a dominant role in 
immunosuppression for skin disorders. However, long-term use of topical steroids can 
cause a multitude of complications such as skin atrophy, telangectasia, osteoporosis and 
diabetes.  Furthermore, topical FK506 appears to be more efficacious than 
hydrocortisone in treating atopic dermatitis (Reitamo, S. et al. 2002).  
 
When introduced, systemic cyclosporine revolutionised immunosuppression in both 
transplantation, and treatment of inflammatory skin disorders.  However, it has low 
topical activity (Lauerma, A.I. et al. 1994).  Pimecrolimus is a macrolide with similar 
properties to FK506.  However, in a head-to-head study topical FK506 was more 
efficacious at treating atopic dermatitis (Fleischer, A.B. Jr. et al. 2007). 
 
Another alternative is to use several of these therapies in combination to maximize the 
immunomodulatory effect while avoiding side-effects.  A rejection episode in one of the 
Louisville hand transplant recipients has already been successfully treating by 
combining topical tacrolimus and steroid treatments. 
 
12.5 CONCLUSION 
Many people still suffer defects that cannot be adequately reconstructed using standard 
techniques.  The first successful clinical composite tissue allotransplants are already 
transforming the lives of their recipients and have demonstrated the potential of these 
techniques.  However, the application of these techniques is likely to remain limited 
until further progress is made in reducing the risks associated with the technique.  
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It is possible that there will be other options for reconstruction in the future due to 
advances in robotics and tissue engineering.  However, these are still a long way off.   
The growing interest generated by these first few cases will intensify research into 
composite tissue allotransplantation, making immanent achievement of the widespread 
application of these techniques a real hope.  It is likely that the key breakthroughs will 
come from centres in which both clinical and research CTA activities are taking place. 
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